{"docstore/data": {"e94efa5e-508e-4712-946a-82f6743526cf": {"__data__": {"id_": "e94efa5e-508e-4712-946a-82f6743526cf", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04fd1cc1-6134-4fb5-b839-afec927aa143", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. "}, "hash": "95c823c589318c04b84c875fe2534e6f89dbee3eeedffdae7b7176f854255144", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion. ", "start_char_idx": 0, "end_char_idx": 542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04fd1cc1-6134-4fb5-b839-afec927aa143": {"__data__": {"id_": "04fd1cc1-6134-4fb5-b839-afec927aa143", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e94efa5e-508e-4712-946a-82f6743526cf", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c65c13a6069180698e97a8379dd3b7e8a553505223bdc8d7488a3cd067172e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c088867-0411-497a-8d52-19e4986beb64", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter. "}, "hash": "def47fbf9b64556b118d2a65dfcb1d8846cd04b2f612ad9436849a5fb02626d3", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 542, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c088867-0411-497a-8d52-19e4986beb64": {"__data__": {"id_": "7c088867-0411-497a-8d52-19e4986beb64", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04fd1cc1-6134-4fb5-b839-afec927aa143", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "458f77b386324ffbf31e7dd2398f01c7f9d02623a55785f3225941c28a7ddd91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "795015aa-4388-4b5a-8fc5-b6be3d33be8a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n"}, "hash": "886604b70da148b053da638f00683a3f309c5669923e6b3aac8befd7be2614bb", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter. ", "start_char_idx": 563, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "795015aa-4388-4b5a-8fc5-b6be3d33be8a": {"__data__": {"id_": "795015aa-4388-4b5a-8fc5-b6be3d33be8a", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c088867-0411-497a-8d52-19e4986beb64", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62723c0164bd1ed26f712a279b7e160a400cc58a87d42aad3f7d67be7f191cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4463fe6b-dc72-4eca-8cba-b924135d62ed", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. "}, "hash": "71f3c6d598e54c5815a70405d830b1c5a57d5035a7407632ebe2144931185d96", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "start_char_idx": 737, "end_char_idx": 886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4463fe6b-dc72-4eca-8cba-b924135d62ed": {"__data__": {"id_": "4463fe6b-dc72-4eca-8cba-b924135d62ed", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "795015aa-4388-4b5a-8fc5-b6be3d33be8a", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7604b40db3a3e6c0c3cb89092894b525308ff0bd812be1323a75dbc14b71a5c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e505af9-42b7-4333-82e4-a8503c0f9b9a", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. "}, "hash": "060f7d956665878955a1e92609aab6959213ebd7c8e9ab4e1aa7283b5b150cb9", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "start_char_idx": 886, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e505af9-42b7-4333-82e4-a8503c0f9b9a": {"__data__": {"id_": "2e505af9-42b7-4333-82e4-a8503c0f9b9a", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4463fe6b-dc72-4eca-8cba-b924135d62ed", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2022. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "828cbc6d3b1ede8c9d040351656b8469f399236dc4bea9f3105c8364cff3e727", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n"}, "hash": "cffd80e2b662ea7527d2a14d88141ae280cf8dde81564695f735f6acaed2744d", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "start_char_idx": 950, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314": {"__data__": {"id_": "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e505af9-42b7-4333-82e4-a8503c0f9b9a", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a005e2d8a251a550704801ae947d85d86caf43255eb71d632e31b814f64b6199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfe83f9f-ace3-4936-8a91-f77544081895", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued. ", "original_text": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. "}, "hash": "1c511832ea96b16cd24d5a0925a6da834da9e6f3aa3158fd0f861766c92aa92f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "start_char_idx": 1074, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfe83f9f-ace3-4936-8a91-f77544081895": {"__data__": {"id_": "bfe83f9f-ace3-4936-8a91-f77544081895", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued. ", "original_text": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eab2ba32faf7a608d811ca3cf31e78ba488a5339919662bfe9f2d2042ba5a41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "original_text": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n"}, "hash": "a7a41c269cd55c5f1899e17935970653e3d8cca2a1e23066a6c106ccb0142b5e", "class_name": "RelatedNodeInfo"}}, "text": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "start_char_idx": 1196, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2": {"__data__": {"id_": "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "original_text": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfe83f9f-ace3-4936-8a91-f77544081895", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2022.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued. ", "original_text": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "421426345635c7e04365d224fc4c425c0960fcbf4ff0e8e22a15eb1b67484bf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c18946d8-1ba0-4e99-82c4-57826bc95a27", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. "}, "hash": "f074e534460cf369a6eda00f9bb5dc23025e45d671b71a0d8ee4ec2aa4fd38f5", "class_name": "RelatedNodeInfo"}}, "text": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "start_char_idx": 1484, "end_char_idx": 1640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c18946d8-1ba0-4e99-82c4-57826bc95a27": {"__data__": {"id_": "c18946d8-1ba0-4e99-82c4-57826bc95a27", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2022 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "original_text": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90274798a3264b225491ae47f2d5a6e7e8277be9f1c5bb3bfe6b6ba779c9efb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646", "node_type": "1", "metadata": {"window": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Collis continued. "}, "hash": "61b3a431a3cca9194f1148d01f89d8c8056d9960cbd0f1db7cf21d9c23a26154", "class_name": "RelatedNodeInfo"}}, "text": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "start_char_idx": 1640, "end_char_idx": 1866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646": {"__data__": {"id_": "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646", "embedding": null, "metadata": {"window": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c18946d8-1ba0-4e99-82c4-57826bc95a27", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $10.60 to $10.90 to a range of $10.80 to $11.05.\n \"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b483c382504d88b5f361797350b1eb8313c8955efc85a03768e2171b2e81fb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b758306d-90b8-4755-a409-66fdf63fc92d", "node_type": "1", "metadata": {"window": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n"}, "hash": "fbeb109979306e3b041965670a46562b7dd45c91b5ccf616dc816727c1a8dc2d", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 1866, "end_char_idx": 1884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b758306d-90b8-4755-a409-66fdf63fc92d": {"__data__": {"id_": "b758306d-90b8-4755-a409-66fdf63fc92d", "embedding": null, "metadata": {"window": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646", "node_type": "1", "metadata": {"window": "\"As a global healthcare solutions leader, AmerisourceBergen is advancing pharmaceutical innovation and access to create a positive\nimpact on the health of people and communities around the world,\" said Steven H. Collis, Chairman, President & Chief Executive\nOfficer of AmerisourceBergen.  \"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dd695b8d38b4db5b71e6518274fdccee3d7fd8817d459b7f7065ad95553636d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64143e5f-fd2c-42c2-a43e-5b51845795af", "node_type": "1", "metadata": {"window": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1"}, "hash": "13a55c05d5207e87469ddd64bbfb71b913920822e915460675d7a2ab8339f96a", "class_name": "RelatedNodeInfo"}}, "text": "\"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "start_char_idx": 1884, "end_char_idx": 2087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64143e5f-fd2c-42c2-a43e-5b51845795af": {"__data__": {"id_": "64143e5f-fd2c-42c2-a43e-5b51845795af", "embedding": null, "metadata": {"window": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e79ce87d48827e1e5990d347cda7f327b2c47de7046870f269abe850764f738", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b758306d-90b8-4755-a409-66fdf63fc92d", "node_type": "1", "metadata": {"window": "\"During the quarter, we delivered strong performance through execution across our business and\ncontinuing to play our vital role in the healthcare system.\"\n \"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "\"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02a7064d0b4452b8cd28c61ed6e6805a87664e8e83d135f5bf79127763c45ca0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e9e3225-451a-4d8a-8da0-9b2b9246f23f", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "original_text": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "ab725a2f5f2165429b749370290eb18fedfab90f68d6e7b97651a73499b3a4ba", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "start_char_idx": 2087, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e9e3225-451a-4d8a-8da0-9b2b9246f23f": {"__data__": {"id_": "3e9e3225-451a-4d8a-8da0-9b2b9246f23f", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "original_text": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64143e5f-fd2c-42c2-a43e-5b51845795af", "node_type": "1", "metadata": {"window": "\"Our strong results in the first half of the year and updated fiscal 2022 guidance reflect the commitment and achievements of our\n42,000 purpose-driven team members as we continue to deliver on our strategic imperatives,\" Mr.  Collis continued.  \"As we move\ninto the second half of our fiscal year with significant momentum, we remain focused on execution and continuing to help our\npartners navigate the complex and evolving healthcare landscape.\"\n Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "original_text": "Second Quar ter Fiscal Y ear 2022 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $57.7B $57.7B\nGross Pr ofit $2.2B $2.2B\nOperating Expenses $1.5B $1.3B\nOperating Income $780M $917M\nInterest Expense, Net $53M $53M\n1", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae07ede5b802bcf0d4c7e50c9aa1f43b8a3538c734d2b7089c1bc68e2f529cb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "b8e54f2084ffba970a6bbe45519dc8a4a13dcc3d242c790b9f8d0e8a67d5389b", "class_name": "RelatedNodeInfo"}}, "text": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35": {"__data__": {"id_": "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e9e3225-451a-4d8a-8da0-9b2b9246f23f", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "original_text": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbe5c063b0517a0d6df2761e6276616548bb7122fa486473cb3c6cc57915c28d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "314084e8-1100-4d35-89f2-c8f5d637128e", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n"}, "hash": "6a2d1718d86a2548758099df905ba7a0b7be3cfe9c1e74fc1cefa0c092fd1a84", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 312, "end_char_idx": 404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "314084e8-1100-4d35-89f2-c8f5d637128e": {"__data__": {"id_": "314084e8-1100-4d35-89f2-c8f5d637128e", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6adb5f171293c4170d45322c2049c85ca0404f9c24adaf6789a80cd61a34210d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11fd6039-a9f7-41fb-99e7-45ef8e134919", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. "}, "hash": "582da96fff360372c0c616ba3e528e3ce87d753a76b49e6e0aeca085e5d32308", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 404, "end_char_idx": 626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11fd6039-a9f7-41fb-99e7-45ef8e134919": {"__data__": {"id_": "11fd6039-a9f7-41fb-99e7-45ef8e134919", "embedding": null, "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "314084e8-1100-4d35-89f2-c8f5d637128e", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf425e9a6cdf1eee92460177416cdfab0f75952215677455bfa7b9c0bc2b2ad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab3200cc-1acf-41c4-a32b-55901fe281dc", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions\nrevenue.\n"}, "hash": "3c4457f870de8db7530c371317291f507537e4855e9f859b490f05d397b21622", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "start_char_idx": 626, "end_char_idx": 1010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab3200cc-1acf-41c4-a32b-55901fe281dc": {"__data__": {"id_": "ab3200cc-1acf-41c4-a32b-55901fe281dc", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions\nrevenue.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11fd6039-a9f7-41fb-99e7-45ef8e134919", "node_type": "1", "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions. ", "original_text": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e9783e49c64a79d572179a8042a4a1a0c265481a9b348b22a8a1f1e71a06ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9875db4-50a3-4ef3-8089-5f327312e6d8", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. "}, "hash": "1e4806c31f66ca3839634c2e378edc686952cc5094abe7f79b5778a0644864be", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nrevenue.\n", "start_char_idx": 1010, "end_char_idx": 1040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9875db4-50a3-4ef3-8089-5f327312e6d8": {"__data__": {"id_": "c9875db4-50a3-4ef3-8089-5f327312e6d8", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab3200cc-1acf-41c4-a32b-55901fe281dc", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions\nrevenue.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a8d1261439fcbe0232ea8405fe108914d06919aea85c4b503b43e8ba7898ea5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bebfea0-2dac-44e2-9c07-ca574b45cab0", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. "}, "hash": "4551ba4e5a80e1ab8ee73d8960f59a925527c61b228e8f42ac4a4531f1d81c57", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "start_char_idx": 1040, "end_char_idx": 1397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bebfea0-2dac-44e2-9c07-ca574b45cab0": {"__data__": {"id_": "2bebfea0-2dac-44e2-9c07-ca574b45cab0", "embedding": null, "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9875db4-50a3-4ef3-8089-5f327312e6d8", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c89615a005107da76627ef7af501dbf8c146dae8a7266edd14264899264cab2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f745ebb1-d467-4957-b965-e9a99e59501c", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "5d7dff4b6bee6740d48a545f1379d72d84fe90332ab69075ffda595061060658", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 1397, "end_char_idx": 1419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f745ebb1-d467-4957-b965-e9a99e59501c": {"__data__": {"id_": "f745ebb1-d467-4957-b965-e9a99e59501c", "embedding": null, "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bebfea0-2dac-44e2-9c07-ca574b45cab0", "node_type": "1", "metadata": {"window": "Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4dbba26a6f8fd6c03a0bf8856bfe9eaf8688abc4105a6a60d324a66cb4b79c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "39e715a67b1b020112abb1265f157ea05a8f01d2a8723e15f38f0464e217c09a", "class_name": "RelatedNodeInfo"}}, "text": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 1419, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c": {"__data__": {"id_": "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f745ebb1-d467-4957-b965-e9a99e59501c", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nrevenue.\n Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbb7c79019068cc37fff811770cbe2b2b65ba18e7855f1ed3dcf676199a719a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90dc0127-1733-4a39-9ba2-58f57f24777f", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. "}, "hash": "9cff7e5fed351f88f83fa970be79d1c195c8539ea17a36451522a6dfeb3bcd43", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 1606, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90dc0127-1733-4a39-9ba2-58f57f24777f": {"__data__": {"id_": "90dc0127-1733-4a39-9ba2-58f57f24777f", "embedding": null, "metadata": {"window": "Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 45.8 percent increase compared to the same\nperiod in the previous fiscal year due to an increase in gross profit in International Healthcare Solutions, which was primarily\ndriven by the June 2021 acquisition of Alliance Healthcare, and an increase in gross profit in U.S.  Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n", "original_text": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2931321b6a7ae947bc08cf609045af80b4f38435a9ca359da3f02e11eebd9f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aca4a2d-78e1-42ad-8323-8e443e085fc4", "node_type": "1", "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. "}, "hash": "fa7bed87da741c0895432a17001e4b179bc083a99dcc435bdb3498a1d33a88f3", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "start_char_idx": 1961, "end_char_idx": 2133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aca4a2d-78e1-42ad-8323-8e443e085fc4": {"__data__": {"id_": "2aca4a2d-78e1-42ad-8323-8e443e085fc4", "embedding": null, "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90dc0127-1733-4a39-9ba2-58f57f24777f", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6daba6771468a455971efe91e8248a6522238e29e2d82417242b838b4f7dbc99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "646bdd04-fa3a-49cb-a238-832cc1aa16a7", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "original_text": "Healthcare Solutions' operating income.\n"}, "hash": "fa1497bae7ccbeb46c63b1d40a4f532bd519399ff58f91b796d36e7631d824f5", "class_name": "RelatedNodeInfo"}}, "text": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "start_char_idx": 2133, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "646bdd04-fa3a-49cb-a238-832cc1aa16a7": {"__data__": {"id_": "646bdd04-fa3a-49cb-a238-832cc1aa16a7", "embedding": null, "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "original_text": "Healthcare Solutions' operating income.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aca4a2d-78e1-42ad-8323-8e443e085fc4", "node_type": "1", "metadata": {"window": "Gross\nprofit as a percentage of revenue was 3.87 percent, an increase of 75 basis points from the prior year quarter primarily driven\nby the June 2021 acquisition of Alliance Healthcare.\n Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43f57e9af32c7558ee5ed7d3a99f710cbd2f6a34aeae68a89643b77223b3504c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c11fbb-b031-4f27-91a3-3d4bb85b9088", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n"}, "hash": "e7b7a657e9c3bd4874c6a61be2429f5ace699bc31b718626b98c0a63b10ecb77", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions' operating income.\n", "start_char_idx": 2281, "end_char_idx": 2321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c11fbb-b031-4f27-91a3-3d4bb85b9088": {"__data__": {"id_": "89c11fbb-b031-4f27-91a3-3d4bb85b9088", "embedding": null, "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "646bdd04-fa3a-49cb-a238-832cc1aa16a7", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the second quarter of fiscal 2022, operating expenses were $1.5 billion, a 60.1 percent increase,\nprimarily as a result of increases in distribution, selling, and administrative expenses and depreciation and amortization\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "original_text": "Healthcare Solutions' operating income.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c11a8e824c7fc1e2d72ff1762e31901a6016f1c01fc464605d5064f65e1a3a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2f7574d-08c8-4a21-9631-2c2e11b9e95e", "node_type": "1", "metadata": {"window": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "9bb4c123f65f21f5d1b9c40e75a36b041afa4b1d725d0eb2a420d41c69cec1e2", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "start_char_idx": 2321, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2f7574d-08c8-4a21-9631-2c2e11b9e95e": {"__data__": {"id_": "d2f7574d-08c8-4a21-9631-2c2e11b9e95e", "embedding": null, "metadata": {"window": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c11fbb-b031-4f27-91a3-3d4bb85b9088", "node_type": "1", "metadata": {"window": "Operating Income:  In the second quarter of fiscal 2022, operating income was $780.2 million, a 25.0 percent increase\ncompared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00cfe3393ba61181b7f52e57bb94bf3a3ff7454a3a6a840bdf97df442b204416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b94b63e-0701-4a99-8e01-d9388f829f94", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n"}, "hash": "dcce8949eb693918f9f8077b775227356e08cfd70a10e32a3df474139364091d", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 2663, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b94b63e-0701-4a99-8e01-d9388f829f94": {"__data__": {"id_": "0b94b63e-0701-4a99-8e01-d9388f829f94", "embedding": null, "metadata": {"window": "Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2f7574d-08c8-4a21-9631-2c2e11b9e95e", "node_type": "1", "metadata": {"window": "The increase was due to a 260.8 percent increase in operating income\nwithin International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "original_text": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4746f9c190ad0dba0ae82eeb63bbb39d748d0c66be0c52b49a8971963b43222a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8eb2b95-ca04-4299-a0c0-333132b143ba", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n"}, "hash": "4e0edb31967157321b631f9658471f0198c62a2e397b89f6839ce0af91936cdb", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "start_char_idx": 2905, "end_char_idx": 3056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8eb2b95-ca04-4299-a0c0-333132b143ba": {"__data__": {"id_": "a8eb2b95-ca04-4299-a0c0-333132b143ba", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b94b63e-0701-4a99-8e01-d9388f829f94", "node_type": "1", "metadata": {"window": "Healthcare Solutions' operating income.\n Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "215cd855f1261297aeb3a390b67ec0835fdb749f046fbad052b125b67af36a67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d636dc89-2ac8-49f3-a90e-38053b7cde4b", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. "}, "hash": "5a8966acfd5ef85bcb66ab9ebe34432d4ffb0a88292a338941e8fb3444dc9c7a", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 3056, "end_char_idx": 3248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d636dc89-2ac8-49f3-a90e-38053b7cde4b": {"__data__": {"id_": "d636dc89-2ac8-49f3-a90e-38053b7cde4b", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8eb2b95-ca04-4299-a0c0-333132b143ba", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.35 percent in the second quarter of fiscal 2022, an increase of 8 basis\npoints when compared to the same period in the previous fiscal year primarily due to the June 2021 acquisition of Alliance\nHealthcare and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3aa7475b313f49dd3bb011cb1ad572006282aacd360cc90b1e406bf829806a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57686d9f-1a29-4dd6-9257-5a94506647bf", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare.\n"}, "hash": "146ab84224c68b73624466061c392b00797876e685dafedde9d29a5e0c161fee", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "start_char_idx": 3248, "end_char_idx": 3632, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57686d9f-1a29-4dd6-9257-5a94506647bf": {"__data__": {"id_": "57686d9f-1a29-4dd6-9257-5a94506647bf", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d636dc89-2ac8-49f3-a90e-38053b7cde4b", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the second quarter of fiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus\nthe prior year quarter due to an increase in debt as a result of the June 2021 acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e6206ad46c6193d728065377e729818a8b48265c9fd6925079cd33789c5216e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1494e4a6-89b9-4289-b02c-31fe773e4788", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "79138bafab1e61a38cf99a0e2a170fd4c1a774ec027e8b0985e942d7e89a8197", "class_name": "RelatedNodeInfo"}}, "text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "start_char_idx": 3632, "end_char_idx": 3699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1494e4a6-89b9-4289-b02c-31fe773e4788": {"__data__": {"id_": "1494e4a6-89b9-4289-b02c-31fe773e4788", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57686d9f-1a29-4dd6-9257-5a94506647bf", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 23.7 percent for the second quarter of fiscal 2022 compared to 23.4 percent in\nthe prior year quarter.\n Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "(\"WBA\") in connection with the acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b8fdef7d518817e90d10f6796d370efc7914f6f0ccccb05ce811f71457cc876", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de64d609-8c02-4043-b374-997eac4a457b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2"}, "hash": "aa0d0a7496d36104711e7e3c2eb9dae5aa11e2cc3028de5ea58796d9383d00cd", "class_name": "RelatedNodeInfo"}}, "text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3699, "end_char_idx": 3817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de64d609-8c02-4043-b374-997eac4a457b": {"__data__": {"id_": "de64d609-8c02-4043-b374-997eac4a457b", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4f7a9b09-b553-4394-9630-d98130a34259", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "357045287fbcfef1486d007fe9f7e4448c53097140ae57e798df01ba4a9761bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1494e4a6-89b9-4289-b02c-31fe773e4788", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $2.59 in the second quarter of fiscal 2022, a 23.3 percent increase\ncompared to $2.10 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "365a1d230b61d0bc36604d08cafeaa384dfdfe728d41c09a72b60ad9ae350f72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e83ba077-aefb-4e8e-8bb7-029ad0096cc4", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "Healthcare, and a 5.8 percent increase in U.S. "}, "hash": "99db836fb7e7b489efe4aeb50c2f539fee764bd56daa7ce3e41426c4f69ae543", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "start_char_idx": 3817, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e83ba077-aefb-4e8e-8bb7-029ad0096cc4": {"__data__": {"id_": "e83ba077-aefb-4e8e-8bb7-029ad0096cc4", "embedding": null, "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "Healthcare, and a 5.8 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de64d609-8c02-4043-b374-997eac4a457b", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the second quarter of fiscal 2022 were 212.0\nmillion, a 2.3 percent increase versus the prior fiscal year second quarter primarily resulting from stock option exercises,\nrestricted stock vesting, and the June 2021 issuance of 2 million shares of the Company's common stock to Walgreens Boots\nAlliance, Inc.  (\"WBA\") in connection with the acquisition of Alliance Healthcare.\n Second Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "original_text": "In the second quarter of fiscal 2022, revenue was\n$57.7 billion, up 17.4 percent compared to the same quarter in the previous fiscal year, reflecting a 585.3 percent increase in\nrevenue within International Healthcare Solutions, which was primarily driven by the June 2021 acquisition of Alliance\n2", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd6391a28d3e4c322e8a8fb258d57923a3ceeee1df04bc77219d4c8c422d88fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f47acf5-b980-47cf-9a6b-4fb4259dbc60", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions revenue.\n"}, "hash": "44fd0c409745020d9a30ba7e7a31305253533dfbc3a4b35f59db62b0ca8b74e2", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare, and a 5.8 percent increase in U.S. ", "start_char_idx": 0, "end_char_idx": 47, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f47acf5-b980-47cf-9a6b-4fb4259dbc60": {"__data__": {"id_": "1f47acf5-b980-47cf-9a6b-4fb4259dbc60", "embedding": null, "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e83ba077-aefb-4e8e-8bb7-029ad0096cc4", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "Healthcare, and a 5.8 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63536da2abe9edce72be9ee68830873bdedb547e722599ac0f8bae539a305d97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46c8645e-0de5-41e1-9f6a-c052ef6a4de2", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. "}, "hash": "13254475aeae42a943a18d14a2aae22995c79cefa05f11cf381036e6b085a6a5", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue.\n", "start_char_idx": 47, "end_char_idx": 77, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46c8645e-0de5-41e1-9f6a-c052ef6a4de2": {"__data__": {"id_": "46c8645e-0de5-41e1-9f6a-c052ef6a4de2", "embedding": null, "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f47acf5-b980-47cf-9a6b-4fb4259dbc60", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions revenue.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24a42b96f7d46a448ae49d4b0053ba3f782291892be6496920562f21a5b30671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "354bd007-e730-4626-8176-c2e98604397b", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. "}, "hash": "0268184e75dab32589a03e51ffed7422e5eb5e0f09a7efae964747a14decba2c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "start_char_idx": 77, "end_char_idx": 419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "354bd007-e730-4626-8176-c2e98604397b": {"__data__": {"id_": "354bd007-e730-4626-8176-c2e98604397b", "embedding": null, "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46c8645e-0de5-41e1-9f6a-c052ef6a4de2", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da985442f0309876577c39a260f77a200ab06466a976122b9de4f288e8ef467c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8f6efa5-2f3b-4ef4-8877-881769f00dc3", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "a5ba14a6319e02b307619d0da492abe6e3feaf7c102b50d7bdb2497449e4cc41", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions. ", "start_char_idx": 419, "end_char_idx": 441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8f6efa5-2f3b-4ef4-8877-881769f00dc3": {"__data__": {"id_": "e8f6efa5-2f3b-4ef4-8877-881769f00dc3", "embedding": null, "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "354bd007-e730-4626-8176-c2e98604397b", "node_type": "1", "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "original_text": "Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b34f196fa3d1e956bc0a71b088ead98d276d8bdcb7c7124028c02310d0e2d8b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb0a37a4-80b1-4825-bb61-ca4537ae757b", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "4e5a35a6a97e496d37e4e35d101896120c31ea2816d7ed23a89b5aa02de7a32c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 441, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb0a37a4-80b1-4825-bb61-ca4537ae757b": {"__data__": {"id_": "eb0a37a4-80b1-4825-bb61-ca4537ae757b", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8f6efa5-2f3b-4ef4-8877-881769f00dc3", "node_type": "1", "metadata": {"window": "Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "original_text": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d788ae476f8c7d61fe8394e182db55d380f8679b9b45f6f69e582fcdba77fc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc54cf40-0fec-43b5-bc6d-2710c18f93eb", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. "}, "hash": "60119c5126ac08b4ab69596dc097896455775599b74aab5b001ca6582c86e005", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 683, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc54cf40-0fec-43b5-bc6d-2710c18f93eb": {"__data__": {"id_": "dc54cf40-0fec-43b5-bc6d-2710c18f93eb", "embedding": null, "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb0a37a4-80b1-4825-bb61-ca4537ae757b", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income. ", "original_text": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e50a26c15c1d3092d2fa2de5cc83e0b859d2cf6bd6342bfbfd665236bdf3508d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "231aa79d-6df6-45e2-b0c9-f5f1a00a92db", "node_type": "1", "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. "}, "hash": "18c43417f918aa6735a02afc7093aaacab7916304ba6215a1b55ba2b57d3e6d1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "start_char_idx": 1039, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "231aa79d-6df6-45e2-b0c9-f5f1a00a92db": {"__data__": {"id_": "231aa79d-6df6-45e2-b0c9-f5f1a00a92db", "embedding": null, "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc54cf40-0fec-43b5-bc6d-2710c18f93eb", "node_type": "1", "metadata": {"window": "Healthcare Solutions.  Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "original_text": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dade7b701d7343f880aa28bd93975c05722b94379fe699537b730d00ad9426fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a26b57e0-e998-4552-9db1-31e28d9031ac", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions'\noperating income. "}, "hash": "2ea773c87f8f5ec0957304bfc8fec635474f0402b094aae7a71db9fdc3566542", "class_name": "RelatedNodeInfo"}}, "text": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "start_char_idx": 1229, "end_char_idx": 1377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a26b57e0-e998-4552-9db1-31e28d9031ac": {"__data__": {"id_": "a26b57e0-e998-4552-9db1-31e28d9031ac", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions'\noperating income. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "231aa79d-6df6-45e2-b0c9-f5f1a00a92db", "node_type": "1", "metadata": {"window": "Adjusted gross\nprofit as a percentage of revenue was 3.84 percent in the fiscal 2022 second quarter, an increase of 76 basis points when\ncompared to the prior year quarter primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42cf80ea230cd9562db189600d044327982a3c2948acf12c6b0ef31fe45898cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n"}, "hash": "dbdc7fc5b067f984488fa74e09b66637f162a5c09f603196ca3c01edfc6318b1", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions'\noperating income. ", "start_char_idx": 1377, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6": {"__data__": {"id_": "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a26b57e0-e998-4552-9db1-31e28d9031ac", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the second quarter of fiscal 2022, adjusted operating expenses were $1.3 billion, a 61.4\npercent increase, primarily as a result of increases in distribution, selling, and administrative expenses and depreciation\nexpense compared to the prior year quarter primarily due to the June 2021 acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Healthcare Solutions'\noperating income. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de0c4e0f6bb805d2292a1fbdb1abd027c015c7eba52fa1bf024659c87cff6bc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e32a2296-085c-40a8-93bd-187461cd2cbc", "node_type": "1", "metadata": {"window": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "0329aaee0275a311730bf9d7b66e0aa654941bfecc3e9ac1411b248b42cf0773", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "start_char_idx": 1417, "end_char_idx": 1742, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e32a2296-085c-40a8-93bd-187461cd2cbc": {"__data__": {"id_": "e32a2296-085c-40a8-93bd-187461cd2cbc", "embedding": null, "metadata": {"window": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the second quarter of fiscal 2022, adjusted operating income was $916.6 million, a 29.7\npercent increase compared to the same period in the prior fiscal year.  The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "original_text": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8164a8569c07e7a65b04ec25f0b2232ed5b970665b5261204df24a77d6a1d27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8adb4f5c-64cf-4768-ab32-a848522e724f", "node_type": "1", "metadata": {"window": "Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "1402abe171acbd41579b221dbb7f191782aa2a2df59f27c32f2fc1aac17ddfb3", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1742, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8adb4f5c-64cf-4768-ab32-a848522e724f": {"__data__": {"id_": "8adb4f5c-64cf-4768-ab32-a848522e724f", "embedding": null, "metadata": {"window": "Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e32a2296-085c-40a8-93bd-187461cd2cbc", "node_type": "1", "metadata": {"window": "The increase was due to a 260.8 percent increase in\noperating income within International Healthcare Solutions and an 11.4 percent increase in U.S.  Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da225ffbf2be8dd73bffdc85ebfa2dc08a7909f279cccba0cbb16a97fccf08b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52353ed9-3a39-4162-b3b4-657b52e76590", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n"}, "hash": "905fc50799a15234d10fb18acea81458a94c59ff4c5462cc131033664c0b92d4", "class_name": "RelatedNodeInfo"}}, "text": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 1841, "end_char_idx": 2059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52353ed9-3a39-4162-b3b4-657b52e76590": {"__data__": {"id_": "52353ed9-3a39-4162-b3b4-657b52e76590", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8adb4f5c-64cf-4768-ab32-a848522e724f", "node_type": "1", "metadata": {"window": "Healthcare Solutions'\noperating income.  Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09d9f542c57b7e044ff33ef32a7b147008da7fe56b8168550988e4ab1b0bbdca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc847b73-574d-4c1c-a052-afa88dd69360", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n"}, "hash": "dad4357dcb3f5e84523016b95cd34ecb6c49c26496554d3a1c6e0f6339a853a3", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "start_char_idx": 2059, "end_char_idx": 2228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc847b73-574d-4c1c-a052-afa88dd69360": {"__data__": {"id_": "bc847b73-574d-4c1c-a052-afa88dd69360", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52353ed9-3a39-4162-b3b4-657b52e76590", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was 1.59 percent in the fiscal 2022 second quarter,\nan increase of 15 basis points when compared to the prior year quarter primarily due to the June 2021 Alliance Healthcare\nacquisition and fees earned relating to the distribution of government-owned COVID-19 treatments.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d52877962e9ff672c5c041c84ca8813de2077883a49e26d62693d9764967f69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cd69bc3-b886-421a-8798-2c1a3fb64c34", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "8582a18b75995e68102ca611824acfb410f618233531ab29655e015f3b431edf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "start_char_idx": 2228, "end_char_idx": 2438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cd69bc3-b886-421a-8798-2c1a3fb64c34": {"__data__": {"id_": "1cd69bc3-b886-421a-8798-2c1a3fb64c34", "embedding": null, "metadata": {"window": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc847b73-574d-4c1c-a052-afa88dd69360", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64be69275b4bb70c6a869c0648f56cdcb9d42df4a17d98d892024ac86e3fe1b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1eacad3-bd48-4d91-8330-e1587cb8c2ae", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n"}, "hash": "3aa8e1f04af9fae7d0a916f91ee2459c8ae3cbecbb82821aaa7f1c5473de11f6", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2438, "end_char_idx": 2548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1eacad3-bd48-4d91-8330-e1587cb8c2ae": {"__data__": {"id_": "c1eacad3-bd48-4d91-8330-e1587cb8c2ae", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cd69bc3-b886-421a-8798-2c1a3fb64c34", "node_type": "1", "metadata": {"window": "In the second quarter of\nfiscal 2022, net interest expense of $52.9 million was up 53.3 percent versus the prior year quarter due to an increase in debt\nas a result of the June 2021 acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e91294d1778bc658bba10bb62812a0763379ae6cc1476c928d815a815bd424ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a1770e9-feb4-4b76-b1b5-9863e3905ac3", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. "}, "hash": "7b10de1338a9215f654e745f6f837fb7ecedd510169f5dc47964fe6ef3beb8e2", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "start_char_idx": 2548, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a1770e9-feb4-4b76-b1b5-9863e3905ac3": {"__data__": {"id_": "7a1770e9-feb4-4b76-b1b5-9863e3905ac3", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1eacad3-bd48-4d91-8330-e1587cb8c2ae", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the second quarter of fiscal 2022 compared\nto 21.9 percent in the prior year quarter.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions. ", "original_text": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "835bba5147e0c4897efd4d92aceadb716be740b04093df1f9a83c4205ff13f97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdf221cd-ec1e-4add-866b-4be0a7416a44", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. "}, "hash": "c67174d37e4ea0004b70dfb8fe96f8d270e244ef59063bfab2846edff79fbe85", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "start_char_idx": 2935, "end_char_idx": 3061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdf221cd-ec1e-4add-866b-4be0a7416a44": {"__data__": {"id_": "cdf221cd-ec1e-4add-866b-4be0a7416a44", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a1770e9-feb4-4b76-b1b5-9863e3905ac3", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was $3.22 in the second quarter of fiscal 2022, a\n27.3 percent increase compared to $2.53 in the previous fiscal year\u2019s second quarter.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S. ", "original_text": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e902f058c750b23572600d804cbd954f7976edd67e61afbfd27f23394b421140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4adebeee-b41b-434f-a2bb-96c92749a420", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. "}, "hash": "927cd1e58f1a9cde16b485f7451b51757745e8a2e3f3bd1c4228042269b219bd", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "start_char_idx": 3061, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4adebeee-b41b-434f-a2bb-96c92749a420": {"__data__": {"id_": "4adebeee-b41b-434f-a2bb-96c92749a420", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdf221cd-ec1e-4add-866b-4be0a7416a44", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "original_text": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c21217636d8d3fb8e7e469214c8414801ffaa30eba78d4af4e38cf0e9997741b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccfc9748-b531-4fb9-8a67-a169d12de2da", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. "}, "hash": "883b4801ba56b1c80c367fb40871a6f28b46d743b2ad69987f3579bf3ffe5afa", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "start_char_idx": 3181, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccfc9748-b531-4fb9-8a67-a169d12de2da": {"__data__": {"id_": "ccfc9748-b531-4fb9-8a67-a169d12de2da", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4adebeee-b41b-434f-a2bb-96c92749a420", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the second quarter of fiscal 2022 were 212.0 million, a 2.3 percent increase versus\nthe prior fiscal year second quarter primarily resulting from stock option exercises, restricted stock vesting, and the June 2021\nissuance of 2 million shares of the Company's common stock to WBA in connection with the acquisition of Alliance\nHealthcare.\n Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "original_text": "Healthcare Solutions and\nInternational Healthcare Solutions. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39ee750c6f9debf214455ce7f566cbc5dbcd3f65c0e8d176900d0b5d0eff2263", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "180553d2-9bd4-4600-b1e0-73803e00e664", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. "}, "hash": "36875c45367bf7a3f039f92f63b2d3341cbe4e632306a836555ad392b68ef21b", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 42, "end_char_idx": 47, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "180553d2-9bd4-4600-b1e0-73803e00e664": {"__data__": {"id_": "180553d2-9bd4-4600-b1e0-73803e00e664", "embedding": null, "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccfc9748-b531-4fb9-8a67-a169d12de2da", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company is organized geographically based upon the products and services it provides to its customers.  In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "baf26a6f747c01c7f92ea45b51bbbc59f7040ffe16c2eaf5389c8e8f3290d0ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. "}, "hash": "1656455e00932ea9ad7deca1d234456a5db5bf28a4e046e0bbc594c207b29075", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "start_char_idx": 3247, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5": {"__data__": {"id_": "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5", "embedding": null, "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "180553d2-9bd4-4600-b1e0-73803e00e664", "node_type": "1", "metadata": {"window": "In the first quarter of\nfiscal 2022, the Company re-aligned its reporting structure under two reportable segments: U.S.  Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S. ", "original_text": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fffc62ef519afd045e7c77c51af517e81f26240314665d42b7c50bd4887218f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n"}, "hash": "6e3236453faaeecfee89d4ff2624767730b02b1e117c39a59a3ecdc2fddc0ee3", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "start_char_idx": 3421, "end_char_idx": 3547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4": {"__data__": {"id_": "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5", "node_type": "1", "metadata": {"window": "Healthcare Solutions and\nInternational Healthcare Solutions.  U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S. ", "original_text": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a9c04b654e3a75520db0ab803df9e99f51b30631f94c7c733c07390d85655732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c55a5155-e1af-4e58-a00a-28bd21d91d8e", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "original_text": "U.S. "}, "hash": "38e927a2137cb79b9ff6c040b7acb3412627ba63b8069e63eff9ff60439b83c4", "class_name": "RelatedNodeInfo"}}, "text": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "start_char_idx": 3547, "end_char_idx": 3665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c55a5155-e1af-4e58-a00a-28bd21d91d8e": {"__data__": {"id_": "c55a5155-e1af-4e58-a00a-28bd21d91d8e", "embedding": null, "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "original_text": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d541e394c5e61b92e43e90a62290be7d4105450d9760f28674897043682b277", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. "}, "hash": "aca3924f1ef21a186578e20791ec20b94be7843ed809f2877620b54bf7350dea", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 42, "end_char_idx": 47, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab": {"__data__": {"id_": "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab", "embedding": null, "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c55a5155-e1af-4e58-a00a-28bd21d91d8e", "node_type": "1", "metadata": {"window": "Healthcare Solutions consists of the legacy Pharmaceutical Distribution Services reportable\nsegment (excluding Profarma), MWI Animal Health, Xcenda, Lash Group, and ICS 3PL.  International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "original_text": "U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9da7034fbd5cbfbb7921a99f4c1e2872b5a7981408ae541b33ea47892ed19200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72d04838-777a-4df5-a88d-76c3421b2d2a", "node_type": "1", "metadata": {"window": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. "}, "hash": "17077101eccea4433086ce0bec98e11a717b4ba0939bb2d6001632b1b16be9e8", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions\nU.S. ", "start_char_idx": 3670, "end_char_idx": 3696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72d04838-777a-4df5-a88d-76c3421b2d2a": {"__data__": {"id_": "72d04838-777a-4df5-a88d-76c3421b2d2a", "embedding": null, "metadata": {"window": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab", "node_type": "1", "metadata": {"window": "International Healthcare Solutions consists of\nAlliance Healthcare, World Courier, Innomar, Profarma, and Profarma Specialty.  The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions\nU.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbe3025312ac84b388a81699c7c1895a979bbac6f4fde7cdf452a7f8aba7be3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac9ece38-2107-4de6-b4fd-a51f703bd3de", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n"}, "hash": "ed6127754b6919510a6514fada9a494d1f8be62a46b1b22860d70ba1480812a9", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "start_char_idx": 3696, "end_char_idx": 4029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac9ece38-2107-4de6-b4fd-a51f703bd3de": {"__data__": {"id_": "ac9ece38-2107-4de6-b4fd-a51f703bd3de", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72d04838-777a-4df5-a88d-76c3421b2d2a", "node_type": "1", "metadata": {"window": "The Company\u2019s previously reported segment results\nhave been revised to conform to its re-aligned reporting structure.\n U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81bbe93bc7e75a863bdbd5caf8a51c76db7766f80a88e0f76e2ade5ef758b33f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b522411a-0bdd-420c-bd93-1311970da561", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3"}, "hash": "62340ea502992bd5a75b546647dfd9399b8ec9ee1178b170cb09464ee0533afe", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "start_char_idx": 4029, "end_char_idx": 4380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b522411a-0bdd-420c-bd93-1311970da561": {"__data__": {"id_": "b522411a-0bdd-420c-bd93-1311970da561", "embedding": null, "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f087d693-900b-4146-a315-74ec095a42d5", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c01c634f8c4b31b9c65f04397409c349c7d87f8b6e8d828335373fbafafa61b3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac9ece38-2107-4de6-b4fd-a51f703bd3de", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a52cafe4e8ded44098dff098588a5d8d378de7ba727d74207c7bed3c4b14398a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b3959f-f443-4ffd-8698-80fcac7785c2", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "original_text": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. "}, "hash": "937d257de80b3228afb9bc4d4886e6d576cca379848ad8a15b184dd42551dd50", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions\n3", "start_char_idx": 4380, "end_char_idx": 4416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b3959f-f443-4ffd-8698-80fcac7785c2": {"__data__": {"id_": "98b3959f-f443-4ffd-8698-80fcac7785c2", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "original_text": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b522411a-0bdd-420c-bd93-1311970da561", "node_type": "1", "metadata": {"window": "Healthcare Solutions\nU.S.  Healthcare Solutions revenue was $50.9 billion in the second quarter of fiscal 2022, an increase of 5.8 percent compared to the\nsame quarter in the prior fiscal year primarily due to overall market growth and increased sales to specialty physician practices,\npartially offset by a decline in sales of commercial COVID-19 treatments.  Segment operating income of $729.5 million in the second\nquarter of fiscal 2022 was up 11.4 percent compared to the same period in the previous fiscal year as a result of an increase in gross\nprofit, including fees earned relating to the distribution of government-owned COVID-19 treatments and gross profit on sales to\nspecialty physician practices.\n International Healthcare Solutions\n3", "original_text": "International Healthcare Solutions\n3", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21280dd615bfc4b68fddb700c20f2ebc68427753b04c8930e89a22ea5d6f761d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21d8a1f3-b77b-4cb7-b358-275a722a9024", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "original_text": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n"}, "hash": "3c7b02f9ddee179efb1239d443f9ba28389b947b7fc41fc188fcc67ca3fe728d", "class_name": "RelatedNodeInfo"}}, "text": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "start_char_idx": 0, "end_char_idx": 245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21d8a1f3-b77b-4cb7-b358-275a722a9024": {"__data__": {"id_": "21d8a1f3-b77b-4cb7-b358-275a722a9024", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "original_text": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b3959f-f443-4ffd-8698-80fcac7785c2", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "original_text": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a781edd8f0a27a03cb7ce3111a62f540ea9af6a1000c9459ba374a195c4a5b4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "462d415d-ca2e-4b44-a2b0-f9c700d5f754", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S. "}, "hash": "fe39582f80b04d2276514aa7f84d21dcee13efd4985a6d3663317341da4e3569", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n", "start_char_idx": 245, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "462d415d-ca2e-4b44-a2b0-f9c700d5f754": {"__data__": {"id_": "462d415d-ca2e-4b44-a2b0-f9c700d5f754", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21d8a1f3-b77b-4cb7-b358-275a722a9024", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "original_text": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "073ab229bb2a3b3f031b97cbde39c0d818869f6eb73c8c48b2c289a963d6d671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "original_text": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. "}, "hash": "26cd92987eeb75f987ecf762f7a1b614d30606df3e462bd0485c7ce03ebd97b4", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S. ", "start_char_idx": 424, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf": {"__data__": {"id_": "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf", "embedding": null, "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "original_text": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "462d415d-ca2e-4b44-a2b0-f9c700d5f754", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "original_text": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae82926671afae6f93946ade46b096590cee0fc3c915df2efe1cf760693e31d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6820aa0c-810d-4ccb-8b8a-959a9fee043b", "node_type": "1", "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "original_text": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n"}, "hash": "4b85e7332328643e86be2bc304e13b997a4ad83c0d81cd56b28ea3c9eb03c54a", "class_name": "RelatedNodeInfo"}}, "text": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "start_char_idx": 663, "end_char_idx": 814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6820aa0c-810d-4ccb-8b8a-959a9fee043b": {"__data__": {"id_": "6820aa0c-810d-4ccb-8b8a-959a9fee043b", "embedding": null, "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "original_text": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf", "node_type": "1", "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "original_text": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f84444cdbe732149fea34af3a5d432d3ce5c3e02afab1e6053aeba7911ddf1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4e622d-b4ee-4221-b30a-af4e5d864616", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "original_text": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. "}, "hash": "45f97f2312a3fceec0a2bd7398c22a2fa875fd78ddff3ded2fbf5546a503ee9f", "class_name": "RelatedNodeInfo"}}, "text": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "start_char_idx": 814, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4e622d-b4ee-4221-b30a-af4e5d864616": {"__data__": {"id_": "ed4e622d-b4ee-4221-b30a-af4e5d864616", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "original_text": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6820aa0c-810d-4ccb-8b8a-959a9fee043b", "node_type": "1", "metadata": {"window": "Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "original_text": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc68620445e6a5e780765bab0dd7336cd0678426191d3f99cd07fedcbd771ce1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71eeb3e4-57e4-4350-9f64-bfa36f5c859d", "node_type": "1", "metadata": {"window": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "original_text": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n"}, "hash": "de203580d4a9d18d902b700455b9ed1d47991778994296b0026d606933e76572", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "start_char_idx": 912, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71eeb3e4-57e4-4350-9f64-bfa36f5c859d": {"__data__": {"id_": "71eeb3e4-57e4-4350-9f64-bfa36f5c859d", "embedding": null, "metadata": {"window": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "original_text": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4e622d-b4ee-4221-b30a-af4e5d864616", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "original_text": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc32bc17b0ae2e2f28596b499fe6fae0c0a842d78f48be11210b010349611b91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ded8d54-4da6-44fa-8f3b-f70fc533a967", "node_type": "1", "metadata": {"window": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n"}, "hash": "f3ed66fe40b70bc2fb2cbce4ae5c6156f1a68b4511dd15be416fbe25e5d69756", "class_name": "RelatedNodeInfo"}}, "text": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "start_char_idx": 1164, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ded8d54-4da6-44fa-8f3b-f70fc533a967": {"__data__": {"id_": "6ded8d54-4da6-44fa-8f3b-f70fc533a967", "embedding": null, "metadata": {"window": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71eeb3e4-57e4-4350-9f64-bfa36f5c859d", "node_type": "1", "metadata": {"window": "This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S.  states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "original_text": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23097ee6462505611b4077ee0f51de34d5bfa3a5b96ebab95890daa8122fb8c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e98362b-4f31-4b00-984a-b9d227e4411c", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. "}, "hash": "9baca4689b6b9a21919145acc9d0f4235f7ca8ab6fea66a25373ad13b91575c0", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "start_char_idx": 1309, "end_char_idx": 1546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e98362b-4f31-4b00-984a-b9d227e4411c": {"__data__": {"id_": "0e98362b-4f31-4b00-984a-b9d227e4411c", "embedding": null, "metadata": {"window": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ded8d54-4da6-44fa-8f3b-f70fc533a967", "node_type": "1", "metadata": {"window": "states and\nterritories, and 21 national pharmacy partners, which includes Good Neighbor Pharmacy.\n AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff7e918fe88159a1062a37ea7b1ade68d6047d717f55bd86ac59cf5561503196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d117743-6f11-4f66-b3c8-a45695582ee3", "node_type": "1", "metadata": {"window": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "original_text": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n"}, "hash": "080a049bfe2b9a1fd64f6382bbbcc7a477af14d5e9747f1674af296fb147c2f4", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "start_char_idx": 1546, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d117743-6f11-4f66-b3c8-a45695582ee3": {"__data__": {"id_": "2d117743-6f11-4f66-b3c8-a45695582ee3", "embedding": null, "metadata": {"window": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "original_text": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e98362b-4f31-4b00-984a-b9d227e4411c", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced the establishment of AB Health Ventures, a dedicated corporate venture capital fund that will\ninvest in and partner with emerging healthcare startup companies working to transform healthcare for people and animals\nglobally.  AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "411c39f9760596c9292ac1fab6509292515f66bb0da75b6919f862961f85741d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d57945e-316a-44b9-8f36-9f3e15ccafc2", "node_type": "1", "metadata": {"window": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "82b7d9ddb6f4d68388421558ae4d63744bd6f566c779ee3305fb22ba129c85d6", "class_name": "RelatedNodeInfo"}}, "text": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "start_char_idx": 1720, "end_char_idx": 2045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d57945e-316a-44b9-8f36-9f3e15ccafc2": {"__data__": {"id_": "7d57945e-316a-44b9-8f36-9f3e15ccafc2", "embedding": null, "metadata": {"window": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d117743-6f11-4f66-b3c8-a45695582ee3", "node_type": "1", "metadata": {"window": "AB Health Ventures initially launched with $150 million allocated for investment in early-to mid-stage health-related\nstartups around the world.\n AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "original_text": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e8c26c4970c6435f6a59a37bf469295913655ee6e401f783a3a312cdc7807a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c710aa-3305-409d-b505-8173f4200474", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "c7828009bda9e20e8379f818d5a8a9ff7abc3d190684a259e15a3c7f4f300f38", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 2045, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c710aa-3305-409d-b505-8173f4200474": {"__data__": {"id_": "51c710aa-3305-409d-b505-8173f4200474", "embedding": null, "metadata": {"window": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d57945e-316a-44b9-8f36-9f3e15ccafc2", "node_type": "1", "metadata": {"window": "AmerisourceBergen signed the United Nations Women\u2019s Empowerment Principles, publicly and firmly committing to taking\nthe necessary steps to advance gender equality and empower women in places of work and in communities around the\nworld.\n AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "original_text": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6118c5b6837c8e9d54465426bdb245c5bdaaabd18bded264780184adbd51c79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19e20805-d032-41da-b073-49da000834e3", "node_type": "1", "metadata": {"window": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. "}, "hash": "67c05a66252a9ef1685e7e7e1d54159e62a793efa61d4dbcd8970e50015e846d", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 2289, "end_char_idx": 2421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19e20805-d032-41da-b073-49da000834e3": {"__data__": {"id_": "19e20805-d032-41da-b073-49da000834e3", "embedding": null, "metadata": {"window": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c710aa-3305-409d-b505-8173f4200474", "node_type": "1", "metadata": {"window": "AmerisourceBergen announced the launch of a supply chain elective course at Xavier University of Louisiana\u2019s College of\nPharmacy, a top-ranked historically Black university.  The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5233f4402882b62dfd8a470459b3c3d0a0d877d5f3a8c78f0a40bc86602886a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "original_text": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. "}, "hash": "6a08f44c2903447203065ca4adfd1c878b497726110d4ef6faaf69bca32e9336", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "start_char_idx": 2421, "end_char_idx": 2639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4": {"__data__": {"id_": "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "original_text": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19e20805-d032-41da-b073-49da000834e3", "node_type": "1", "metadata": {"window": "The Advanced Pharmacy Practice Experience Pharmacy Distribution\nLeadership Rotation course exposes students to the interconnectivity between pharmaceutical supply chain stakeholders such\nas distributors, manufacturers, and providers, and gives students an understanding of its essential role in the delivery of\npatient care.\n Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "original_text": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1935b6f2afd3977b73a132bb67ac3a2c321919a1f2501959e91f09b96bfcb0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n"}, "hash": "eb8f2e664d89350e12d1dee733069987c35bb146f91b7d05c060898f6d9a68ab", "class_name": "RelatedNodeInfo"}}, "text": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "start_char_idx": 2639, "end_char_idx": 2853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7": {"__data__": {"id_": "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "original_text": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b833177b307d063647c5a6f3a422467819132515c81b36af4c38a342787b811", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f47fe40-f102-44f9-bc64-1707ee2be94e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. "}, "hash": "35aabb7577543f4b4d6bfc9c79aeab1817f6c99b5d37578eef29777469db1d2a", "class_name": "RelatedNodeInfo"}}, "text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "start_char_idx": 2853, "end_char_idx": 3006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f47fe40-f102-44f9-bc64-1707ee2be94e": {"__data__": {"id_": "3f47fe40-f102-44f9-bc64-1707ee2be94e", "embedding": null, "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "original_text": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c39879a070df20ba702a202fe459bbecd909b053dcb9163a2bb16137d5b29efa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a3872e-02c9-4919-825e-def5ef9a7cfd", "node_type": "1", "metadata": {"window": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n"}, "hash": "0151fd4397347416b95824371cdd777670d8879d115c99a49abcfae725228f27", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "start_char_idx": 3006, "end_char_idx": 3172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a3872e-02c9-4919-825e-def5ef9a7cfd": {"__data__": {"id_": "16a3872e-02c9-4919-825e-def5ef9a7cfd", "embedding": null, "metadata": {"window": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f47fe40-f102-44f9-bc64-1707ee2be94e", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2022 Expectations on an Adjust ed (non-GAAP) Basis\nAmerisourceBergen is now updating its fiscal year 2022 financial guidance to reflect the stronger than expected performance of\nseveral of its businesses.  While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58c8596f528694f1a2a838169affc037eb98fdfacb3902b3c0190cc4289b75e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85f8c535-b4f3-4b22-b6ab-a032a76499d2", "node_type": "1", "metadata": {"window": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n"}, "hash": "bae57bc9e8f0a747b833094be6bbbd8d84db8f04bd8d47314556b70e2f734eb6", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "start_char_idx": 3172, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85f8c535-b4f3-4b22-b6ab-a032a76499d2": {"__data__": {"id_": "85f8c535-b4f3-4b22-b6ab-a032a76499d2", "embedding": null, "metadata": {"window": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a3872e-02c9-4919-825e-def5ef9a7cfd", "node_type": "1", "metadata": {"window": "While the contribution from COVID treatment distribution was higher than expected in the second quarter\nof fiscal 2022, the Company\u2019s full year expectations from COVID treatment distribution are largely unchanged.  The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4720fdf52e9c98c2d32bedd1ab6317b331225b1e92e84e33edbc4c6338384602", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4"}, "hash": "3f80ad6c476b0a51a06aabbaaae7add815cc3d047a35d8589ad6db59a10fb469", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "start_char_idx": 3334, "end_char_idx": 3462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b": {"__data__": {"id_": "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b", "embedding": null, "metadata": {"window": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91dbd7b34fb373a33813f3aea7911f773af5c23f4371c824498b8b107435fd38", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85f8c535-b4f3-4b22-b6ab-a032a76499d2", "node_type": "1", "metadata": {"window": "The Company now\nexpects:\nAdjusted Diluted Earnings Per Share to be in the range of $10.80 to $11.05, raised from the previous range of $10.60 to\n$10.90.\n Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0498faa8f96dc8e1f63e734a7caef60b4bd57b0434e7c77879e80ad1262d84b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4242b347-f9d9-4153-8483-237443db8a2f", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "original_text": "stockholders of record at the close of business on May 16, 2022.\n"}, "hash": "b97bea090eae10a38f91b24ca3a865c271e16f6eeef4c91e9174e0443d674a95", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "start_char_idx": 3462, "end_char_idx": 3604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4242b347-f9d9-4153-8483-237443db8a2f": {"__data__": {"id_": "4242b347-f9d9-4153-8483-237443db8a2f", "embedding": null, "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "original_text": "stockholders of record at the close of business on May 16, 2022.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b", "node_type": "1", "metadata": {"window": "Additional expectations now include:\nAdjusted operating income to grow at least in the high-teens percent range, up from growth in the high-teens percent range;\nU.S.  Healthcare Solutions operating income to be in the range of $2.42 to $2.48 billion, representing growth of 7% to\n10%, up from a range of $2.375 to $2.45 billion.\n All other previously communicated aspects of the Company's fiscal year 2022 financial guidance and assumptions remain the same.\n Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "original_text": "Dividend Declaration\nThe Company's Board of Directors declared a quarterly cash dividend of $0.46 per common share, payable May 31, 2022, to\n4", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88d5a6c6e47791d9d28b10a30e314475c8637b9faee1110bcdd3ce53d31b9ecf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "488adf8c-47cd-47bb-a703-4265d09feabf", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "original_text": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective. "}, "hash": "cc3ce88dc72dd415026b30643fcd22d325ef4d758c20cd57c0d8a0d5c5c465d1", "class_name": "RelatedNodeInfo"}}, "text": "stockholders of record at the close of business on May 16, 2022.\n", "start_char_idx": 0, "end_char_idx": 65, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "488adf8c-47cd-47bb-a703-4265d09feabf": {"__data__": {"id_": "488adf8c-47cd-47bb-a703-4265d09feabf", "embedding": null, "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "original_text": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4242b347-f9d9-4153-8483-237443db8a2f", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "original_text": "stockholders of record at the close of business on May 16, 2022.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "287d148e640a4f97eb00bc7222edf31914e35dfb5c71f4844cb1bb231015b086", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "103aacfe-271b-48e9-bf23-07819c3c14f5", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "original_text": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement. "}, "hash": "9379109d9c6bc72a64a32cb9b57ca1b78b2c50dcdd99c2c9aae6b23ebab2ba34", "class_name": "RelatedNodeInfo"}}, "text": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective. ", "start_char_idx": 65, "end_char_idx": 280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "103aacfe-271b-48e9-bf23-07819c3c14f5": {"__data__": {"id_": "103aacfe-271b-48e9-bf23-07819c3c14f5", "embedding": null, "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "original_text": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "488adf8c-47cd-47bb-a703-4265d09feabf", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "original_text": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e07067c9107aa4871c6a87a8d8134eac6356539433415a515fffa6cd47f98f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44f94ba3-53ee-4d0c-b791-0e03b8dedd13", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. "}, "hash": "c34107d7172e938ac093fc2219c5a2979718803bf21b7a332a6d378f87f3d051", "class_name": "RelatedNodeInfo"}}, "text": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement. ", "start_char_idx": 280, "end_char_idx": 550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44f94ba3-53ee-4d0c-b791-0e03b8dedd13": {"__data__": {"id_": "44f94ba3-53ee-4d0c-b791-0e03b8dedd13", "embedding": null, "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "103aacfe-271b-48e9-bf23-07819c3c14f5", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "original_text": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1192d2df84ec1a259741697f46a8dc1e839b499494293605538c5468528cdcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4740808e-9b16-4b71-b391-ad4fb3c9fa4e", "node_type": "1", "metadata": {"window": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022. ", "original_text": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. "}, "hash": "f3085b8ec8741cdb9230fc7d60d51ea2334b401c514f69665a298b34f3547ad5", "class_name": "RelatedNodeInfo"}}, "text": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "start_char_idx": 550, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4740808e-9b16-4b71-b391-ad4fb3c9fa4e": {"__data__": {"id_": "4740808e-9b16-4b71-b391-ad4fb3c9fa4e", "embedding": null, "metadata": {"window": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022. ", "original_text": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44f94ba3-53ee-4d0c-b791-0e03b8dedd13", "node_type": "1", "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "original_text": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab8fe3733a9aa7ad40a2bb1a2a73525607341c4f90567822b0b04f3ad4f3051b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b017f882-8322-45ed-acea-ee694b2528be", "node_type": "1", "metadata": {"window": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n"}, "hash": "94c286ad53599f17cc1c20ecd5f205c72630c0af669cc2a0de5bcb0d1c2017df", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "start_char_idx": 760, "end_char_idx": 1148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b017f882-8322-45ed-acea-ee694b2528be": {"__data__": {"id_": "b017f882-8322-45ed-acea-ee694b2528be", "embedding": null, "metadata": {"window": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4740808e-9b16-4b71-b391-ad4fb3c9fa4e", "node_type": "1", "metadata": {"window": "Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022. ", "original_text": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a07eedb6e8054c5c465e3b1afe74e4ea2313e11d5c210d6281599e82ae0d240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b3e931b-da63-4662-a218-9dbca34a9b81", "node_type": "1", "metadata": {"window": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "9ca11ada6629e0aa5fc3d1a59900506cd3d91dd2ecfcfc4af820522ca48bdb44", "class_name": "RelatedNodeInfo"}}, "text": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "start_char_idx": 1148, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b3e931b-da63-4662-a218-9dbca34a9b81": {"__data__": {"id_": "4b3e931b-da63-4662-a218-9dbca34a9b81", "embedding": null, "metadata": {"window": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b017f882-8322-45ed-acea-ee694b2528be", "node_type": "1", "metadata": {"window": "As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c15fbbf716d3267d608375279ace9ab10afdaea9eb609a248a4948bcb6c832b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22fde089-bdcb-408e-a970-abedcbefe5f3", "node_type": "1", "metadata": {"window": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on May 4, 2022. "}, "hash": "c6a91a04c96a119f8eaaae10c0f34ffeaa245f153e4d2dd87ba9712712f7a5f7", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 1306, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22fde089-bdcb-408e-a970-abedcbefe5f3": {"__data__": {"id_": "22fde089-bdcb-408e-a970-abedcbefe5f3", "embedding": null, "metadata": {"window": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on May 4, 2022. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b3e931b-da63-4662-a218-9dbca34a9b81", "node_type": "1", "metadata": {"window": "The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors.  Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b6930ac7d80240655c6f3d4889cd59241e94729b2208d6861d44b561da07c39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e", "node_type": "1", "metadata": {"window": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "73d58795dcbb37e4a778fbdc0b6ead45b0480c92f7fde38a94e6e4149b710d52", "class_name": "RelatedNodeInfo"}}, "text": "ET on May 4, 2022. ", "start_char_idx": 1421, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e": {"__data__": {"id_": "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e", "embedding": null, "metadata": {"window": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22fde089-bdcb-408e-a970-abedcbefe5f3", "node_type": "1", "metadata": {"window": "Additionally, on May 2, 2022, the Company and the two other national pharmaceutical distributors reached an\nagreement to pay up to $518 million in a settlement with the State of Washington and participating subdivisions to resolve opioid-\nrelated claims, consistent with Washington\u2019s allocations under the comprehensive settlement agreement, as well as certain\nattorneys\u2019 fees and costs.  The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599. ", "original_text": "ET on May 4, 2022. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2bd19b246c04a6f59b5f75012e990f38870dadfc97caf22128e7ffb76f57a5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b97032b-c710-4582-9318-fdc441afd6a5", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. "}, "hash": "4528ba2a7bfc64d75e7bb8806559fe51c07ec816bcbd630fca2e4b0b758dc53e", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 1440, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b97032b-c710-4582-9318-fdc441afd6a5": {"__data__": {"id_": "7b97032b-c710-4582-9318-fdc441afd6a5", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e", "node_type": "1", "metadata": {"window": "The Washington settlement agreement brings the number of States with whom the Company has recently\nsettled opioid-related claims to 47 of 49 eligible states.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752. ", "original_text": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "495ba634f1d768c15d0da83a2bea48dc8cd2e553b8bd83739e3624f4dcaa7027", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6257716d-6e80-460b-bb94-edb98db4c886", "node_type": "1", "metadata": {"window": "ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. "}, "hash": "3de94f30a74971597bb09d98f82530645d7200eb58d84a1cb16fcef7291b21c3", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "start_char_idx": 1557, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6257716d-6e80-460b-bb94-edb98db4c886": {"__data__": {"id_": "6257716d-6e80-460b-bb94-edb98db4c886", "embedding": null, "metadata": {"window": "ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b97032b-c710-4582-9318-fdc441afd6a5", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afe4c1b8be210de2822aa4a5a7406bf678a8caa0b7e7a66570ba02d6f0821345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf08625-1431-4b93-8de7-c596669296a7", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 562752. "}, "hash": "5899e592662fa6bd9e8971e5bb15cea9dafba721cf635382b46a910314860710", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "start_char_idx": 1796, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf08625-1431-4b93-8de7-c596669296a7": {"__data__": {"id_": "0cf08625-1431-4b93-8de7-c596669296a7", "embedding": null, "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 562752. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6257716d-6e80-460b-bb94-edb98db4c886", "node_type": "1", "metadata": {"window": "ET on May 4, 2022.  A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "original_text": "From outside the United States and Canada, dial +1 (929) 526-1599. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26e2bdcaac9646ebc2befc46eaa9babe37672c09368a0bfc71544834b4dccc1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "593f6045-bf18-47fc-8f05-2b29f31d585a", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . "}, "hash": "18ad08b0b59b4e9294edbea07d55be1be906308818bb05a9c1d07ba4c0a859f6", "class_name": "RelatedNodeInfo"}}, "text": "The\naccess code for the call will be 562752. ", "start_char_idx": 1863, "end_char_idx": 1908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "593f6045-bf18-47fc-8f05-2b29f31d585a": {"__data__": {"id_": "593f6045-bf18-47fc-8f05-2b29f31d585a", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf08625-1431-4b93-8de7-c596669296a7", "node_type": "1", "metadata": {"window": "A slide presentation for investors has\nalso been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "The\naccess code for the call will be 562752. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7a016710a4118241dfc587d45dad84603119fd2c0b3df1ce100fd7eda8f7db5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2faac357-bf13-4beb-867c-453b77dac32c", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n"}, "hash": "84ea1bb80a7b504fbb9cc9edcfebed7c130a2831c112f193e74aacfbbc31619e", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "start_char_idx": 1908, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2faac357-bf13-4beb-867c-453b77dac32c": {"__data__": {"id_": "2faac357-bf13-4beb-867c-453b77dac32c", "embedding": null, "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "593f6045-bf18-47fc-8f05-2b29f31d585a", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 200-6205.  From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fa82cc881a2809356e32f9c88877dcdfc4f34a02effe4b563fbb2d7de9d1956", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "597e4b85-0c8c-4383-a475-40c27f804b5a", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "811516fdd399e2de32e3883208019126e4c0e89a0ca5bfc4d407f8a1de386fc7", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "start_char_idx": 2005, "end_char_idx": 2128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "597e4b85-0c8c-4383-a475-40c27f804b5a": {"__data__": {"id_": "597e4b85-0c8c-4383-a475-40c27f804b5a", "embedding": null, "metadata": {"window": "The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2faac357-bf13-4beb-867c-453b77dac32c", "node_type": "1", "metadata": {"window": "From outside the United States and Canada, dial +1 (929) 526-1599.  The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78778c06beb88d49c425c6fdd22fa255fdf675fd5291dd6e66b786d157bf8ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ef014f3-43a1-4c58-8a43-27190091ef23", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "46c89cbd30b0ddceb6dd6ebb0c164a2549cd67c6833ed2db1d25c53da0d0351b", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 2128, "end_char_idx": 2198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ef014f3-43a1-4c58-8a43-27190091ef23": {"__data__": {"id_": "6ef014f3-43a1-4c58-8a43-27190091ef23", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "597e4b85-0c8c-4383-a475-40c27f804b5a", "node_type": "1", "metadata": {"window": "The\naccess code for the call will be 562752.  The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b45d939bb60c255e94ebfecf22f595232b6cd4574962beed99f6fc3cfb16fb55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "484e598f-1ac1-400c-ba0c-f1197042861b", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "1f656ca1db59cc5e0eef313bc40fbc4cebef02af39e5a0f3865a418178f24ec6", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 2198, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "484e598f-1ac1-400c-ba0c-f1197042861b": {"__data__": {"id_": "484e598f-1ac1-400c-ba0c-f1197042861b", "embedding": null, "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ef014f3-43a1-4c58-8a43-27190091ef23", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at\ninvestor.amerisourcebergen.com .  Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "024d79141185a475542520be423d988dcc33af4fef17fd514e00f6245c156e6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc9b46fd-5649-4177-9e13-42d5510fef11", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n", "original_text": "To access the telephone replay from within the U.S. "}, "hash": "08bf9d9c48feeec437ecbd60252d33ddc524c5369141b5a6faa377af04213105", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 2368, "end_char_idx": 2510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc9b46fd-5649-4177-9e13-42d5510fef11": {"__data__": {"id_": "cc9b46fd-5649-4177-9e13-42d5510fef11", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "484e598f-1ac1-400c-ba0c-f1197042861b", "node_type": "1", "metadata": {"window": "Users are encouraged to log on to the webcast approximately 10 minutes in advance of the\nscheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b41b722c83fbd0348d5ca544b3811b5024d3975b2e568ac4d8c94dfe88ba3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "833a17d1-2323-434c-bfa7-e1a085e39577", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "original_text": "and Canada, dial (866) 813-9403. "}, "hash": "a238c24096a345d4b60be25290c411b5c311815666703dfebf737db4d950f689", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S. ", "start_char_idx": 2510, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "833a17d1-2323-434c-bfa7-e1a085e39577": {"__data__": {"id_": "833a17d1-2323-434c-bfa7-e1a085e39577", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc9b46fd-5649-4177-9e13-42d5510fef11", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n", "original_text": "To access the telephone replay from within the U.S. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d67a461b9bd6892cabde59c4819aaaa9ffb487134fea45bc4de86f1f0030fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. "}, "hash": "6ba2bbf61ec23c45eb71417f5091aa6ec8e45c5bef64fc9fe7254cf99f6720b2", "class_name": "RelatedNodeInfo"}}, "text": "and Canada, dial (866) 813-9403. ", "start_char_idx": 2562, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9": {"__data__": {"id_": "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "833a17d1-2323-434c-bfa7-e1a085e39577", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "original_text": "and Canada, dial (866) 813-9403. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89194a06fdd6e19e11e92973b11edaf9a5b6bb1ec5526b02a08e976a03be2b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ca59679-c366-442d-80d7-36cdda02b700", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "The access code for the replay is 796214.\n"}, "hash": "bc8c479dc9345f3c116af5c02cbbae536ba730098d897514cd14207be6a6ec22", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "start_char_idx": 2595, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ca59679-c366-442d-80d7-36cdda02b700": {"__data__": {"id_": "6ca59679-c366-442d-80d7-36cdda02b700", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "The access code for the replay is 796214.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From outside the United States and\nCanada, dial +44 (204) 525-0658. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7df284fd0012eb09dfa218a725e66ffa886712f4999d7bb653b0b6e900c4065f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4157708-8f92-43cb-a55d-2f610856720f", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n"}, "hash": "ee7ed2a9bb1fb6d58e8ad9ea9361278cdd095f479d0ea8057ca5a62276bd8626", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 796214.\n", "start_char_idx": 2663, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4157708-8f92-43cb-a55d-2f610856720f": {"__data__": {"id_": "d4157708-8f92-43cb-a55d-2f610856720f", "embedding": null, "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ca59679-c366-442d-80d7-36cdda02b700", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S.  and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "The access code for the replay is 796214.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "912a2de8dd8524fad4130c38d2a81fdf478ec07a3c7c2455a575720accaef7ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d065aa5c-1999-454b-865c-aba17464c457", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "5e834126b8e1effb3887ae8036cd2b9b0391ca1acbef4520978a3a218670eb7c", "class_name": "RelatedNodeInfo"}}, "text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "start_char_idx": 2705, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d065aa5c-1999-454b-865c-aba17464c457": {"__data__": {"id_": "d065aa5c-1999-454b-865c-aba17464c457", "embedding": null, "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4157708-8f92-43cb-a55d-2f610856720f", "node_type": "1", "metadata": {"window": "and Canada, dial (866) 813-9403.  From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa189ac0343caeef21c1aca38e1acdd610d3ecafb9271bf9bb2a2df704e70343", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f241e625-2f9c-48bc-9fec-c06ea3bf6c74", "node_type": "1", "metadata": {"window": "The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "327b8091e37847b4a7511628801a891559c0564e7ceebdf2af34a18293e7c460", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 2930, "end_char_idx": 3143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f241e625-2f9c-48bc-9fec-c06ea3bf6c74": {"__data__": {"id_": "f241e625-2f9c-48bc-9fec-c06ea3bf6c74", "embedding": null, "metadata": {"window": "The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d065aa5c-1999-454b-865c-aba17464c457", "node_type": "1", "metadata": {"window": "From outside the United States and\nCanada, dial +44 (204) 525-0658.  The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "046e40c24b8b1c2d6fbfb229792c5aee739c2d0237de0458aeaa0b9ce40be4e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "6180db2297bc1161bd38ba3afc114dab56ad6a3778392eb2c770fe22ed1040a1", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 3143, "end_char_idx": 3378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1": {"__data__": {"id_": "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1", "embedding": null, "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f241e625-2f9c-48bc-9fec-c06ea3bf6c74", "node_type": "1", "metadata": {"window": "The access code for the replay is 796214.\n Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae8531541aedf5d10c9e4c290a34b75db52f67daebd3bf21df2e7bb24c199571", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. "}, "hash": "97ea5e3d5e660deb8d2dab3476504ad31fceada10bf9e3f2717947278980d9cf", "class_name": "RelatedNodeInfo"}}, "text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 3378, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df": {"__data__": {"id_": "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1", "node_type": "1", "metadata": {"window": "Upcoming Inv estor Ev ents\nAmerisourceBergen management will be attending the following investor events in the coming months:\nBank of America Healthcare Conference, May 11, 2022;\nAmerisourceBergen Investor Day, June 1, 2022.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a236016df921f64e5977efa2065cb1149a45c5dcab264352a7b35b46ab9d7b83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "705ca2c7-a175-4404-9a60-de1da4b879b7", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "e375e0bcf6ebf8a690c7957a1e9ac9db4c81a4191027eeb62c650e08649c5609", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "start_char_idx": 3493, "end_char_idx": 3590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "705ca2c7-a175-4404-9a60-de1da4b879b7": {"__data__": {"id_": "705ca2c7-a175-4404-9a60-de1da4b879b7", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a0ccfd79176d8941b113a0e46b52e0dc72b9f283ffe146c74fb9817a56f8802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5"}, "hash": "7387413ea92603e12f7f19b8a97f69ee85684540f8ce8fbd0109683e965ee8e5", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 3590, "end_char_idx": 3637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2": {"__data__": {"id_": "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2", "embedding": null, "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "83f99185-ff18-4075-8aeb-8a775bfd1307", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42e948cfac2a1f8de866dfa00ad51c200d4162e7dff64f141b0811a7a8a0844b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "705ca2c7-a175-4404-9a60-de1da4b879b7", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edfc992d63cd87fe87900a8dc56d669c90532494a4597d4bc1ff5e4eac4ad597", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c079881e-f114-4a48-a7db-2aabf8e89d1c", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "original_text": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\"). "}, "hash": "c7177169331fc8d56711576383dfdb12474d71edbd57612770f3ebd6358a1d7d", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "start_char_idx": 3637, "end_char_idx": 3717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c079881e-f114-4a48-a7db-2aabf8e89d1c": {"__data__": {"id_": "c079881e-f114-4a48-a7db-2aabf8e89d1c", "embedding": null, "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "original_text": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\"). ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2", "node_type": "1", "metadata": {"window": "Our 42,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\n5", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68dd5cda2642975c34cec175f7646e41eddd787206a8b8d16e92751b9f7e915c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e025d946-88f4-4f27-9985-22495e59db27", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements. "}, "hash": "1b5d5ee077f1e901a390b527ef0f2354cdd6e24100618831870af0d09297dca5", "class_name": "RelatedNodeInfo"}}, "text": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\"). ", "start_char_idx": 0, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e025d946-88f4-4f27-9985-22495e59db27": {"__data__": {"id_": "e025d946-88f4-4f27-9985-22495e59db27", "embedding": null, "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c079881e-f114-4a48-a7db-2aabf8e89d1c", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "original_text": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\"). ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7d1ecf181a1e3a846ffc3345512b86aa22789e25d4f9acc7f8fc02025bfa1a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7f5569a-7c96-4564-9ba3-66c67245142b", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof. "}, "hash": "eb4d3e489c3ac3aa36668f9b9b459fa422f05ff880eb62229cbc858966847973", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 269, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7f5569a-7c96-4564-9ba3-66c67245142b": {"__data__": {"id_": "b7f5569a-7c96-4564-9ba3-66c67245142b", "embedding": null, "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e025d946-88f4-4f27-9985-22495e59db27", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cac5fc558064757482dbf6bd4643789314326e092e418f983953a0ea693040f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22af84e4-724d-4229-9c41-71315f000233", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. "}, "hash": "35a368ae2d17710f761bcb453c9e7d583310898b611f37b1b0ec25cd3975ce99", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof. ", "start_char_idx": 618, "end_char_idx": 780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22af84e4-724d-4229-9c41-71315f000233": {"__data__": {"id_": "22af84e4-724d-4229-9c41-71315f000233", "embedding": null, "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7f5569a-7c96-4564-9ba3-66c67245142b", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "original_text": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6425a67c441a33d3609dcab26eb65cedb34c901338ae0b14318f30602e2580b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. "}, "hash": "9439fde42191cd1632f01199f3300cf94ce41bd795f3c8115825e617f47f4156", "class_name": "RelatedNodeInfo"}}, "text": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "start_char_idx": 780, "end_char_idx": 979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5": {"__data__": {"id_": "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22af84e4-724d-4229-9c41-71315f000233", "node_type": "1", "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "original_text": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ac4a0c655af491aac75d2d5f6a1faf6bdd93f25aa0856620bc2316297f4b330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "098af4ff-9881-4fb1-ba71-c08f53460feb", "node_type": "1", "metadata": {"window": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n"}, "hash": "5175a9d139d7ef9d3168f6114a96368d95dd834c56b77a82455d6ca1477c03bf", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "start_char_idx": 979, "end_char_idx": 4527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "098af4ff-9881-4fb1-ba71-c08f53460feb": {"__data__": {"id_": "098af4ff-9881-4fb1-ba71-c08f53460feb", "embedding": null, "metadata": {"window": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e8f4ccb5a3a459d1bd0cbf6b1f057744116e72dc275ea3d989697d0f56cef58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2a53a42-0297-474d-9b82-ad070b73d156", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. "}, "hash": "58911d15a71dedd4fc26fe8e8893ab223458b90767ed4ee57282d38eef420846", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "start_char_idx": 4527, "end_char_idx": 4738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2a53a42-0297-474d-9b82-ad070b73d156": {"__data__": {"id_": "f2a53a42-0297-474d-9b82-ad070b73d156", "embedding": null, "metadata": {"window": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "098af4ff-9881-4fb1-ba71-c08f53460feb", "node_type": "1", "metadata": {"window": "These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fb10c33374a57ce487e2f1c8b3efd7f6e528fbd7810b07d40688214042b7c99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46f6747d-ef25-445e-9c19-019314018ff6", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6"}, "hash": "8f3c3b945b349180e7f67c552d67c0f923d0b84ff6aafb641d7fa30bb0f0d0e0", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "start_char_idx": 4738, "end_char_idx": 6619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f6747d-ef25-445e-9c19-019314018ff6": {"__data__": {"id_": "46f6747d-ef25-445e-9c19-019314018ff6", "embedding": null, "metadata": {"window": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f803da6e-e164-4c57-a964-33e1db35ad98", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3a28323e5a013179a475750849395d2183808009ddefca5b981c2f17cd29385", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2a53a42-0297-474d-9b82-ad070b73d156", "node_type": "1", "metadata": {"window": "These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated.  Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e785d11e5a458d96f30df654de4f74f8ca572c6c0624b0c36acf92e244ad9ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2355ee4e-15c7-4a60-851e-525ca5cd5383", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "b1166afc92c79550ab20d191fc713aa3ca58196df51a4b9eb26a0a807e7df983", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "start_char_idx": 6619, "end_char_idx": 6819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2355ee4e-15c7-4a60-851e-525ca5cd5383": {"__data__": {"id_": "2355ee4e-15c7-4a60-851e-525ca5cd5383", "embedding": null, "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95096ce6507f04d5db4b17a49b9004cd3c3bfeba8ef084ac80cbede982b4ec04", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f6747d-ef25-445e-9c19-019314018ff6", "node_type": "1", "metadata": {"window": "Among the factors that could cause actual results to\ndiffer materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the\nongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the\nCOVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic\nconditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our\nbusiness; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand\nand generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry\nconsolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services;\nchanges in the United States healthcare and regulatory environment, including changes that could impact prescription drug\nreimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental\nregulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect\nand prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by\nfederal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of\nalleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder\nderivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and\nregulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated\nreserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental\nproceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of\nkey customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute\nwith customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such\npayment terms; the integration of the Alliance Healthcare businesses into the Company being more difficult, time consuming or\ncostly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial and operating\nperformance and results; the effects of disruption from the acquisition and related strategic transactions on the respective\nbusinesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions may make it\nmore difficult to establish or maintain relationships with employees, suppliers and other business partners; the acquisition of\nbusinesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do not perform as\nexpected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related thereto or to\ncapture the anticipated synergies within the expected time period; risks associated with the strategic, long-term relationship\nbetween Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution agreement\nand/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with the U.S.\n Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to\nfinancial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax\npositions and/or the Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; the loss,\nbankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss,\nbankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our\noperations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data\nprivacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical\ntrends and events, including the unfolding situation in Russia and Ukraine and its regional and global ramifications; natural disasters\nor other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the impairment of goodwill or\nother intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings;\nthe Company's ability to manage and complete divestitures; the disruption of the Company's cash flow and ability to return value to\nits stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining\neconomic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or\noperational factors affecting the Company's business generally.  Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "original_text": "Certain additional factors that management believes could cause\nactual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk\n6", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60e8d58be80d2c81f881046507051d1711238264738807ee3393d4ea88166033", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6116c66-c2ad-4f33-8fdf-96057aa15a2a", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n"}, "hash": "eba0af560635efbba66c127a64998dc81bc7cc81cac72a654e1446b72d667a59", "class_name": "RelatedNodeInfo"}}, "text": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 0, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6116c66-c2ad-4f33-8fdf-96057aa15a2a": {"__data__": {"id_": "e6116c66-c2ad-4f33-8fdf-96057aa15a2a", "embedding": null, "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95096ce6507f04d5db4b17a49b9004cd3c3bfeba8ef084ac80cbede982b4ec04", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2355ee4e-15c7-4a60-851e-525ca5cd5383", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b71e9ade90014c10d727f9262d8e3dde5846769d215499c4f5008613ec1b773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82de5b40-996a-4d3d-b5ff-dcf11a914c54", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7"}, "hash": "363e7f30670f0ba909a871fe0f0b6a78fa54d1c148fcd283bae012f32ef965ae", "class_name": "RelatedNodeInfo"}}, "text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n", "start_char_idx": 216, "end_char_idx": 366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82de5b40-996a-4d3d-b5ff-dcf11a914c54": {"__data__": {"id_": "82de5b40-996a-4d3d-b5ff-dcf11a914c54", "embedding": null, "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95096ce6507f04d5db4b17a49b9004cd3c3bfeba8ef084ac80cbede982b4ec04", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6116c66-c2ad-4f33-8fdf-96057aa15a2a", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a633b44ce656943d6f7f000450ebf5fbfa06f7c47d682fd674561fabe87fd98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4c32ca0-3930-44ed-a82a-515e5c20f4ab", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "original_text": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n"}, "hash": "8b246beec40a14b43373819e1b2dd612bb9e7b2a309245a19c456627ee6154e2", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "start_char_idx": 366, "end_char_idx": 1453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4c32ca0-3930-44ed-a82a-515e5c20f4ab": {"__data__": {"id_": "a4c32ca0-3930-44ed-a82a-515e5c20f4ab", "embedding": null, "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "original_text": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "458275a2-71b5-45ea-a781-2656edd18979", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bc3f1fb732028580e89eb42492643e7a6a0c7d66acc0e1428417baa76883d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82de5b40-996a-4d3d-b5ff-dcf11a914c54", "node_type": "1", "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "443e6d68aea3bcb1582c9850d67f81bc5a48867cf7c9b7beffb75bc3e25eb697", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6df763b-df29-4aaa-878a-cd9a076b0bea", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022. "}, "hash": "a64c77a6f19e0432543b6f7319602f3c6da7f4ad73a20f1a8d5c66bf18564ad3", "class_name": "RelatedNodeInfo"}}, "text": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6df763b-df29-4aaa-878a-cd9a076b0bea": {"__data__": {"id_": "b6df763b-df29-4aaa-878a-cd9a076b0bea", "embedding": null, "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022. ", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "458275a2-71b5-45ea-a781-2656edd18979", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bc3f1fb732028580e89eb42492643e7a6a0c7d66acc0e1428417baa76883d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4c32ca0-3930-44ed-a82a-515e5c20f4ab", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "original_text": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0b7c9630687f3de47032a65a935f147d11d9a17743c4d3c9bc72cb94e74fc045", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db634f03-f47c-4654-a5c9-413bf1aa90f7", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n"}, "hash": "6f8c6fa6f0154ba5f4a423d9ce2ca2fb6620c966a3b68612941aa9b4cbaa63cd", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022. ", "start_char_idx": 789, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db634f03-f47c-4654-a5c9-413bf1aa90f7": {"__data__": {"id_": "db634f03-f47c-4654-a5c9-413bf1aa90f7", "embedding": null, "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "458275a2-71b5-45ea-a781-2656edd18979", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bc3f1fb732028580e89eb42492643e7a6a0c7d66acc0e1428417baa76883d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6df763b-df29-4aaa-878a-cd9a076b0bea", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022. ", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ae6e86eb053b04d8a866e80c4295af84468223b87be3ee0ab0be27172998cdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a50e3555-ded4-4979-ac68-014ba5e7a894", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n"}, "hash": "d5e37089b6350eaf6c37b519cedd16d56f1b615da0786c9117a5af59688916b8", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n", "start_char_idx": 1201, "end_char_idx": 1578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a50e3555-ded4-4979-ac68-014ba5e7a894": {"__data__": {"id_": "a50e3555-ded4-4979-ac68-014ba5e7a894", "embedding": null, "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "458275a2-71b5-45ea-a781-2656edd18979", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bc3f1fb732028580e89eb42492643e7a6a0c7d66acc0e1428417baa76883d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db634f03-f47c-4654-a5c9-413bf1aa90f7", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00d9633edb3965a892b79a29969ce74c98ab455a74f8cb1f8d1a1f7f1a76acda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "135be957-9f9d-4eb8-b6a1-38099b170c47", "node_type": "1", "metadata": {"window": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8"}, "hash": "01f315d85f1c10b1b5d9f7e5de197153e6a20759bb67c397490578424ccdb696", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "start_char_idx": 1578, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "135be957-9f9d-4eb8-b6a1-38099b170c47": {"__data__": {"id_": "135be957-9f9d-4eb8-b6a1-38099b170c47", "embedding": null, "metadata": {"window": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "458275a2-71b5-45ea-a781-2656edd18979", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71bc3f1fb732028580e89eb42492643e7a6a0c7d66acc0e1428417baa76883d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a50e3555-ded4-4979-ac68-014ba5e7a894", "node_type": "1", "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8a09d80f1ff39d2c9d90af2054b536db8a9ab0b3b68b37c2086f6b3c2fa429f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "585eb775-e6a4-4025-a526-3236708cfef7", "node_type": "1", "metadata": {"window": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "original_text": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9"}, "hash": "254a56dea1a801ff23efddf98028b1262944709e3b65dfac6230f1fdf8834637", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\n8", "start_char_idx": 1777, "end_char_idx": 1808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "585eb775-e6a4-4025-a526-3236708cfef7": {"__data__": {"id_": "585eb775-e6a4-4025-a526-3236708cfef7", "embedding": null, "metadata": {"window": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "original_text": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "page_label": "9", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a8cb832c-05d7-47d7-bf07-4094322403aa", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec0890fe84526b51edac40bbcf33d6441189fcddd4b490ffd42c802965308861", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "135be957-9f9d-4eb8-b6a1-38099b170c47", "node_type": "1", "metadata": {"window": "2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\n8", "original_text": "AMERISOURCEBERGEN CORPORATION\n8", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fad19fc6d077d25f5d200dba5aee653ae8db21ddcce53cba1436339a38515c87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a518b054-8323-4a1d-a1aa-6b79925be813", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n"}, "hash": "1c1f5ff405b5ea9fb111361e0baa7031a8cdea85e237786ef6acae3b61961bba", "class_name": "RelatedNodeInfo"}}, "text": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "start_char_idx": 0, "end_char_idx": 1251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a518b054-8323-4a1d-a1aa-6b79925be813": {"__data__": {"id_": "a518b054-8323-4a1d-a1aa-6b79925be813", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861b274a2d2e47a050732bc1f5751f5b9da8dc3f8f2afe8ee3538cd0b5582a96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "585eb775-e6a4-4025-a526-3236708cfef7", "node_type": "1", "metadata": {"window": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "original_text": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "page_label": "9", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9cfc89c7aed4af8ce1e94a5b9e5bc4a83df24ae4fba8a9f751d32425e5cb697", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "001a89c8-f839-4ac5-b57f-278c47c0531b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022. "}, "hash": "44ab0f96a36dbefdea7f41ebc76a519b993bb3fbef73a94c606219d8cff0d469", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "001a89c8-f839-4ac5-b57f-278c47c0531b": {"__data__": {"id_": "001a89c8-f839-4ac5-b57f-278c47c0531b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022. ", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861b274a2d2e47a050732bc1f5751f5b9da8dc3f8f2afe8ee3538cd0b5582a96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a518b054-8323-4a1d-a1aa-6b79925be813", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2afbef9e4be646a412f947030fca6a6ee5268d51674528fbea44cff359fdc27a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84fcb708-fdde-41dc-b189-271ba7da22bc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n"}, "hash": "9b6fa1144c5cc9e497662c3271c32a7aa10f5f840d4735a63f34658e549f1450", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022. ", "start_char_idx": 667, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84fcb708-fdde-41dc-b189-271ba7da22bc": {"__data__": {"id_": "84fcb708-fdde-41dc-b189-271ba7da22bc", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861b274a2d2e47a050732bc1f5751f5b9da8dc3f8f2afe8ee3538cd0b5582a96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "001a89c8-f839-4ac5-b57f-278c47c0531b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022. ", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "082f43e40ce6f888d0bbb9f0551f7ef389e27eb5198926fdd447d6401b8aabb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8737215-aa25-4ed1-94df-c7c9f1060ffb", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n"}, "hash": "05f8cd41075dbf7fadccfe14c1f5f28ffc1502c21647e5df2e1f10e8b9f02241", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n", "start_char_idx": 1077, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8737215-aa25-4ed1-94df-c7c9f1060ffb": {"__data__": {"id_": "d8737215-aa25-4ed1-94df-c7c9f1060ffb", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861b274a2d2e47a050732bc1f5751f5b9da8dc3f8f2afe8ee3538cd0b5582a96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84fcb708-fdde-41dc-b189-271ba7da22bc", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74ae68a0fb21876df103a9544801fcb0663fc92515ffd712fa42471f8c3d4430", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4260692c-3a0a-4a6c-9cb3-446787a3ff05", "node_type": "1", "metadata": {"window": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10"}, "hash": "dee28b4ce7f0ce613a2904b9bbde9a3b07fc0588e253a556e1802b4ee82404c0", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "start_char_idx": 1452, "end_char_idx": 1652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4260692c-3a0a-4a6c-9cb3-446787a3ff05": {"__data__": {"id_": "4260692c-3a0a-4a6c-9cb3-446787a3ff05", "embedding": null, "metadata": {"window": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "861b274a2d2e47a050732bc1f5751f5b9da8dc3f8f2afe8ee3538cd0b5582a96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8737215-aa25-4ed1-94df-c7c9f1060ffb", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50cfb9eb1c1a5bbd84d7575e9c3060a056f44e326c46eca33be083c6011365b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ecc5fa-1d73-4ae6-846b-853115165e2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n"}, "hash": "3bf1661027056fa2886fc67fa9f77af6519c2b3d4d41bb8131fc895e4bbeaca8", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "start_char_idx": 1652, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ecc5fa-1d73-4ae6-846b-853115165e2f": {"__data__": {"id_": "f9ecc5fa-1d73-4ae6-846b-853115165e2f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5234217e-100a-4867-9e7e-13297173591a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab4c02f5ef7aa9161f99e2ba2950d07ac10bd02c5d8fd5b5a0dea2204fdd9d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4260692c-3a0a-4a6c-9cb3-446787a3ff05", "node_type": "1", "metadata": {"window": "2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n10", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "71e57ed21c5e7c417d2e99a74866161fab734344411951dbcd3624257f4db72d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96f565c9-2f32-446a-8094-820363845bc3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11"}, "hash": "bed95bcc337d003ea152844797d03738bbe8fa119cafa212e7af7db605616561", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "start_char_idx": 0, "end_char_idx": 1265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96f565c9-2f32-446a-8094-820363845bc3": {"__data__": {"id_": "96f565c9-2f32-446a-8094-820363845bc3", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5234217e-100a-4867-9e7e-13297173591a", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab4c02f5ef7aa9161f99e2ba2950d07ac10bd02c5d8fd5b5a0dea2204fdd9d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ecc5fa-1d73-4ae6-846b-853115165e2f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4582089718c1ef888cb7fe5339b7744a06aec0e07c5ee845a4b67c3470b7c7f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54c24de9-d2c7-44e9-aa06-b80ab0648f6a", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "64f017352ceecdfa3f9acf969030d8eeffc52288b90c845ab9f82d7e0e6244cb", "class_name": "RelatedNodeInfo"}}, "text": "prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "start_char_idx": 1265, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54c24de9-d2c7-44e9-aa06-b80ab0648f6a": {"__data__": {"id_": "54c24de9-d2c7-44e9-aa06-b80ab0648f6a", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7944d213e3cb7b5145f6bae5a6ba780b6b09a457a43802d4fa7ed4953ad7520", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96f565c9-2f32-446a-8094-820363845bc3", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "576f8476deda48307b3367c2dacc044b3a1108db68db5ff39c33f79b90f66940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0cd34de-16ac-47f0-9ebe-1711b0235718", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "6fbf3646113feeb1896bafe31078daba724046a500d64d3494daf41962c7b3a9", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0cd34de-16ac-47f0-9ebe-1711b0235718": {"__data__": {"id_": "d0cd34de-16ac-47f0-9ebe-1711b0235718", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7944d213e3cb7b5145f6bae5a6ba780b6b09a457a43802d4fa7ed4953ad7520", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54c24de9-d2c7-44e9-aa06-b80ab0648f6a", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be38f1cbf2a4989b3099f7cf299a123ca4d88df9c6b7b812d551c42e3de0a299", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d0f0cf-adf7-4c18-93af-da9465a7771f", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12"}, "hash": "59fcb0b6042d9634a201673ee9ee391afb656db66c6f3e3ffe0afe04e62fefa0", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 367, "end_char_idx": 544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d0f0cf-adf7-4c18-93af-da9465a7771f": {"__data__": {"id_": "92d0f0cf-adf7-4c18-93af-da9465a7771f", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b7944d213e3cb7b5145f6bae5a6ba780b6b09a457a43802d4fa7ed4953ad7520", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0cd34de-16ac-47f0-9ebe-1711b0235718", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e4ab3960a4b5ad1bf13c0c75d1bdab5e4d0d4630775e41d1f75f90cfd2133ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "353d6b08-4fd6-4b0b-a177-5021d59454c7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "4aa248831eb087c270ed9755f1033605b240e5891e9bfd11711a75666c163dd0", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "start_char_idx": 544, "end_char_idx": 1408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "353d6b08-4fd6-4b0b-a177-5021d59454c7": {"__data__": {"id_": "353d6b08-4fd6-4b0b-a177-5021d59454c7", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40d0e19c-4972-473d-aaae-cbcd2233b421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5884e4295b16bf30dcf3d5e52af49f9f3d96e03ac9cd6246afa0d829abcc6886", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d0f0cf-adf7-4c18-93af-da9465a7771f", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "10c37f9be98cfe93e75587ad811818057751252ca37e9d1d6c2796bf06291484", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "51815f789c53693f43682b0791b1edac2753bdbe8ef3623320a062de101bb18c", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b": {"__data__": {"id_": "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40d0e19c-4972-473d-aaae-cbcd2233b421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5884e4295b16bf30dcf3d5e52af49f9f3d96e03ac9cd6246afa0d829abcc6886", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "353d6b08-4fd6-4b0b-a177-5021d59454c7", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03fcc16fd63b8bf4ab2794a3fd1704240ef18296add8728143f578fd587ec5a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e5f99e1-5d6e-451f-806c-13dfb0172016", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13"}, "hash": "c7cb76b2ae690bf1a21f593ccd07c1653ac9595ffbd3e27c4e239a19abf14240", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 594, "end_char_idx": 771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e5f99e1-5d6e-451f-806c-13dfb0172016": {"__data__": {"id_": "4e5f99e1-5d6e-451f-806c-13dfb0172016", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "40d0e19c-4972-473d-aaae-cbcd2233b421", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5884e4295b16bf30dcf3d5e52af49f9f3d96e03ac9cd6246afa0d829abcc6886", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7eb2c0341bf6b8b577fc3ed4215b17b3358165f38754f3fc2aec21496b5536e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51cbdc35-73e9-4f0a-86fd-8a257bd9306c", "node_type": "1", "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "259488badc583ceeef490afb7638d1b5d1bfafd8ef87281577a55de7fe46d61c", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "start_char_idx": 771, "end_char_idx": 1299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51cbdc35-73e9-4f0a-86fd-8a257bd9306c": {"__data__": {"id_": "51cbdc35-73e9-4f0a-86fd-8a257bd9306c", "embedding": null, "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a4f6c20-e183-4d33-8b81-cef783d12165", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7751c65997a0e2701a7d03803b3bc9fbf45f0e31daa9ae2665488bfe7e06aba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e5f99e1-5d6e-451f-806c-13dfb0172016", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a18ca0c08a74ad7ab3d5bdcbee931a516b4ed1758dda5d3aa53dbf9f12965173", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4", "node_type": "1", "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14"}, "hash": "0114eb48b2c6d550938efb2429754cf9aabd0bb71726e5d17e5930e9881a5bdc", "class_name": "RelatedNodeInfo"}}, "text": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4": {"__data__": {"id_": "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4", "embedding": null, "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7a4f6c20-e183-4d33-8b81-cef783d12165", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7751c65997a0e2701a7d03803b3bc9fbf45f0e31daa9ae2665488bfe7e06aba", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51cbdc35-73e9-4f0a-86fd-8a257bd9306c", "node_type": "1", "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea722f675156e6204fca61e1f44d43d7f89e427793db3988e1df7e67a67a499b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11789843-5d5a-4be4-9dc9-6f9531bcb2a0", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "5d54de5af9386685c85db340b0e5cd8a773851cd2cf3205069b919bea5b814cb", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "start_char_idx": 1047, "end_char_idx": 1201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11789843-5d5a-4be4-9dc9-6f9531bcb2a0": {"__data__": {"id_": "11789843-5d5a-4be4-9dc9-6f9531bcb2a0", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b460bc3357c30ff20163bbccb40b1ef070de87b4001b56fa23b5daf90234d132", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4", "node_type": "1", "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4effc5b8eddea30037fe00c377f433d051a7702d5cfcbb8fd83583be33a5f19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee67690e-9d15-4a4a-b3b6-5268a62044cf", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "86057486a7d39bf1d054d1790d4ff9db2d0349d6ad36a41a6296db7a81f659e0", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee67690e-9d15-4a4a-b3b6-5268a62044cf": {"__data__": {"id_": "ee67690e-9d15-4a4a-b3b6-5268a62044cf", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b460bc3357c30ff20163bbccb40b1ef070de87b4001b56fa23b5daf90234d132", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11789843-5d5a-4be4-9dc9-6f9531bcb2a0", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f738a02dbeb6b73952d1794efebc6ab4154899f8a38fa80f655b503310f6a737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16f485c-30fb-4d53-b3cd-06c5e34f4781", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "1e10b71c93338e76fdf57b2790a6ea3036d4e54de942f33f921657bd3f7f94fa", "class_name": "RelatedNodeInfo"}}, "text": "2 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 287, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16f485c-30fb-4d53-b3cd-06c5e34f4781": {"__data__": {"id_": "c16f485c-30fb-4d53-b3cd-06c5e34f4781", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b460bc3357c30ff20163bbccb40b1ef070de87b4001b56fa23b5daf90234d132", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee67690e-9d15-4a4a-b3b6-5268a62044cf", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "2 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12e7b795ed950bc9657021b1e036f83e030139b4ee814722fa3a585c7cbf1ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28dedf1b-6c18-47f8-a8ce-c6a393ca746d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15"}, "hash": "c840d99828f6ac2a6a9ad778700f25e2946bf51f971b20c92def7c6268cc15ae", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 359, "end_char_idx": 536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28dedf1b-6c18-47f8-a8ce-c6a393ca746d": {"__data__": {"id_": "28dedf1b-6c18-47f8-a8ce-c6a393ca746d", "embedding": null, "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b460bc3357c30ff20163bbccb40b1ef070de87b4001b56fa23b5daf90234d132", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16f485c-30fb-4d53-b3cd-06c5e34f4781", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eca29d875383f83fd2a12066bfff724095e1a6cd6f9fd699f314552ee0dc5f97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6848c4e-35ef-4c16-9fa9-e93f784350a0", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n"}, "hash": "5b59568ea56ba8f6822fd6ef843458fc83042d3bb0419cdcd239e04af2ab7305", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "start_char_idx": 536, "end_char_idx": 1332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6848c4e-35ef-4c16-9fa9-e93f784350a0": {"__data__": {"id_": "e6848c4e-35ef-4c16-9fa9-e93f784350a0", "embedding": null, "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c361af57a3faf533d02885f7182aee40b4a59368bf06ff67454fccf2ed835a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28dedf1b-6c18-47f8-a8ce-c6a393ca746d", "node_type": "1", "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fb74a014fcb53c207bc53a5c14f5f23e07c101502a93b673edc8ba253fe1839", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1b785e4-303d-4fce-bc52-caee2fb051f0", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n"}, "hash": "950051c5c974fdef94dc4cc00fc9a72976b8be0be7dd07ce4ab996222859e250", "class_name": "RelatedNodeInfo"}}, "text": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "start_char_idx": 0, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1b785e4-303d-4fce-bc52-caee2fb051f0": {"__data__": {"id_": "c1b785e4-303d-4fce-bc52-caee2fb051f0", "embedding": null, "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c361af57a3faf533d02885f7182aee40b4a59368bf06ff67454fccf2ed835a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6848c4e-35ef-4c16-9fa9-e93f784350a0", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fb7745655cea76caab1d33d38ec30852608334ddcd2ebf3f143ba81cc0969b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3e170d2-0a9c-4505-ba0e-9322395d61ff", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "3 The sum of the components does not equal the total due to rounding.\n\u00a0\n"}, "hash": "e094c18f7cfa9ac5d97e7434ae942659d843baea1fbc4ba394814c61a8486af4", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "start_char_idx": 738, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3e170d2-0a9c-4505-ba0e-9322395d61ff": {"__data__": {"id_": "d3e170d2-0a9c-4505-ba0e-9322395d61ff", "embedding": null, "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "3 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c361af57a3faf533d02885f7182aee40b4a59368bf06ff67454fccf2ed835a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1b785e4-303d-4fce-bc52-caee2fb051f0", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20e27f552ea92f165abb7f39ebf836179d9dc90b4bc3b31833fc350b1b952e96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9bff665-24e6-454d-8011-9b36d752eb6e", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "e742bdeef1d3e8814d59a8cadb05c66ec2ce67f330803bc67ac03acdecf845b9", "class_name": "RelatedNodeInfo"}}, "text": "3 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "start_char_idx": 920, "end_char_idx": 992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9bff665-24e6-454d-8011-9b36d752eb6e": {"__data__": {"id_": "c9bff665-24e6-454d-8011-9b36d752eb6e", "embedding": null, "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c361af57a3faf533d02885f7182aee40b4a59368bf06ff67454fccf2ed835a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3e170d2-0a9c-4505-ba0e-9322395d61ff", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "3 The sum of the components does not equal the total due to rounding.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58e0676ee37e11bac33cd6b68c93bdfc22001368f0ad1227512d6b4c997efc8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbe14817-0498-4526-b797-437f98508788", "node_type": "1", "metadata": {"window": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16"}, "hash": "8280bb962bfd7b56048f688691441665075558ea3cd264c9c3e333accf494f3a", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 992, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbe14817-0498-4526-b797-437f98508788": {"__data__": {"id_": "cbe14817-0498-4526-b797-437f98508788", "embedding": null, "metadata": {"window": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e8c361af57a3faf533d02885f7182aee40b4a59368bf06ff67454fccf2ed835a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9bff665-24e6-454d-8011-9b36d752eb6e", "node_type": "1", "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cb51ef3fd9e1d6565f2baf1e78c183cd1f7881e9941429420142f558af40e01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d8cb3a4-1036-4cbc-a9c5-c0d846742570", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. "}, "hash": "dd4b25a63637c739cf99a4e5f7f8eae95f919eb7b9c8b779d3049bb757382fb1", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "start_char_idx": 1169, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d8cb3a4-1036-4cbc-a9c5-c0d846742570": {"__data__": {"id_": "1d8cb3a4-1036-4cbc-a9c5-c0d846742570", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c205791-403d-4d88-bfb4-785968f8e65d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd4a909557cfab27fa117c6faf08061a0a1db1a38f34fcc0626901bbee72a44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbe14817-0498-4526-b797-437f98508788", "node_type": "1", "metadata": {"window": "2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n16", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78aa68909f98a559266de01bee387a938574999f68f9745e3382750118fb5b4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "cdb3667fc73c6d2bc419a32accbf5b4d62aec0daca4f11c07ea701112589340b", "class_name": "RelatedNodeInfo"}}, "text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f": {"__data__": {"id_": "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c205791-403d-4d88-bfb4-785968f8e65d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd4a909557cfab27fa117c6faf08061a0a1db1a38f34fcc0626901bbee72a44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d8cb3a4-1036-4cbc-a9c5-c0d846742570", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b9913026d7665bb917c412aca3bb9f670d9b45a4284c48613ec5b91d1ed524d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ba61ebc-f434-425e-aa97-924f5ac3caf9", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "a258e903c287cd0b920da596631b41d14b3094735bad6752fb5aef178360343d", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 98, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ba61ebc-f434-425e-aa97-924f5ac3caf9": {"__data__": {"id_": "5ba61ebc-f434-425e-aa97-924f5ac3caf9", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c205791-403d-4d88-bfb4-785968f8e65d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd4a909557cfab27fa117c6faf08061a0a1db1a38f34fcc0626901bbee72a44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ae6a468f97e8b50b5ee9f6ebb4df29310c39630e58621be7ba1daf86883250f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c13e53-716d-4f7e-a2db-fd0de583dbb8", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17"}, "hash": "af6f708b0c49da16602c912b167e3adb0a92f40b5c1d1c7276a8f22dd422c8cb", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 401, "end_char_idx": 924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c13e53-716d-4f7e-a2db-fd0de583dbb8": {"__data__": {"id_": "74c13e53-716d-4f7e-a2db-fd0de583dbb8", "embedding": null, "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5c205791-403d-4d88-bfb4-785968f8e65d", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd4a909557cfab27fa117c6faf08061a0a1db1a38f34fcc0626901bbee72a44", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ba61ebc-f434-425e-aa97-924f5ac3caf9", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cf3bf2637734d8d80e203a975bf59ade9988d987d9ffde0ca4a4b7ae00d36ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9207d99c-05d7-4198-b5dc-adcc15b74f77", "node_type": "1", "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "818af67c6325655ab64a2772c7301d813d501c5a9d8424cb5ba82f1daa7c0123", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "start_char_idx": 924, "end_char_idx": 988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9207d99c-05d7-4198-b5dc-adcc15b74f77": {"__data__": {"id_": "9207d99c-05d7-4198-b5dc-adcc15b74f77", "embedding": null, "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d24bf951-b9df-4bf0-872c-f71ee8c7d329", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0df0a7b405fc0270f0ba412e43baf15323dbc5b580c7b28e7a930f40d2bc8c07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c13e53-716d-4f7e-a2db-fd0de583dbb8", "node_type": "1", "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dce216b19830a7d2c73533dfa388686e4cd00a37084c7eb2dcbfb8b9f1ac0908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83b88e64-61d3-4657-96e4-e0828024c6a6", "node_type": "1", "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18"}, "hash": "3bbd9589555361832d410b1cee2fc2c9b27f6eb67bccc09d5cb33b2b12d5fda5", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83b88e64-61d3-4657-96e4-e0828024c6a6": {"__data__": {"id_": "83b88e64-61d3-4657-96e4-e0828024c6a6", "embedding": null, "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d24bf951-b9df-4bf0-872c-f71ee8c7d329", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0df0a7b405fc0270f0ba412e43baf15323dbc5b580c7b28e7a930f40d2bc8c07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9207d99c-05d7-4198-b5dc-adcc15b74f77", "node_type": "1", "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51d7a92418a926fbf17e7f8cdf8e4647a6066940f9f18b3db541a9b4434f37ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "993f2780-0368-404c-9693-23fe51ee6b62", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "U.S. "}, "hash": "affe5b2a32dd036b884541ff27e7c327cfa9a5851a0cb7408c2bd426682c1651", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "start_char_idx": 772, "end_char_idx": 922, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "993f2780-0368-404c-9693-23fe51ee6b62": {"__data__": {"id_": "993f2780-0368-404c-9693-23fe51ee6b62", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "U.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d91dd428-3273-426e-aa59-2c6b6451e994", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f1b7a6fa24fb058abd69d5e8f225431237c49ce9d33acc44a849150ec84087e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83b88e64-61d3-4657-96e4-e0828024c6a6", "node_type": "1", "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6532be795f63b9fc01007a2fb7041480f731df831d1b9c6f741c75e215aa9399", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf5ecf2-f8d2-47e4-8555-a33d303f2990", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. "}, "hash": "c35929872e620b71102612b1da1c90ceac77fb8f19b2a85e67962f43904c151e", "class_name": "RelatedNodeInfo"}}, "text": "U.S. ", "start_char_idx": 0, "end_char_idx": 5, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf5ecf2-f8d2-47e4-8555-a33d303f2990": {"__data__": {"id_": "8cf5ecf2-f8d2-47e4-8555-a33d303f2990", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d91dd428-3273-426e-aa59-2c6b6451e994", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f1b7a6fa24fb058abd69d5e8f225431237c49ce9d33acc44a849150ec84087e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "993f2780-0368-404c-9693-23fe51ee6b62", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "U.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98ba7c95f60149d639b644bf3ec7fe5d37cb9dfbd7101ab183dec69f58819829", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62030fc7-5f99-4edb-840e-9052d898cadf", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. "}, "hash": "d2bc88283205c6a9bb81012db9c7daabb3541c2fafe26b4a1300523c89a0c343", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "start_char_idx": 5, "end_char_idx": 312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62030fc7-5f99-4edb-840e-9052d898cadf": {"__data__": {"id_": "62030fc7-5f99-4edb-840e-9052d898cadf", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d91dd428-3273-426e-aa59-2c6b6451e994", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f1b7a6fa24fb058abd69d5e8f225431237c49ce9d33acc44a849150ec84087e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf5ecf2-f8d2-47e4-8555-a33d303f2990", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb38448853aec230bdceb4bd707a6956d65b5dd4e1135637fb2a091fd154ea9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3060a3a0-58b0-460c-b305-fad338f3c384", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19"}, "hash": "844f567350462f4236dad204da3a0259174d1cc6a0ed080cb37b09e02650bfd6", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "start_char_idx": 312, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3060a3a0-58b0-460c-b305-fad338f3c384": {"__data__": {"id_": "3060a3a0-58b0-460c-b305-fad338f3c384", "embedding": null, "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d91dd428-3273-426e-aa59-2c6b6451e994", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f1b7a6fa24fb058abd69d5e8f225431237c49ce9d33acc44a849150ec84087e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62030fc7-5f99-4edb-840e-9052d898cadf", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c6320343d8977aa2cc5a44c78496cbc92e28bdeee6d3f129eb908c680f8eb17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "094ce54d-107f-4ad5-9403-75add22b35c0", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "d93a52bf9f400215f6676f7642d847b9c3b0a0a011f98b77b4da3960adc8a6ac", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "start_char_idx": 889, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "094ce54d-107f-4ad5-9403-75add22b35c0": {"__data__": {"id_": "094ce54d-107f-4ad5-9403-75add22b35c0", "embedding": null, "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44db08ce-466b-43cb-9f83-18d9eae976f5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a477e73424ff87f67652a17951094e51e3ac469a0f07131146c4d46eb2efe6e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3060a3a0-58b0-460c-b305-fad338f3c384", "node_type": "1", "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "878bb8d66b64fbae5036cf231296e5666f7d661fb032a5e066820656e9eac056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaadef10-4643-4833-b79a-7d8a10d3c0d6", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20"}, "hash": "81529f9a11eea005270dae19897298d1cb92fca82b528f93e80833b5be2158f2", "class_name": "RelatedNodeInfo"}}, "text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaadef10-4643-4833-b79a-7d8a10d3c0d6": {"__data__": {"id_": "aaadef10-4643-4833-b79a-7d8a10d3c0d6", "embedding": null, "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "44db08ce-466b-43cb-9f83-18d9eae976f5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a477e73424ff87f67652a17951094e51e3ac469a0f07131146c4d46eb2efe6e8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "094ce54d-107f-4ad5-9403-75add22b35c0", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbc17b8dc8e58d916991f462717b252f9e3f8c8e1f515c6ea424846ccfee6978", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44da69d5-b5e4-43ff-a9df-6d4a6e0c184e", "node_type": "1", "metadata": {"window": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "original_text": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21"}, "hash": "1c82eec6bf3a120e0e7f85f6dc5036bece5571b59f38795aa7519c66c9a31a96", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "start_char_idx": 687, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44da69d5-b5e4-43ff-a9df-6d4a6e0c184e": {"__data__": {"id_": "44da69d5-b5e4-43ff-a9df-6d4a6e0c184e", "embedding": null, "metadata": {"window": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "original_text": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "page_label": "21", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a59449a8-516a-48fa-9d30-a5af4a37abf6", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23d03f14e9701acb3eafdc211670544818cb5bdd9b2f60aadd770b2b044de279", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaadef10-4643-4833-b79a-7d8a10d3c0d6", "node_type": "1", "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a9f0ab068ced5b49cd23af6b4328130278ce97bbf393cff38624b252710e135", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "534376e3-8853-4b1b-bc4c-db85a0b1319f", "node_type": "1", "metadata": {"window": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "original_text": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22"}, "hash": "41fff66ebd89cee973cddc35eff6942c7c3ef7a3df79450662d5619fde8b2748", "class_name": "RelatedNodeInfo"}}, "text": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "start_char_idx": 0, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "534376e3-8853-4b1b-bc4c-db85a0b1319f": {"__data__": {"id_": "534376e3-8853-4b1b-bc4c-db85a0b1319f", "embedding": null, "metadata": {"window": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "original_text": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "140b4649-c00d-49cb-891d-ea10aa648372", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6591765b1fd8d21b302b245b8caa8299b227b5324a5847e29e3bbb9819158748", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44da69d5-b5e4-43ff-a9df-6d4a6e0c184e", "node_type": "1", "metadata": {"window": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "original_text": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "page_label": "21", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9d83df48f2199142a552ae4ec71f48d270a031ce415099abb6c29ffa56e87a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9", "node_type": "1", "metadata": {"window": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "original_text": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23"}, "hash": "455b72831e19c0a4adeefef27ca585815c99dfa87fa665181de12032a48288e8", "class_name": "RelatedNodeInfo"}}, "text": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "start_char_idx": 0, "end_char_idx": 1006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9": {"__data__": {"id_": "a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9", "embedding": null, "metadata": {"window": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "original_text": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "page_label": "23", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f12da2ed-7d12-4574-a7f1-73d6cf693dfd", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "afd276543a93f7f0cfb9e4e9a31ec5645af47abe641d351f094413af069e3e7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "534376e3-8853-4b1b-bc4c-db85a0b1319f", "node_type": "1", "metadata": {"window": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "original_text": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1e7712ef1e2346545da370a490f6878ad62c9458175ea26ad5b07dcdcd02010", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cde0875d-e0e0-403f-8d66-48b239fb5d83", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "ac6d10e52ce21a3bb7ac9aecbf8734f140b26262acacc2c6f5a6cf1d28427637", "class_name": "RelatedNodeInfo"}}, "text": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "start_char_idx": 0, "end_char_idx": 1365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cde0875d-e0e0-403f-8d66-48b239fb5d83": {"__data__": {"id_": "cde0875d-e0e0-403f-8d66-48b239fb5d83", "embedding": null, "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9", "node_type": "1", "metadata": {"window": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "original_text": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "page_label": "23", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e79342848852ab3dfe02821a91658bcb354d42ee37171a87b767b5317d6a6df5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "116d8525-d9ae-4b38-9dbb-b0ff041b17ad", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "c8b19792240466354f6693a66473011d8edadf0128155ecc1921780fe693602a", "class_name": "RelatedNodeInfo"}}, "text": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 0, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "116d8525-d9ae-4b38-9dbb-b0ff041b17ad": {"__data__": {"id_": "116d8525-d9ae-4b38-9dbb-b0ff041b17ad", "embedding": null, "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cde0875d-e0e0-403f-8d66-48b239fb5d83", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a22221054e642c75bcb62c10204d1199582929e398b742e8bcad55d097234c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51072f9d-ea79-453c-a19c-0958f6a650e7", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "c3a545b4ca464ae1ff8bbb681d109236ae29015f5b3bd529b0ea16796980ca41", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 357, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51072f9d-ea79-453c-a19c-0958f6a650e7": {"__data__": {"id_": "51072f9d-ea79-453c-a19c-0958f6a650e7", "embedding": null, "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "116d8525-d9ae-4b38-9dbb-b0ff041b17ad", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "63bf8583977edd7a47add9f1813019bc6be3eb989a15a99d660a65a229111908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce9d676a-7d2c-48ec-a4dc-14a8f602df52", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d01552453cf476e7e96c47510ff013f1de447c53334bc203470d11b4cb087fe6", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 472, "end_char_idx": 612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce9d676a-7d2c-48ec-a4dc-14a8f602df52": {"__data__": {"id_": "ce9d676a-7d2c-48ec-a4dc-14a8f602df52", "embedding": null, "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51072f9d-ea79-453c-a19c-0958f6a650e7", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00497586f20a5673ffe642d0d7462256c1d752aa1219ca9dcf27c28833f2a340", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efc52a5b-46f2-4dfe-9d87-94fa6acbd630", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "4e95c5ff7d68ee6daf1412c3c72e95daff15c4fdf159d53ed786c5b5814f92e7", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 612, "end_char_idx": 731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efc52a5b-46f2-4dfe-9d87-94fa6acbd630": {"__data__": {"id_": "efc52a5b-46f2-4dfe-9d87-94fa6acbd630", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce9d676a-7d2c-48ec-a4dc-14a8f602df52", "node_type": "1", "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "362e1eb8ab3bc268f0852263f555f5c0ca22ab3c85ae2c59fcd8b6ab4f079f14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "7ad98a25e8b667d20690afcb085f5e0a9f476496eb2a2868ec2ca050c5ebc83f", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 731, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247": {"__data__": {"id_": "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efc52a5b-46f2-4dfe-9d87-94fa6acbd630", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf2e36e72380ed0ac99b5af53e5c6ab348ea2af5e9f9e3f44af34cd982e20147", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b7eddd4-4bb7-4db9-871c-7aad83a6689a", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "a85c6494c642e156e0d6a041dc3ea461699180c71f978af48efeadf0bd33efb4", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 950, "end_char_idx": 1132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b7eddd4-4bb7-4db9-871c-7aad83a6689a": {"__data__": {"id_": "2b7eddd4-4bb7-4db9-871c-7aad83a6689a", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ea34df55a05251a5f0fc0c5cc272e572025ea9251111a82a2778ba40714275f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df18d41b-d265-45bb-9c43-f438ec9227d7", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). "}, "hash": "851ea85f39e9c40ea6bf826a716aa513703515d252a56a8ab8e312c9fade10da", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1132, "end_char_idx": 1413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df18d41b-d265-45bb-9c43-f438ec9227d7": {"__data__": {"id_": "df18d41b-d265-45bb-9c43-f438ec9227d7", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b7eddd4-4bb7-4db9-871c-7aad83a6689a", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1a8dc5772ed0140ff2161c4a447143fb668054883e2202b56b2ad0b6f56dad2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "663b95e0-9562-4796-a711-f3f7e8c36dce", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. "}, "hash": "205b13b9a439d6812dbb6853404465cad5c8e3d6fa768c39ff70d832f6ad5a1b", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "start_char_idx": 1413, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "663b95e0-9562-4796-a711-f3f7e8c36dce": {"__data__": {"id_": "663b95e0-9562-4796-a711-f3f7e8c36dce", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df18d41b-d265-45bb-9c43-f438ec9227d7", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit). ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05369f7d5fa079d044c5fb136723ca55f2d6f28013215627785947345fe4a064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e59f16b9-08ef-4151-9e4a-8a7cc6742023", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. "}, "hash": "4fa457251c459914401dc76f2d6b9254979df2cbe1eea5ce9c7489b5ab8323c4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "start_char_idx": 1702, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e59f16b9-08ef-4151-9e4a-8a7cc6742023": {"__data__": {"id_": "e59f16b9-08ef-4151-9e4a-8a7cc6742023", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "663b95e0-9562-4796-a711-f3f7e8c36dce", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb4f675971fee9eb591dbf9cec6b706aab5e99891f81db15b4134eca61ba041c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15e9b2dd-b31c-4fb9-836c-d62820386994", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "original_text": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n"}, "hash": "9fbd4c6c507c272242e9c63306a878c6e69d78ecafd2e665de56b90b0d3afea6", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "start_char_idx": 1787, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15e9b2dd-b31c-4fb9-836c-d62820386994": {"__data__": {"id_": "15e9b2dd-b31c-4fb9-836c-d62820386994", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "original_text": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e59f16b9-08ef-4151-9e4a-8a7cc6742023", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b9207fb6c1809d6e291e4bfa2a9899a0415cb8b3e8b117255904b58e266e360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. "}, "hash": "501ba0549e04016d8cc8d433e2329d7b1146a0e67c92d49f958ef9f5f8e44a60", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "start_char_idx": 1944, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28": {"__data__": {"id_": "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15e9b2dd-b31c-4fb9-836c-d62820386994", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements and LIFO expense (credit).  Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "original_text": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61c38daf280e5c2b0545690b0b15da3ae316ea4b41bfce696ca83db9a5ca5bdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n"}, "hash": "44c85cb9e21c461f8b14836b725f27e789ac2a14cc1881d289b0a133b133ac76", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "start_char_idx": 2111, "end_char_idx": 2407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1": {"__data__": {"id_": "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted\ngross profit to total revenue.  Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "original_text": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b154a2d2ea199a770867f1762e5eea06682bd89db5836d433c78c4da98f214fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b130470a-5503-4256-80a8-fa09c68bfa6f", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. "}, "hash": "25ebce3ba3f8a4137fcfb7d2130419c90beac715da6e6ba7d1166968458ef6ff", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "start_char_idx": 2407, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b130470a-5503-4256-80a8-fa09c68bfa6f": {"__data__": {"id_": "b130470a-5503-4256-80a8-fa09c68bfa6f", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a\nsupplemental measure of the Company\u2019s ongoing operating performance.  Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "original_text": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7ee92067a1e6edd4b38db8b8a3114c4fa2b74debbd4c9b0512c6036c37e27a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fde7b26d-2196-4fde-8ced-d433f54ec88e", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n"}, "hash": "61d193f781b625c780945a29129d5ca92999cd46d010ce06711a876ca9eaa69f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "start_char_idx": 2589, "end_char_idx": 2845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fde7b26d-2196-4fde-8ced-d433f54ec88e": {"__data__": {"id_": "fde7b26d-2196-4fde-8ced-d433f54ec88e", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b130470a-5503-4256-80a8-fa09c68bfa6f", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements and\nLIFO expense (credit) are excluded because the Company cannot control the amounts recognized or timing of these items.\n Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "338441d593ee762565806ac12e3cad38cf8cf3fde442fd235eedf70227180d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "962c1627-cc6b-4b76-ab3b-f6e53942d33c", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. "}, "hash": "23847d5aa2fadfb401f3fb9cb18d868f3cc0545712f69567e0ab6626bee84d91", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "start_char_idx": 2845, "end_char_idx": 2941, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "962c1627-cc6b-4b76-ab3b-f6e53942d33c": {"__data__": {"id_": "962c1627-cc6b-4b76-ab3b-f6e53942d33c", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fde7b26d-2196-4fde-8ced-d433f54ec88e", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements relate to the settlement of lawsuits that have been filed against brand\npharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to\ndelay or prevent generic drugs from entering the market.  LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f7a921e8b19e5a26b8f87a6050f6d8857c1fbe314d6a5b1c8a7b6aec981bc9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03660060-2a1a-461f-95be-68bc149be816", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. "}, "hash": "262398e3d7c83d80d944fb86cc662c9fee5863739b6b9e1bfc517a7cb78ce893", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "start_char_idx": 2941, "end_char_idx": 3102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03660060-2a1a-461f-95be-68bc149be816": {"__data__": {"id_": "03660060-2a1a-461f-95be-68bc149be816", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "962c1627-cc6b-4b76-ab3b-f6e53942d33c", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by changes in inventory quantities,\nproduct mix, and manufacturer pricing practices, which may be impacted by market and other external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc71d0a09d1e8d692cb4ab55a78337dc3454c8fa2e309683d98d32e6adde7d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56387cc2-1cac-4b93-b0da-98a50de88e3b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n"}, "hash": "8de663cf09f4b661e081e87105c43d88b893147419134a580734ae736fb24845", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "start_char_idx": 3102, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56387cc2-1cac-4b93-b0da-98a50de88e3b": {"__data__": {"id_": "56387cc2-1cac-4b93-b0da-98a50de88e3b", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03660060-2a1a-461f-95be-68bc149be816", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, and\nimpairment of assets.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "772cf166cfd628030dcc3d67cd2aea5a97bcddfb920b9a10ed41babd8e2e0a1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8bc301b-ef19-41ef-bb3b-006b77d99327", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "39e49c79c57f6c65886a3c7879a5f257e8293660e0c872db2b3b93749cbf869d", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "start_char_idx": 3215, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8bc301b-ef19-41ef-bb3b-006b77d99327": {"__data__": {"id_": "d8bc301b-ef19-41ef-bb3b-006b77d99327", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56387cc2-1cac-4b93-b0da-98a50de88e3b", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.\n Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21f1f75b91a7a68d590c512b13dd79af2647d9ce573360fc6435bec720a3cc60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2fb26cf-26be-47b2-9101-3930412859c6", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "46b14ca4905dbc80afb5b5a282500d8236ea341464a8b285051cea8073c6a88c", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 3495, "end_char_idx": 3744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2fb26cf-26be-47b2-9101-3930412859c6": {"__data__": {"id_": "c2fb26cf-26be-47b2-9101-3930412859c6", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8bc301b-ef19-41ef-bb3b-006b77d99327", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization is excluded because it is a non-cash item and does not reflect the operating\nperformance of the acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2539240309270f04cc0b996c95f39bce877c34453247e780fd1ad780627f5a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95873e01-c9cd-4822-b8fb-dadc85e0446c", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "54241a8d5609232203936aa0dd57520b6bd4d91dafcf469f2ccdd5381eef3b27", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 3744, "end_char_idx": 3837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95873e01-c9cd-4822-b8fb-dadc85e0446c": {"__data__": {"id_": "95873e01-c9cd-4822-b8fb-dadc85e0446c", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2fb26cf-26be-47b2-9101-3930412859c6", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-\nrecurring business restructuring.  We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3fa1842d24284227a4ad1e6ef18ab8359250f1f275bc0bbbfb219feab9e51b48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1db362ef-c16f-4cc3-8385-9416412ffb48", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. "}, "hash": "8d619803fb3d3f037b300bd12895a71e656598d8c0cd56f8c260a68eb4674e65", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 3837, "end_char_idx": 4084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1db362ef-c16f-4cc3-8385-9416412ffb48": {"__data__": {"id_": "1db362ef-c16f-4cc3-8385-9416412ffb48", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95873e01-c9cd-4822-b8fb-dadc85e0446c", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses and the impairment of\nassets that are unusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these\nexclusions facilitate the analysis of our ongoing operational performance.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59877abd4f429f4243b297e24884b4f1237c6af4671e3689b22c7b93be4f5a0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06384128-4446-4dbb-82b3-b28fbc9fe756", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "1ecfd1a33182a54ff77f2753b9ee95f589a2b889201bce5d2790eeea0b966b0e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 4084, "end_char_idx": 4289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06384128-4446-4dbb-82b3-b28fbc9fe756": {"__data__": {"id_": "06384128-4446-4dbb-82b3-b28fbc9fe756", "embedding": null, "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1db362ef-c16f-4cc3-8385-9416412ffb48", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "794149731abf08832e563cea4508f3d80d3293690cf0dd967053f417164d04fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85795e66-3c1c-4e46-aa12-41156f1b5739", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24"}, "hash": "d768a7317cabf0cc5d9a14675bcf05777a987b8e49fc12f05ac189de8b786787", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 4289, "end_char_idx": 4525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85795e66-3c1c-4e46-aa12-41156f1b5739": {"__data__": {"id_": "85795e66-3c1c-4e46-aa12-41156f1b5739", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a1c7425a807914e3725f528e7d7f9b9bf4cc38436c63f3c4bfacd52e019f07", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06384128-4446-4dbb-82b3-b28fbc9fe756", "node_type": "1", "metadata": {"window": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e072cd60896428258738174a4f55d3e9be87df4cba74a3a19f968c2b82167943", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7762a227-b8a5-45d8-88f9-63a719dc8afc", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "rate.\n"}, "hash": "0dea112ee67d7d4a6938456f051d33a126ae468cd01bed53fd50b3dd40d84b4f", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "start_char_idx": 4525, "end_char_idx": 4687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7762a227-b8a5-45d8-88f9-63a719dc8afc": {"__data__": {"id_": "7762a227-b8a5-45d8-88f9-63a719dc8afc", "embedding": null, "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "rate.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85795e66-3c1c-4e46-aa12-41156f1b5739", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\nthe same items that are described above and excluded from adjusted operating income.  In addition, the gain (loss) on the\ncurrency remeasurement of the deferred tax asset relating to Swiss tax reform is excluded from adjusted income before\nincome taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "original_text": "Management believes that this non-\nGAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted effective tax\n24", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1de532cf9892a7e79eca9afd4dcb1df2aac370e59cbe639d086ca341692ba323", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7aee071-862a-47d6-b0b6-097cdae9003d", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "e84ec01bc1c8bc19e957b772a927b893e0c8106d9c050844b68c8232c5c2e6cc", "class_name": "RelatedNodeInfo"}}, "text": "rate.\n", "start_char_idx": 0, "end_char_idx": 6, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7aee071-862a-47d6-b0b6-097cdae9003d": {"__data__": {"id_": "b7aee071-862a-47d6-b0b6-097cdae9003d", "embedding": null, "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7762a227-b8a5-45d8-88f9-63a719dc8afc", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "rate.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc288696d5a8e2b3fbe7e3d04f8c6c2854364b9211f922781b62b8afa23d1eea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9522e131-6b25-46d7-89ee-82fd3ff30f9e", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "b55b193bd2092a37786d82c62991017bca0bb935927a1032999277a40e327a6e", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 6, "end_char_idx": 203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9522e131-6b25-46d7-89ee-82fd3ff30f9e": {"__data__": {"id_": "9522e131-6b25-46d7-89ee-82fd3ff30f9e", "embedding": null, "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7aee071-862a-47d6-b0b6-097cdae9003d", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8159bdee45b51a5d74eee009ad2cab7ee074ad15a61aab98004c29fab220a830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38dd4cd5-128a-49a6-b675-5b0edf9c4e84", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "bb6f44c4a6715d571a28b316880b5077511b5a3f50be7f3114bd1a7993617d65", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 203, "end_char_idx": 475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38dd4cd5-128a-49a6-b675-5b0edf9c4e84": {"__data__": {"id_": "38dd4cd5-128a-49a6-b675-5b0edf9c4e84", "embedding": null, "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9522e131-6b25-46d7-89ee-82fd3ff30f9e", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5df16e2b1d48eae603d2c2f814cf7fdea4e0e135f9825c0a1e62b60e108d0f76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa52b698-0f61-4c6d-bd34-2cd73a376484", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. "}, "hash": "5968be9d8f488bb1005513bb7233f4d6191efed841da3018e1d6f39a2142f42b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 475, "end_char_idx": 713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa52b698-0f61-4c6d-bd34-2cd73a376484": {"__data__": {"id_": "fa52b698-0f61-4c6d-bd34-2cd73a376484", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38dd4cd5-128a-49a6-b675-5b0edf9c4e84", "node_type": "1", "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57016ddad11103a912bd557eadef1f2fdcb71e59fbca76bc5d66aca666fa3b3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b85ef90a-6b5a-4931-b83d-804db84156bc", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n"}, "hash": "73707e3a3cdded85264eafe5b0ad084634c2a818248b050845f02ef9d412bc9a", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "start_char_idx": 713, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b85ef90a-6b5a-4931-b83d-804db84156bc": {"__data__": {"id_": "b85ef90a-6b5a-4931-b83d-804db84156bc", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa52b698-0f61-4c6d-bd34-2cd73a376484", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "original_text": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0fd25268171ead3190aee963e426bb4d473e7f8bd246a28519256e053183a80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "275f5f0d-dbdd-4298-ad25-8c6e07c551f8", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "9c955241e9f87f5909e72bc93a7a7442bb277847d444134e940a971cb7d6852c", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "start_char_idx": 1140, "end_char_idx": 1310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "275f5f0d-dbdd-4298-ad25-8c6e07c551f8": {"__data__": {"id_": "275f5f0d-dbdd-4298-ad25-8c6e07c551f8", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b85ef90a-6b5a-4931-b83d-804db84156bc", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "original_text": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dd668b222cc7f0f7fe3a2af935231a585f3bcb5ea224b63bd86c0bf620eac7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72aee4de-f57a-4db3-9b5d-7ee87f67b17e", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. "}, "hash": "763cc74f0c537669091b3a05662a4eb722e29dae9ca78ebbebcfa903cbb0d945", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 1310, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72aee4de-f57a-4db3-9b5d-7ee87f67b17e": {"__data__": {"id_": "72aee4de-f57a-4db3-9b5d-7ee87f67b17e", "embedding": null, "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "275f5f0d-dbdd-4298-ad25-8c6e07c551f8", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec7b66b1df9c4bfb3c8b0203e8b1f3c7a24706604813b9a902098020af74fbb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c2ae45f-62e2-4fe5-8d13-419cf069e150", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n"}, "hash": "0ff57b1cadbc82e29d8c37a1e7da19a802d703b7f21e38ca1b7ed5a7c8ac5c48", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "start_char_idx": 1554, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c2ae45f-62e2-4fe5-8d13-419cf069e150": {"__data__": {"id_": "6c2ae45f-62e2-4fe5-8d13-419cf069e150", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72aee4de-f57a-4db3-9b5d-7ee87f67b17e", "node_type": "1", "metadata": {"window": "Certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments for the three and six\nmonths ended March 31, 2022 and the income tax deduction recognized in connection with the permanent shutdown of\nPharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also excluded from\nadjusted income tax expense for the six months ended March 31, 2021.  Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d510f1154ab5ee5786958f34a48da484b6bd4ce3034565db7d9ce4a05e05ceb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "664a7b21-8db4-43c0-896a-0483caa962f1", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. "}, "hash": "980003e04f5d7eec525506e93a1a63839a022ba5ddbec468c627e8e939cc543c", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "start_char_idx": 1768, "end_char_idx": 1939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "664a7b21-8db4-43c0-896a-0483caa962f1": {"__data__": {"id_": "664a7b21-8db4-43c0-896a-0483caa962f1", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c2ae45f-62e2-4fe5-8d13-419cf069e150", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in\nSwitzerland are excluded from adjusted income tax expense for the three and six months ended March 31, 2022 and 2021.\n Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c50df6ec7aaa4f015b72d3e5cfdcf8ec99748de11669494e279ba00492c7bb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b752543a-3ee5-49fb-8ef7-c349192c3864", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "b434a2e2ab469f88fa9c7dc44480c781853618fba3ff4b08fba59c9953e8cdb6", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "start_char_idx": 1939, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b752543a-3ee5-49fb-8ef7-c349192c3864": {"__data__": {"id_": "b752543a-3ee5-49fb-8ef7-c349192c3864", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "664a7b21-8db4-43c0-896a-0483caa962f1", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "original_text": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc44832c603fb769e34e984d5db9fe3b30190d1dd5304ed593fec6aa2a871ea3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc96b775-b3a5-4960-a754-395e46a75d26", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "756e79393f3c397eacf19be879e169a8be852e4b11f73529498bbe50489fee53", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2124, "end_char_idx": 2368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc96b775-b3a5-4960-a754-395e46a75d26": {"__data__": {"id_": "dc96b775-b3a5-4960-a754-395e46a75d26", "embedding": null, "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b752543a-3ee5-49fb-8ef7-c349192c3864", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of the same items described above.  Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bed1219de3e439c668800867bd8455687b4a293341dff47840f24de88a806a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6989bb7-5439-4667-b222-dcbfa59440c8", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. "}, "hash": "2bdc07fa67d96c5dd0fffefe338674e15be716556fbe0baec839265ab13579da", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 2368, "end_char_idx": 2850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6989bb7-5439-4667-b222-dcbfa59440c8": {"__data__": {"id_": "a6989bb7-5439-4667-b222-dcbfa59440c8", "embedding": null, "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc96b775-b3a5-4960-a754-395e46a75d26", "node_type": "1", "metadata": {"window": "Management believes that this\nnon-GAAP financial measure is useful to investors because it facilitates the calculation of adjusted net income attributable to\nthe Company.\n Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4da8fbf04ccf782f2975cec06a0118eba2a214c96b12d8272ae5e0b6112e6d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79fa5a85-dff9-422b-a9f8-e5effd00074e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n"}, "hash": "35e703e6eaee42993d5770505b4437dddd137fcd473583a3b1553e626b6d62a8", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "start_char_idx": 2850, "end_char_idx": 3407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79fa5a85-dff9-422b-a9f8-e5effd00074e": {"__data__": {"id_": "79fa5a85-dff9-422b-a9f8-e5effd00074e", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6989bb7-5439-4667-b222-dcbfa59440c8", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to the Company:  Adjusted net income attributable to the Company is a non-GAAP financial\nmeasure that excludes the same items that are described above.  Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "original_text": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef9518a2c7e64dd784ab414e7d610729e5db05091877faa4b7b7617fb3c63391", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "067dffd4-d88f-4555-a20d-fe232cfee26e", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. "}, "hash": "ee903039c4f68ba93cf2ab906bfdd9d227f51de1f78a0f3486aa38bef69573b6", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 3407, "end_char_idx": 3761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "067dffd4-d88f-4555-a20d-fe232cfee26e": {"__data__": {"id_": "067dffd4-d88f-4555-a20d-fe232cfee26e", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79fa5a85-dff9-422b-a9f8-e5effd00074e", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure\nis useful to investors as a supplemental way to evaluate the Company's performance because the adjustments are unusual,\nnon-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "original_text": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcc44c8b9addfe781c6983ec12085766b504d1f7eeab7850248dd287bdb3225c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc37d72-b987-47db-bb74-b84031914057", "node_type": "1", "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. "}, "hash": "1d63be45de768fd7f28cf28e1165622ae309eeb866d6d81f7e21b3e683f67056", "class_name": "RelatedNodeInfo"}}, "text": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "start_char_idx": 3761, "end_char_idx": 3915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc37d72-b987-47db-bb74-b84031914057": {"__data__": {"id_": "8bc37d72-b987-47db-bb74-b84031914057", "embedding": null, "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "067dffd4-d88f-4555-a20d-fe232cfee26e", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); acquisition-related intangibles amortization;\nemployee severance, litigation, and other; impairment of assets; and the loss on the currency remeasurement related to Swiss\ntax reform, in each case net of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "original_text": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ff68a784c56e2ce7a5e1c54b631255803deb688116c958bf3a36bbbc979c899", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a145451b-04aa-411e-852c-1d240e1953f4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. "}, "hash": "8bf535308b74b485e2b9563838ff8791f5b5c645f0719a7f1aaea5de713e209b", "class_name": "RelatedNodeInfo"}}, "text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "start_char_idx": 3915, "end_char_idx": 4070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a145451b-04aa-411e-852c-1d240e1953f4": {"__data__": {"id_": "a145451b-04aa-411e-852c-1d240e1953f4", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc37d72-b987-47db-bb74-b84031914057", "node_type": "1", "metadata": {"window": "In addition, the\nper share impact of certain discrete tax expense (benefits) primarily attributable to foreign valuation allowance adjustments\nfor the three and six months ended March 31, 2022 and the income tax deduction recognized in connection with the\npermanent shutdown of PharMEDium as well as the CARES Act for the six months ended March 31, 2021, and the per share\nimpact of certain expenses relating to tax reform in Switzerland are also excluded from adjusted diluted earnings per share\nfor the three and six months ended March 31, 2022 and 2021.  Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "original_text": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a25ba9b07a37507c56b7321e76822e42669deee49a15844efbf1a83f9d99f9f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2b4689b-7706-4cee-9cf7-579e598a2c5e", "node_type": "1", "metadata": {"window": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n"}, "hash": "1a24b9a9e832213e4c90dc9e975f5974fc78e7db98278339095da7b113eb8934", "class_name": "RelatedNodeInfo"}}, "text": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "start_char_idx": 4070, "end_char_idx": 4247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2b4689b-7706-4cee-9cf7-579e598a2c5e": {"__data__": {"id_": "c2b4689b-7706-4cee-9cf7-579e598a2c5e", "embedding": null, "metadata": {"window": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a145451b-04aa-411e-852c-1d240e1953f4", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is\nuseful to investors because it eliminates the per share impact of the items that are outside the control of the Company or that\nwe consider to not be indicative of our ongoing operating performance due to their inherent unusual, non-operating,\nunpredictable, non-recurring, or non-cash nature.\n The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "original_text": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b708c067fb911fc6bb9349431d95db8f1a3e6c202a1275b998cb32dcbc1cae4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8093fde2-b664-4e7e-8b0b-b82dc45479d4", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. "}, "hash": "f08428f0eb2303e3d5e31e58aa37cff00d2662d6b6d7720201c0b510f40760c8", "class_name": "RelatedNodeInfo"}}, "text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "start_char_idx": 4247, "end_char_idx": 4403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8093fde2-b664-4e7e-8b0b-b82dc45479d4": {"__data__": {"id_": "8093fde2-b664-4e7e-8b0b-b82dc45479d4", "embedding": null, "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2b4689b-7706-4cee-9cf7-579e598a2c5e", "node_type": "1", "metadata": {"window": "The company also presents certain information related to current period operating results in \u201cconstant currency,\u201d which is a non-\nGAAP financial measure.  These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "original_text": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb2c66a0506ed10e82e0017d790b256bc9f87d56d892a02671eeb3eb1926ff10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0733c2dd-009a-4dce-9208-a181b613f1fb", "node_type": "1", "metadata": {"window": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. "}, "hash": "a58f391c46bc9535fc2ed215ebc3326c667781a759c7025301416e5de6250a49", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "start_char_idx": 4403, "end_char_idx": 4650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0733c2dd-009a-4dce-9208-a181b613f1fb": {"__data__": {"id_": "0733c2dd-009a-4dce-9208-a181b613f1fb", "embedding": null, "metadata": {"window": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8093fde2-b664-4e7e-8b0b-b82dc45479d4", "node_type": "1", "metadata": {"window": "These amounts are calculated by translating current period results at the foreign currency exchange rates\nused in the comparable period in the prior year.  The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e81305d4378cec2d03ba2fa2a43eb96b6a3aa49ab1843aaa89383fca3834a5b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da4fc845-3f5a-4d76-98a6-df19c3268f67", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. "}, "hash": "fcb6340806ab47154bbf19406e97dbee816acfbed5b69f7121549a1157906bb6", "class_name": "RelatedNodeInfo"}}, "text": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "start_char_idx": 4650, "end_char_idx": 4954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da4fc845-3f5a-4d76-98a6-df19c3268f67": {"__data__": {"id_": "da4fc845-3f5a-4d76-98a6-df19c3268f67", "embedding": null, "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0733c2dd-009a-4dce-9208-a181b613f1fb", "node_type": "1", "metadata": {"window": "The company presents such constant currency financial information because it has\nsignificant operations outside of the United States reporting in currencies other than the U.S.  dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27ad7f65fb843c9525ba1a730e40cfd5f5d0873527ded798dc5791a7c898f18c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "accbe91d-4ab3-42ca-be66-4ba269f7d9e7", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. "}, "hash": "c94c362de6e54a2aa3cc5bf8e5c28c8bbb6c38ee69d07d5540361057569da0dc", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "start_char_idx": 4954, "end_char_idx": 5240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "accbe91d-4ab3-42ca-be66-4ba269f7d9e7": {"__data__": {"id_": "accbe91d-4ab3-42ca-be66-4ba269f7d9e7", "embedding": null, "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da4fc845-3f5a-4d76-98a6-df19c3268f67", "node_type": "1", "metadata": {"window": "dollar and this presentation provides a\nframework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations.\n In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "77ebd081542cba39885f05bcdc554880e91c9204d1b1e34349f2671077ebcd14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d043c55b-659b-4144-b2e4-10b6ee234216", "node_type": "1", "metadata": {"window": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The Company does not provide forward\n25"}, "hash": "d773f10a82c9588f844786ec4e55a56ce580eb9d988afe8b2c9d7cd1acdf05be", "class_name": "RelatedNodeInfo"}}, "text": "For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "start_char_idx": 5240, "end_char_idx": 5542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d043c55b-659b-4144-b2e4-10b6ee234216": {"__data__": {"id_": "d043c55b-659b-4144-b2e4-10b6ee234216", "embedding": null, "metadata": {"window": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The Company does not provide forward\n25", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "24ca6300-8582-410b-ac65-383620795996", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7383570ded0637558ccb73482604087b5ee996b907578ced449ca4a5970ba915", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "accbe91d-4ab3-42ca-be66-4ba269f7d9e7", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2022 guidance for diluted earnings per share and operating income, and\nhas previously provided non-GAAP fiscal year 2022 guidance for adjusted free cash flow and effective income tax rate.  The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million. ", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6429f8f61e5e706f47cd9fb7ccd732d2f3da5f525f1b43b63e89b1899690374", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0339c0b-72f4-4168-a947-200eeeb8c279", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. "}, "hash": "0f7d1cc3bec6eca2d60161f5ed1fd91fb20b74d38c2fa03448ddbf1b37f04a90", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward\n25", "start_char_idx": 5542, "end_char_idx": 5581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0339c0b-72f4-4168-a947-200eeeb8c279": {"__data__": {"id_": "b0339c0b-72f4-4168-a947-200eeeb8c279", "embedding": null, "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8f8f4f3066e1775f5dd480e941c7199e786ba78a6d63c8fd5fcdbcb8715c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d043c55b-659b-4144-b2e4-10b6ee234216", "node_type": "1", "metadata": {"window": "The guidance\nfor each metric excludes the same or similar items as those that are excluded from the historical non-GAAP financial measures, as\nwell as significant items that are outside the control of the Company or inherently unusual, non-operating, unpredictable, non-\nrecurring or non-cash in nature.  For fiscal year 2022, we have defined the non-GAAP financial measure of adjusted free cash flow as\nnet cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts\nrelating to legal settlements, minus capital expenditures.  For the six months ended March 31, 2022 adjusted free cash flow of $951.0\nmillion consisted of net cash provided by operating activities of $1,130.0 million minus capital expenditures of $209.3 million, plus\nlegal settlement payments of $32.2 million, less favorable legal settlements of $1.8 million.  The Company does not provide forward\n25", "original_text": "The Company does not provide forward\n25", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1a5604ed7e21316745cff8968b5c35b86cf037e5662ccbc20e257706ad1461a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b5403c0-8977-4326-aa70-5ad85b94a629", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n"}, "hash": "c75cf8c76b33ba82e5c018e85ac6ea59a517b4be9af7f6f7c43e1303c9a05589", "class_name": "RelatedNodeInfo"}}, "text": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 0, "end_char_idx": 199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b5403c0-8977-4326-aa70-5ad85b94a629": {"__data__": {"id_": "5b5403c0-8977-4326-aa70-5ad85b94a629", "embedding": null, "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8f8f4f3066e1775f5dd480e941c7199e786ba78a6d63c8fd5fcdbcb8715c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0339c0b-72f4-4168-a947-200eeeb8c279", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4394cf792a108c95b6a3cb512bfdbafe1d74f77e87e29c94da0edd6bd3f4467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7409afff-ae03-4163-abd4-ea41288a1ce6", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n"}, "hash": "3654611990f615093ed3e677fdfde4661b158d7e39a02a2b08ffc3c25a14341a", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "start_char_idx": 199, "end_char_idx": 516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7409afff-ae03-4163-abd4-ea41288a1ce6": {"__data__": {"id_": "7409afff-ae03-4163-abd4-ea41288a1ce6", "embedding": null, "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8f8f4f3066e1775f5dd480e941c7199e786ba78a6d63c8fd5fcdbcb8715c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b5403c0-8977-4326-aa70-5ad85b94a629", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15893e98b0754903eb48dd231cdd5b47ea89f8b8f332526bb35d3fb5a95e9402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4303b010-b572-4c42-8a8d-8a9ef3f857f6", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26"}, "hash": "09cc724445d08c27802a2ca7a55a7db14f70a3409c32538d2a22b7eb4828ce6f", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "start_char_idx": 516, "end_char_idx": 611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4303b010-b572-4c42-8a8d-8a9ef3f857f6": {"__data__": {"id_": "4303b010-b572-4c42-8a8d-8a9ef3f857f6", "embedding": null, "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a8f8f4f3066e1775f5dd480e941c7199e786ba78a6d63c8fd5fcdbcb8715c94", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7409afff-ae03-4163-abd4-ea41288a1ce6", "node_type": "1", "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "877f1937f50f6df266e1ed4fada968d871e34fa70a4a4147a6b93772d7c8b77f", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "start_char_idx": 611, "end_char_idx": 861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"e94efa5e-508e-4712-946a-82f6743526cf": {"doc_hash": "4c65c13a6069180698e97a8379dd3b7e8a553505223bdc8d7488a3cd067172e6", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "04fd1cc1-6134-4fb5-b839-afec927aa143": {"doc_hash": "458f77b386324ffbf31e7dd2398f01c7f9d02623a55785f3225941c28a7ddd91", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "7c088867-0411-497a-8d52-19e4986beb64": {"doc_hash": "62723c0164bd1ed26f712a279b7e160a400cc58a87d42aad3f7d67be7f191cdd", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "795015aa-4388-4b5a-8fc5-b6be3d33be8a": {"doc_hash": "7604b40db3a3e6c0c3cb89092894b525308ff0bd812be1323a75dbc14b71a5c2", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "4463fe6b-dc72-4eca-8cba-b924135d62ed": {"doc_hash": "828cbc6d3b1ede8c9d040351656b8469f399236dc4bea9f3105c8364cff3e727", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "2e505af9-42b7-4333-82e4-a8503c0f9b9a": {"doc_hash": "a005e2d8a251a550704801ae947d85d86caf43255eb71d632e31b814f64b6199", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314": {"doc_hash": "2eab2ba32faf7a608d811ca3cf31e78ba488a5339919662bfe9f2d2042ba5a41", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "bfe83f9f-ace3-4936-8a91-f77544081895": {"doc_hash": "421426345635c7e04365d224fc4c425c0960fcbf4ff0e8e22a15eb1b67484bf3", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2": {"doc_hash": "90274798a3264b225491ae47f2d5a6e7e8277be9f1c5bb3bfe6b6ba779c9efb0", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "c18946d8-1ba0-4e99-82c4-57826bc95a27": {"doc_hash": "0b483c382504d88b5f361797350b1eb8313c8955efc85a03768e2171b2e81fb9", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646": {"doc_hash": "6dd695b8d38b4db5b71e6518274fdccee3d7fd8817d459b7f7065ad95553636d", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "b758306d-90b8-4755-a409-66fdf63fc92d": {"doc_hash": "02a7064d0b4452b8cd28c61ed6e6805a87664e8e83d135f5bf79127763c45ca0", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "64143e5f-fd2c-42c2-a43e-5b51845795af": {"doc_hash": "ae07ede5b802bcf0d4c7e50c9aa1f43b8a3538c734d2b7089c1bc68e2f529cb3", "ref_doc_id": "258f3f3e-c961-438e-8fa1-ae7ef3aa5684"}, "3e9e3225-451a-4d8a-8da0-9b2b9246f23f": {"doc_hash": "dbe5c063b0517a0d6df2761e6276616548bb7122fa486473cb3c6cc57915c28d", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35": {"doc_hash": "6adb5f171293c4170d45322c2049c85ca0404f9c24adaf6789a80cd61a34210d", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "314084e8-1100-4d35-89f2-c8f5d637128e": {"doc_hash": "bf425e9a6cdf1eee92460177416cdfab0f75952215677455bfa7b9c0bc2b2ad9", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "11fd6039-a9f7-41fb-99e7-45ef8e134919": {"doc_hash": "7e9783e49c64a79d572179a8042a4a1a0c265481a9b348b22a8a1f1e71a06ff5", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "ab3200cc-1acf-41c4-a32b-55901fe281dc": {"doc_hash": "6a8d1261439fcbe0232ea8405fe108914d06919aea85c4b503b43e8ba7898ea5", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "c9875db4-50a3-4ef3-8089-5f327312e6d8": {"doc_hash": "c89615a005107da76627ef7af501dbf8c146dae8a7266edd14264899264cab2f", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "2bebfea0-2dac-44e2-9c07-ca574b45cab0": {"doc_hash": "e4dbba26a6f8fd6c03a0bf8856bfe9eaf8688abc4105a6a60d324a66cb4b79c9", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "f745ebb1-d467-4957-b965-e9a99e59501c": {"doc_hash": "cbb7c79019068cc37fff811770cbe2b2b65ba18e7855f1ed3dcf676199a719a9", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c": {"doc_hash": "a2931321b6a7ae947bc08cf609045af80b4f38435a9ca359da3f02e11eebd9f4", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "90dc0127-1733-4a39-9ba2-58f57f24777f": {"doc_hash": "6daba6771468a455971efe91e8248a6522238e29e2d82417242b838b4f7dbc99", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "2aca4a2d-78e1-42ad-8323-8e443e085fc4": {"doc_hash": "43f57e9af32c7558ee5ed7d3a99f710cbd2f6a34aeae68a89643b77223b3504c", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "646bdd04-fa3a-49cb-a238-832cc1aa16a7": {"doc_hash": "0c11a8e824c7fc1e2d72ff1762e31901a6016f1c01fc464605d5064f65e1a3a2", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "89c11fbb-b031-4f27-91a3-3d4bb85b9088": {"doc_hash": "00cfe3393ba61181b7f52e57bb94bf3a3ff7454a3a6a840bdf97df442b204416", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "d2f7574d-08c8-4a21-9631-2c2e11b9e95e": {"doc_hash": "4746f9c190ad0dba0ae82eeb63bbb39d748d0c66be0c52b49a8971963b43222a", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "0b94b63e-0701-4a99-8e01-d9388f829f94": {"doc_hash": "215cd855f1261297aeb3a390b67ec0835fdb749f046fbad052b125b67af36a67", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "a8eb2b95-ca04-4299-a0c0-333132b143ba": {"doc_hash": "b3aa7475b313f49dd3bb011cb1ad572006282aacd360cc90b1e406bf829806a2", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "d636dc89-2ac8-49f3-a90e-38053b7cde4b": {"doc_hash": "0e6206ad46c6193d728065377e729818a8b48265c9fd6925079cd33789c5216e", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "57686d9f-1a29-4dd6-9257-5a94506647bf": {"doc_hash": "5b8fdef7d518817e90d10f6796d370efc7914f6f0ccccb05ce811f71457cc876", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "1494e4a6-89b9-4289-b02c-31fe773e4788": {"doc_hash": "365a1d230b61d0bc36604d08cafeaa384dfdfe728d41c09a72b60ad9ae350f72", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "de64d609-8c02-4043-b374-997eac4a457b": {"doc_hash": "cd6391a28d3e4c322e8a8fb258d57923a3ceeee1df04bc77219d4c8c422d88fc", "ref_doc_id": "4f7a9b09-b553-4394-9630-d98130a34259"}, "e83ba077-aefb-4e8e-8bb7-029ad0096cc4": {"doc_hash": "63536da2abe9edce72be9ee68830873bdedb547e722599ac0f8bae539a305d97", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "1f47acf5-b980-47cf-9a6b-4fb4259dbc60": {"doc_hash": "24a42b96f7d46a448ae49d4b0053ba3f782291892be6496920562f21a5b30671", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "46c8645e-0de5-41e1-9f6a-c052ef6a4de2": {"doc_hash": "da985442f0309876577c39a260f77a200ab06466a976122b9de4f288e8ef467c", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "354bd007-e730-4626-8176-c2e98604397b": {"doc_hash": "b34f196fa3d1e956bc0a71b088ead98d276d8bdcb7c7124028c02310d0e2d8b5", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "e8f6efa5-2f3b-4ef4-8877-881769f00dc3": {"doc_hash": "8d788ae476f8c7d61fe8394e182db55d380f8679b9b45f6f69e582fcdba77fc6", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "eb0a37a4-80b1-4825-bb61-ca4537ae757b": {"doc_hash": "e50a26c15c1d3092d2fa2de5cc83e0b859d2cf6bd6342bfbfd665236bdf3508d", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "dc54cf40-0fec-43b5-bc6d-2710c18f93eb": {"doc_hash": "dade7b701d7343f880aa28bd93975c05722b94379fe699537b730d00ad9426fd", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "231aa79d-6df6-45e2-b0c9-f5f1a00a92db": {"doc_hash": "42cf80ea230cd9562db189600d044327982a3c2948acf12c6b0ef31fe45898cd", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "a26b57e0-e998-4552-9db1-31e28d9031ac": {"doc_hash": "de0c4e0f6bb805d2292a1fbdb1abd027c015c7eba52fa1bf024659c87cff6bc2", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6": {"doc_hash": "b8164a8569c07e7a65b04ec25f0b2232ed5b970665b5261204df24a77d6a1d27", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "e32a2296-085c-40a8-93bd-187461cd2cbc": {"doc_hash": "8da225ffbf2be8dd73bffdc85ebfa2dc08a7909f279cccba0cbb16a97fccf08b", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "8adb4f5c-64cf-4768-ab32-a848522e724f": {"doc_hash": "09d9f542c57b7e044ff33ef32a7b147008da7fe56b8168550988e4ab1b0bbdca", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "52353ed9-3a39-4162-b3b4-657b52e76590": {"doc_hash": "5d52877962e9ff672c5c041c84ca8813de2077883a49e26d62693d9764967f69", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "bc847b73-574d-4c1c-a052-afa88dd69360": {"doc_hash": "64be69275b4bb70c6a869c0648f56cdcb9d42df4a17d98d892024ac86e3fe1b4", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "1cd69bc3-b886-421a-8798-2c1a3fb64c34": {"doc_hash": "e91294d1778bc658bba10bb62812a0763379ae6cc1476c928d815a815bd424ba", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "c1eacad3-bd48-4d91-8330-e1587cb8c2ae": {"doc_hash": "835bba5147e0c4897efd4d92aceadb716be740b04093df1f9a83c4205ff13f97", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "7a1770e9-feb4-4b76-b1b5-9863e3905ac3": {"doc_hash": "e902f058c750b23572600d804cbd954f7976edd67e61afbfd27f23394b421140", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "cdf221cd-ec1e-4add-866b-4be0a7416a44": {"doc_hash": "c21217636d8d3fb8e7e469214c8414801ffaa30eba78d4af4e38cf0e9997741b", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "4adebeee-b41b-434f-a2bb-96c92749a420": {"doc_hash": "39ee750c6f9debf214455ce7f566cbc5dbcd3f65c0e8d176900d0b5d0eff2263", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "ccfc9748-b531-4fb9-8a67-a169d12de2da": {"doc_hash": "baf26a6f747c01c7f92ea45b51bbbc59f7040ffe16c2eaf5389c8e8f3290d0ab", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "180553d2-9bd4-4600-b1e0-73803e00e664": {"doc_hash": "5fffc62ef519afd045e7c77c51af517e81f26240314665d42b7c50bd4887218f", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5": {"doc_hash": "a9c04b654e3a75520db0ab803df9e99f51b30631f94c7c733c07390d85655732", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4": {"doc_hash": "0d541e394c5e61b92e43e90a62290be7d4105450d9760f28674897043682b277", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "c55a5155-e1af-4e58-a00a-28bd21d91d8e": {"doc_hash": "9da7034fbd5cbfbb7921a99f4c1e2872b5a7981408ae541b33ea47892ed19200", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab": {"doc_hash": "dbe3025312ac84b388a81699c7c1895a979bbac6f4fde7cdf452a7f8aba7be3d", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "72d04838-777a-4df5-a88d-76c3421b2d2a": {"doc_hash": "81bbe93bc7e75a863bdbd5caf8a51c76db7766f80a88e0f76e2ade5ef758b33f", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "ac9ece38-2107-4de6-b4fd-a51f703bd3de": {"doc_hash": "a52cafe4e8ded44098dff098588a5d8d378de7ba727d74207c7bed3c4b14398a", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "b522411a-0bdd-420c-bd93-1311970da561": {"doc_hash": "21280dd615bfc4b68fddb700c20f2ebc68427753b04c8930e89a22ea5d6f761d", "ref_doc_id": "f087d693-900b-4146-a315-74ec095a42d5"}, "98b3959f-f443-4ffd-8698-80fcac7785c2": {"doc_hash": "a781edd8f0a27a03cb7ce3111a62f540ea9af6a1000c9459ba374a195c4a5b4c", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "21d8a1f3-b77b-4cb7-b358-275a722a9024": {"doc_hash": "073ab229bb2a3b3f031b97cbde39c0d818869f6eb73c8c48b2c289a963d6d671", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "462d415d-ca2e-4b44-a2b0-f9c700d5f754": {"doc_hash": "ae82926671afae6f93946ade46b096590cee0fc3c915df2efe1cf760693e31d2", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf": {"doc_hash": "1f84444cdbe732149fea34af3a5d432d3ce5c3e02afab1e6053aeba7911ddf1f", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "6820aa0c-810d-4ccb-8b8a-959a9fee043b": {"doc_hash": "dc68620445e6a5e780765bab0dd7336cd0678426191d3f99cd07fedcbd771ce1", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "ed4e622d-b4ee-4221-b30a-af4e5d864616": {"doc_hash": "dc32bc17b0ae2e2f28596b499fe6fae0c0a842d78f48be11210b010349611b91", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "71eeb3e4-57e4-4350-9f64-bfa36f5c859d": {"doc_hash": "23097ee6462505611b4077ee0f51de34d5bfa3a5b96ebab95890daa8122fb8c1", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "6ded8d54-4da6-44fa-8f3b-f70fc533a967": {"doc_hash": "ff7e918fe88159a1062a37ea7b1ade68d6047d717f55bd86ac59cf5561503196", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "0e98362b-4f31-4b00-984a-b9d227e4411c": {"doc_hash": "411c39f9760596c9292ac1fab6509292515f66bb0da75b6919f862961f85741d", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "2d117743-6f11-4f66-b3c8-a45695582ee3": {"doc_hash": "1e8c26c4970c6435f6a59a37bf469295913655ee6e401f783a3a312cdc7807a7", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "7d57945e-316a-44b9-8f36-9f3e15ccafc2": {"doc_hash": "b6118c5b6837c8e9d54465426bdb245c5bdaaabd18bded264780184adbd51c79", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "51c710aa-3305-409d-b505-8173f4200474": {"doc_hash": "5233f4402882b62dfd8a470459b3c3d0a0d877d5f3a8c78f0a40bc86602886a9", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "19e20805-d032-41da-b073-49da000834e3": {"doc_hash": "a1935b6f2afd3977b73a132bb67ac3a2c321919a1f2501959e91f09b96bfcb0f", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4": {"doc_hash": "1b833177b307d063647c5a6f3a422467819132515c81b36af4c38a342787b811", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7": {"doc_hash": "c39879a070df20ba702a202fe459bbecd909b053dcb9163a2bb16137d5b29efa", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "3f47fe40-f102-44f9-bc64-1707ee2be94e": {"doc_hash": "58c8596f528694f1a2a838169affc037eb98fdfacb3902b3c0190cc4289b75e6", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "16a3872e-02c9-4919-825e-def5ef9a7cfd": {"doc_hash": "4720fdf52e9c98c2d32bedd1ab6317b331225b1e92e84e33edbc4c6338384602", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "85f8c535-b4f3-4b22-b6ab-a032a76499d2": {"doc_hash": "c0498faa8f96dc8e1f63e734a7caef60b4bd57b0434e7c77879e80ad1262d84b", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b": {"doc_hash": "88d5a6c6e47791d9d28b10a30e314475c8637b9faee1110bcdd3ce53d31b9ecf", "ref_doc_id": "6d9e2b04-cb98-416d-aed3-cdae338d095c"}, "4242b347-f9d9-4153-8483-237443db8a2f": {"doc_hash": "287d148e640a4f97eb00bc7222edf31914e35dfb5c71f4844cb1bb231015b086", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "488adf8c-47cd-47bb-a703-4265d09feabf": {"doc_hash": "e07067c9107aa4871c6a87a8d8134eac6356539433415a515fffa6cd47f98f2e", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "103aacfe-271b-48e9-bf23-07819c3c14f5": {"doc_hash": "b1192d2df84ec1a259741697f46a8dc1e839b499494293605538c5468528cdcb", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "44f94ba3-53ee-4d0c-b791-0e03b8dedd13": {"doc_hash": "ab8fe3733a9aa7ad40a2bb1a2a73525607341c4f90567822b0b04f3ad4f3051b", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "4740808e-9b16-4b71-b391-ad4fb3c9fa4e": {"doc_hash": "1a07eedb6e8054c5c465e3b1afe74e4ea2313e11d5c210d6281599e82ae0d240", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "b017f882-8322-45ed-acea-ee694b2528be": {"doc_hash": "0c15fbbf716d3267d608375279ace9ab10afdaea9eb609a248a4948bcb6c832b", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "4b3e931b-da63-4662-a218-9dbca34a9b81": {"doc_hash": "6b6930ac7d80240655c6f3d4889cd59241e94729b2208d6861d44b561da07c39", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "22fde089-bdcb-408e-a970-abedcbefe5f3": {"doc_hash": "d2bd19b246c04a6f59b5f75012e990f38870dadfc97caf22128e7ffb76f57a5e", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e": {"doc_hash": "495ba634f1d768c15d0da83a2bea48dc8cd2e553b8bd83739e3624f4dcaa7027", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "7b97032b-c710-4582-9318-fdc441afd6a5": {"doc_hash": "afe4c1b8be210de2822aa4a5a7406bf678a8caa0b7e7a66570ba02d6f0821345", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "6257716d-6e80-460b-bb94-edb98db4c886": {"doc_hash": "26e2bdcaac9646ebc2befc46eaa9babe37672c09368a0bfc71544834b4dccc1a", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "0cf08625-1431-4b93-8de7-c596669296a7": {"doc_hash": "e7a016710a4118241dfc587d45dad84603119fd2c0b3df1ce100fd7eda8f7db5", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "593f6045-bf18-47fc-8f05-2b29f31d585a": {"doc_hash": "9fa82cc881a2809356e32f9c88877dcdfc4f34a02effe4b563fbb2d7de9d1956", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "2faac357-bf13-4beb-867c-453b77dac32c": {"doc_hash": "78778c06beb88d49c425c6fdd22fa255fdf675fd5291dd6e66b786d157bf8ff5", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "597e4b85-0c8c-4383-a475-40c27f804b5a": {"doc_hash": "b45d939bb60c255e94ebfecf22f595232b6cd4574962beed99f6fc3cfb16fb55", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "6ef014f3-43a1-4c58-8a43-27190091ef23": {"doc_hash": "024d79141185a475542520be423d988dcc33af4fef17fd514e00f6245c156e6f", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "484e598f-1ac1-400c-ba0c-f1197042861b": {"doc_hash": "81b41b722c83fbd0348d5ca544b3811b5024d3975b2e568ac4d8c94dfe88ba3e", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "cc9b46fd-5649-4177-9e13-42d5510fef11": {"doc_hash": "01d67a461b9bd6892cabde59c4819aaaa9ffb487134fea45bc4de86f1f0030fa", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "833a17d1-2323-434c-bfa7-e1a085e39577": {"doc_hash": "89194a06fdd6e19e11e92973b11edaf9a5b6bb1ec5526b02a08e976a03be2b55", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9": {"doc_hash": "7df284fd0012eb09dfa218a725e66ffa886712f4999d7bb653b0b6e900c4065f", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "6ca59679-c366-442d-80d7-36cdda02b700": {"doc_hash": "912a2de8dd8524fad4130c38d2a81fdf478ec07a3c7c2455a575720accaef7ee", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "d4157708-8f92-43cb-a55d-2f610856720f": {"doc_hash": "aa189ac0343caeef21c1aca38e1acdd610d3ecafb9271bf9bb2a2df704e70343", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "d065aa5c-1999-454b-865c-aba17464c457": {"doc_hash": "046e40c24b8b1c2d6fbfb229792c5aee739c2d0237de0458aeaa0b9ce40be4e7", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "f241e625-2f9c-48bc-9fec-c06ea3bf6c74": {"doc_hash": "ae8531541aedf5d10c9e4c290a34b75db52f67daebd3bf21df2e7bb24c199571", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1": {"doc_hash": "a236016df921f64e5977efa2065cb1149a45c5dcab264352a7b35b46ab9d7b83", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df": {"doc_hash": "6a0ccfd79176d8941b113a0e46b52e0dc72b9f283ffe146c74fb9817a56f8802", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "705ca2c7-a175-4404-9a60-de1da4b879b7": {"doc_hash": "edfc992d63cd87fe87900a8dc56d669c90532494a4597d4bc1ff5e4eac4ad597", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2": {"doc_hash": "68dd5cda2642975c34cec175f7646e41eddd787206a8b8d16e92751b9f7e915c", "ref_doc_id": "83f99185-ff18-4075-8aeb-8a775bfd1307"}, "c079881e-f114-4a48-a7db-2aabf8e89d1c": {"doc_hash": "c7d1ecf181a1e3a846ffc3345512b86aa22789e25d4f9acc7f8fc02025bfa1a0", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "e025d946-88f4-4f27-9985-22495e59db27": {"doc_hash": "2cac5fc558064757482dbf6bd4643789314326e092e418f983953a0ea693040f", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "b7f5569a-7c96-4564-9ba3-66c67245142b": {"doc_hash": "6425a67c441a33d3609dcab26eb65cedb34c901338ae0b14318f30602e2580b4", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "22af84e4-724d-4229-9c41-71315f000233": {"doc_hash": "5ac4a0c655af491aac75d2d5f6a1faf6bdd93f25aa0856620bc2316297f4b330", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5": {"doc_hash": "8e8f4ccb5a3a459d1bd0cbf6b1f057744116e72dc275ea3d989697d0f56cef58", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "098af4ff-9881-4fb1-ba71-c08f53460feb": {"doc_hash": "0fb10c33374a57ce487e2f1c8b3efd7f6e528fbd7810b07d40688214042b7c99", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "f2a53a42-0297-474d-9b82-ad070b73d156": {"doc_hash": "e785d11e5a458d96f30df654de4f74f8ca572c6c0624b0c36acf92e244ad9ac3", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "46f6747d-ef25-445e-9c19-019314018ff6": {"doc_hash": "60e8d58be80d2c81f881046507051d1711238264738807ee3393d4ea88166033", "ref_doc_id": "f803da6e-e164-4c57-a964-33e1db35ad98"}, "2355ee4e-15c7-4a60-851e-525ca5cd5383": {"doc_hash": "7b71e9ade90014c10d727f9262d8e3dde5846769d215499c4f5008613ec1b773", "ref_doc_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3"}, "e6116c66-c2ad-4f33-8fdf-96057aa15a2a": {"doc_hash": "a633b44ce656943d6f7f000450ebf5fbfa06f7c47d682fd674561fabe87fd98b", "ref_doc_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3"}, "82de5b40-996a-4d3d-b5ff-dcf11a914c54": {"doc_hash": "443e6d68aea3bcb1582c9850d67f81bc5a48867cf7c9b7beffb75bc3e25eb697", "ref_doc_id": "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3"}, "a4c32ca0-3930-44ed-a82a-515e5c20f4ab": {"doc_hash": "0b7c9630687f3de47032a65a935f147d11d9a17743c4d3c9bc72cb94e74fc045", "ref_doc_id": "458275a2-71b5-45ea-a781-2656edd18979"}, "b6df763b-df29-4aaa-878a-cd9a076b0bea": {"doc_hash": "7ae6e86eb053b04d8a866e80c4295af84468223b87be3ee0ab0be27172998cdc", "ref_doc_id": "458275a2-71b5-45ea-a781-2656edd18979"}, "db634f03-f47c-4654-a5c9-413bf1aa90f7": {"doc_hash": "00d9633edb3965a892b79a29969ce74c98ab455a74f8cb1f8d1a1f7f1a76acda", "ref_doc_id": "458275a2-71b5-45ea-a781-2656edd18979"}, "a50e3555-ded4-4979-ac68-014ba5e7a894": {"doc_hash": "d8a09d80f1ff39d2c9d90af2054b536db8a9ab0b3b68b37c2086f6b3c2fa429f", "ref_doc_id": "458275a2-71b5-45ea-a781-2656edd18979"}, "135be957-9f9d-4eb8-b6a1-38099b170c47": {"doc_hash": "fad19fc6d077d25f5d200dba5aee653ae8db21ddcce53cba1436339a38515c87", "ref_doc_id": "458275a2-71b5-45ea-a781-2656edd18979"}, "585eb775-e6a4-4025-a526-3236708cfef7": {"doc_hash": "e9cfc89c7aed4af8ce1e94a5b9e5bc4a83df24ae4fba8a9f751d32425e5cb697", "ref_doc_id": "a8cb832c-05d7-47d7-bf07-4094322403aa"}, "a518b054-8323-4a1d-a1aa-6b79925be813": {"doc_hash": "2afbef9e4be646a412f947030fca6a6ee5268d51674528fbea44cff359fdc27a", "ref_doc_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18"}, "001a89c8-f839-4ac5-b57f-278c47c0531b": {"doc_hash": "082f43e40ce6f888d0bbb9f0551f7ef389e27eb5198926fdd447d6401b8aabb6", "ref_doc_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18"}, "84fcb708-fdde-41dc-b189-271ba7da22bc": {"doc_hash": "74ae68a0fb21876df103a9544801fcb0663fc92515ffd712fa42471f8c3d4430", "ref_doc_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18"}, "d8737215-aa25-4ed1-94df-c7c9f1060ffb": {"doc_hash": "50cfb9eb1c1a5bbd84d7575e9c3060a056f44e326c46eca33be083c6011365b5", "ref_doc_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18"}, "4260692c-3a0a-4a6c-9cb3-446787a3ff05": {"doc_hash": "71e57ed21c5e7c417d2e99a74866161fab734344411951dbcd3624257f4db72d", "ref_doc_id": "ee75d1a8-ad67-4f17-a43c-dc609c51af18"}, "f9ecc5fa-1d73-4ae6-846b-853115165e2f": {"doc_hash": "4582089718c1ef888cb7fe5339b7744a06aec0e07c5ee845a4b67c3470b7c7f9", "ref_doc_id": "5234217e-100a-4867-9e7e-13297173591a"}, "96f565c9-2f32-446a-8094-820363845bc3": {"doc_hash": "576f8476deda48307b3367c2dacc044b3a1108db68db5ff39c33f79b90f66940", "ref_doc_id": "5234217e-100a-4867-9e7e-13297173591a"}, "54c24de9-d2c7-44e9-aa06-b80ab0648f6a": {"doc_hash": "be38f1cbf2a4989b3099f7cf299a123ca4d88df9c6b7b812d551c42e3de0a299", "ref_doc_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c"}, "d0cd34de-16ac-47f0-9ebe-1711b0235718": {"doc_hash": "9e4ab3960a4b5ad1bf13c0c75d1bdab5e4d0d4630775e41d1f75f90cfd2133ef", "ref_doc_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c"}, "92d0f0cf-adf7-4c18-93af-da9465a7771f": {"doc_hash": "10c37f9be98cfe93e75587ad811818057751252ca37e9d1d6c2796bf06291484", "ref_doc_id": "b0aa7eba-703f-4312-a005-04dc17c0df5c"}, "353d6b08-4fd6-4b0b-a177-5021d59454c7": {"doc_hash": "03fcc16fd63b8bf4ab2794a3fd1704240ef18296add8728143f578fd587ec5a3", "ref_doc_id": "40d0e19c-4972-473d-aaae-cbcd2233b421"}, "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b": {"doc_hash": "e7eb2c0341bf6b8b577fc3ed4215b17b3358165f38754f3fc2aec21496b5536e", "ref_doc_id": "40d0e19c-4972-473d-aaae-cbcd2233b421"}, "4e5f99e1-5d6e-451f-806c-13dfb0172016": {"doc_hash": "a18ca0c08a74ad7ab3d5bdcbee931a516b4ed1758dda5d3aa53dbf9f12965173", "ref_doc_id": "40d0e19c-4972-473d-aaae-cbcd2233b421"}, "51cbdc35-73e9-4f0a-86fd-8a257bd9306c": {"doc_hash": "ea722f675156e6204fca61e1f44d43d7f89e427793db3988e1df7e67a67a499b", "ref_doc_id": "7a4f6c20-e183-4d33-8b81-cef783d12165"}, "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4": {"doc_hash": "f4effc5b8eddea30037fe00c377f433d051a7702d5cfcbb8fd83583be33a5f19", "ref_doc_id": "7a4f6c20-e183-4d33-8b81-cef783d12165"}, "11789843-5d5a-4be4-9dc9-6f9531bcb2a0": {"doc_hash": "f738a02dbeb6b73952d1794efebc6ab4154899f8a38fa80f655b503310f6a737", "ref_doc_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d"}, "ee67690e-9d15-4a4a-b3b6-5268a62044cf": {"doc_hash": "12e7b795ed950bc9657021b1e036f83e030139b4ee814722fa3a585c7cbf1ca2", "ref_doc_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d"}, "c16f485c-30fb-4d53-b3cd-06c5e34f4781": {"doc_hash": "eca29d875383f83fd2a12066bfff724095e1a6cd6f9fd699f314552ee0dc5f97", "ref_doc_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d"}, "28dedf1b-6c18-47f8-a8ce-c6a393ca746d": {"doc_hash": "4fb74a014fcb53c207bc53a5c14f5f23e07c101502a93b673edc8ba253fe1839", "ref_doc_id": "fe06b43e-7c81-4884-92bc-2ad416d9a21d"}, "e6848c4e-35ef-4c16-9fa9-e93f784350a0": {"doc_hash": "6fb7745655cea76caab1d33d38ec30852608334ddcd2ebf3f143ba81cc0969b2", "ref_doc_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190"}, "c1b785e4-303d-4fce-bc52-caee2fb051f0": {"doc_hash": "20e27f552ea92f165abb7f39ebf836179d9dc90b4bc3b31833fc350b1b952e96", "ref_doc_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190"}, "d3e170d2-0a9c-4505-ba0e-9322395d61ff": {"doc_hash": "58e0676ee37e11bac33cd6b68c93bdfc22001368f0ad1227512d6b4c997efc8a", "ref_doc_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190"}, "c9bff665-24e6-454d-8011-9b36d752eb6e": {"doc_hash": "8cb51ef3fd9e1d6565f2baf1e78c183cd1f7881e9941429420142f558af40e01", "ref_doc_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190"}, "cbe14817-0498-4526-b797-437f98508788": {"doc_hash": "78aa68909f98a559266de01bee387a938574999f68f9745e3382750118fb5b4a", "ref_doc_id": "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190"}, "1d8cb3a4-1036-4cbc-a9c5-c0d846742570": {"doc_hash": "3b9913026d7665bb917c412aca3bb9f670d9b45a4284c48613ec5b91d1ed524d", "ref_doc_id": "5c205791-403d-4d88-bfb4-785968f8e65d"}, "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f": {"doc_hash": "2ae6a468f97e8b50b5ee9f6ebb4df29310c39630e58621be7ba1daf86883250f", "ref_doc_id": "5c205791-403d-4d88-bfb4-785968f8e65d"}, "5ba61ebc-f434-425e-aa97-924f5ac3caf9": {"doc_hash": "6cf3bf2637734d8d80e203a975bf59ade9988d987d9ffde0ca4a4b7ae00d36ec", "ref_doc_id": "5c205791-403d-4d88-bfb4-785968f8e65d"}, "74c13e53-716d-4f7e-a2db-fd0de583dbb8": {"doc_hash": "dce216b19830a7d2c73533dfa388686e4cd00a37084c7eb2dcbfb8b9f1ac0908", "ref_doc_id": "5c205791-403d-4d88-bfb4-785968f8e65d"}, "9207d99c-05d7-4198-b5dc-adcc15b74f77": {"doc_hash": "51d7a92418a926fbf17e7f8cdf8e4647a6066940f9f18b3db541a9b4434f37ca", "ref_doc_id": "d24bf951-b9df-4bf0-872c-f71ee8c7d329"}, "83b88e64-61d3-4657-96e4-e0828024c6a6": {"doc_hash": "6532be795f63b9fc01007a2fb7041480f731df831d1b9c6f741c75e215aa9399", "ref_doc_id": "d24bf951-b9df-4bf0-872c-f71ee8c7d329"}, "993f2780-0368-404c-9693-23fe51ee6b62": {"doc_hash": "98ba7c95f60149d639b644bf3ec7fe5d37cb9dfbd7101ab183dec69f58819829", "ref_doc_id": "d91dd428-3273-426e-aa59-2c6b6451e994"}, "8cf5ecf2-f8d2-47e4-8555-a33d303f2990": {"doc_hash": "fb38448853aec230bdceb4bd707a6956d65b5dd4e1135637fb2a091fd154ea9a", "ref_doc_id": "d91dd428-3273-426e-aa59-2c6b6451e994"}, "62030fc7-5f99-4edb-840e-9052d898cadf": {"doc_hash": "7c6320343d8977aa2cc5a44c78496cbc92e28bdeee6d3f129eb908c680f8eb17", "ref_doc_id": "d91dd428-3273-426e-aa59-2c6b6451e994"}, "3060a3a0-58b0-460c-b305-fad338f3c384": {"doc_hash": "878bb8d66b64fbae5036cf231296e5666f7d661fb032a5e066820656e9eac056", "ref_doc_id": "d91dd428-3273-426e-aa59-2c6b6451e994"}, "094ce54d-107f-4ad5-9403-75add22b35c0": {"doc_hash": "dbc17b8dc8e58d916991f462717b252f9e3f8c8e1f515c6ea424846ccfee6978", "ref_doc_id": "44db08ce-466b-43cb-9f83-18d9eae976f5"}, "aaadef10-4643-4833-b79a-7d8a10d3c0d6": {"doc_hash": "0a9f0ab068ced5b49cd23af6b4328130278ce97bbf393cff38624b252710e135", "ref_doc_id": "44db08ce-466b-43cb-9f83-18d9eae976f5"}, "44da69d5-b5e4-43ff-a9df-6d4a6e0c184e": {"doc_hash": "d9d83df48f2199142a552ae4ec71f48d270a031ce415099abb6c29ffa56e87a8", "ref_doc_id": "a59449a8-516a-48fa-9d30-a5af4a37abf6"}, "534376e3-8853-4b1b-bc4c-db85a0b1319f": {"doc_hash": "e1e7712ef1e2346545da370a490f6878ad62c9458175ea26ad5b07dcdcd02010", "ref_doc_id": "140b4649-c00d-49cb-891d-ea10aa648372"}, "a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9": {"doc_hash": "e79342848852ab3dfe02821a91658bcb354d42ee37171a87b767b5317d6a6df5", "ref_doc_id": "f12da2ed-7d12-4574-a7f1-73d6cf693dfd"}, "cde0875d-e0e0-403f-8d66-48b239fb5d83": {"doc_hash": "a22221054e642c75bcb62c10204d1199582929e398b742e8bcad55d097234c35", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "116d8525-d9ae-4b38-9dbb-b0ff041b17ad": {"doc_hash": "63bf8583977edd7a47add9f1813019bc6be3eb989a15a99d660a65a229111908", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "51072f9d-ea79-453c-a19c-0958f6a650e7": {"doc_hash": "00497586f20a5673ffe642d0d7462256c1d752aa1219ca9dcf27c28833f2a340", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "ce9d676a-7d2c-48ec-a4dc-14a8f602df52": {"doc_hash": "362e1eb8ab3bc268f0852263f555f5c0ca22ab3c85ae2c59fcd8b6ab4f079f14", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "efc52a5b-46f2-4dfe-9d87-94fa6acbd630": {"doc_hash": "cf2e36e72380ed0ac99b5af53e5c6ab348ea2af5e9f9e3f44af34cd982e20147", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247": {"doc_hash": "5ea34df55a05251a5f0fc0c5cc272e572025ea9251111a82a2778ba40714275f", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "2b7eddd4-4bb7-4db9-871c-7aad83a6689a": {"doc_hash": "1a8dc5772ed0140ff2161c4a447143fb668054883e2202b56b2ad0b6f56dad2f", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "df18d41b-d265-45bb-9c43-f438ec9227d7": {"doc_hash": "05369f7d5fa079d044c5fb136723ca55f2d6f28013215627785947345fe4a064", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "663b95e0-9562-4796-a711-f3f7e8c36dce": {"doc_hash": "cb4f675971fee9eb591dbf9cec6b706aab5e99891f81db15b4134eca61ba041c", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "e59f16b9-08ef-4151-9e4a-8a7cc6742023": {"doc_hash": "1b9207fb6c1809d6e291e4bfa2a9899a0415cb8b3e8b117255904b58e266e360", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "15e9b2dd-b31c-4fb9-836c-d62820386994": {"doc_hash": "61c38daf280e5c2b0545690b0b15da3ae316ea4b41bfce696ca83db9a5ca5bdc", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28": {"doc_hash": "b154a2d2ea199a770867f1762e5eea06682bd89db5836d433c78c4da98f214fa", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1": {"doc_hash": "d7ee92067a1e6edd4b38db8b8a3114c4fa2b74debbd4c9b0512c6036c37e27a1", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "b130470a-5503-4256-80a8-fa09c68bfa6f": {"doc_hash": "338441d593ee762565806ac12e3cad38cf8cf3fde442fd235eedf70227180d6a", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "fde7b26d-2196-4fde-8ced-d433f54ec88e": {"doc_hash": "2f7a921e8b19e5a26b8f87a6050f6d8857c1fbe314d6a5b1c8a7b6aec981bc9a", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "962c1627-cc6b-4b76-ab3b-f6e53942d33c": {"doc_hash": "cc71d0a09d1e8d692cb4ab55a78337dc3454c8fa2e309683d98d32e6adde7d61", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "03660060-2a1a-461f-95be-68bc149be816": {"doc_hash": "772cf166cfd628030dcc3d67cd2aea5a97bcddfb920b9a10ed41babd8e2e0a1e", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "56387cc2-1cac-4b93-b0da-98a50de88e3b": {"doc_hash": "21f1f75b91a7a68d590c512b13dd79af2647d9ce573360fc6435bec720a3cc60", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "d8bc301b-ef19-41ef-bb3b-006b77d99327": {"doc_hash": "d2539240309270f04cc0b996c95f39bce877c34453247e780fd1ad780627f5a3", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "c2fb26cf-26be-47b2-9101-3930412859c6": {"doc_hash": "3fa1842d24284227a4ad1e6ef18ab8359250f1f275bc0bbbfb219feab9e51b48", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "95873e01-c9cd-4822-b8fb-dadc85e0446c": {"doc_hash": "59877abd4f429f4243b297e24884b4f1237c6af4671e3689b22c7b93be4f5a0c", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "1db362ef-c16f-4cc3-8385-9416412ffb48": {"doc_hash": "794149731abf08832e563cea4508f3d80d3293690cf0dd967053f417164d04fd", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "06384128-4446-4dbb-82b3-b28fbc9fe756": {"doc_hash": "e072cd60896428258738174a4f55d3e9be87df4cba74a3a19f968c2b82167943", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "85795e66-3c1c-4e46-aa12-41156f1b5739": {"doc_hash": "1de532cf9892a7e79eca9afd4dcb1df2aac370e59cbe639d086ca341692ba323", "ref_doc_id": "c52faaa4-e7ab-4672-b6c9-8974262d6f3f"}, "7762a227-b8a5-45d8-88f9-63a719dc8afc": {"doc_hash": "fc288696d5a8e2b3fbe7e3d04f8c6c2854364b9211f922781b62b8afa23d1eea", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "b7aee071-862a-47d6-b0b6-097cdae9003d": {"doc_hash": "8159bdee45b51a5d74eee009ad2cab7ee074ad15a61aab98004c29fab220a830", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "9522e131-6b25-46d7-89ee-82fd3ff30f9e": {"doc_hash": "5df16e2b1d48eae603d2c2f814cf7fdea4e0e135f9825c0a1e62b60e108d0f76", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "38dd4cd5-128a-49a6-b675-5b0edf9c4e84": {"doc_hash": "57016ddad11103a912bd557eadef1f2fdcb71e59fbca76bc5d66aca666fa3b3f", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "fa52b698-0f61-4c6d-bd34-2cd73a376484": {"doc_hash": "a0fd25268171ead3190aee963e426bb4d473e7f8bd246a28519256e053183a80", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "b85ef90a-6b5a-4931-b83d-804db84156bc": {"doc_hash": "9dd668b222cc7f0f7fe3a2af935231a585f3bcb5ea224b63bd86c0bf620eac7a", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "275f5f0d-dbdd-4298-ad25-8c6e07c551f8": {"doc_hash": "ec7b66b1df9c4bfb3c8b0203e8b1f3c7a24706604813b9a902098020af74fbb4", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "72aee4de-f57a-4db3-9b5d-7ee87f67b17e": {"doc_hash": "d510f1154ab5ee5786958f34a48da484b6bd4ce3034565db7d9ce4a05e05ceb4", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "6c2ae45f-62e2-4fe5-8d13-419cf069e150": {"doc_hash": "6c50df6ec7aaa4f015b72d3e5cfdcf8ec99748de11669494e279ba00492c7bb5", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "664a7b21-8db4-43c0-896a-0483caa962f1": {"doc_hash": "fc44832c603fb769e34e984d5db9fe3b30190d1dd5304ed593fec6aa2a871ea3", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "b752543a-3ee5-49fb-8ef7-c349192c3864": {"doc_hash": "5bed1219de3e439c668800867bd8455687b4a293341dff47840f24de88a806a2", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "dc96b775-b3a5-4960-a754-395e46a75d26": {"doc_hash": "b4da8fbf04ccf782f2975cec06a0118eba2a214c96b12d8272ae5e0b6112e6d0", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "a6989bb7-5439-4667-b222-dcbfa59440c8": {"doc_hash": "ef9518a2c7e64dd784ab414e7d610729e5db05091877faa4b7b7617fb3c63391", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "79fa5a85-dff9-422b-a9f8-e5effd00074e": {"doc_hash": "fcc44c8b9addfe781c6983ec12085766b504d1f7eeab7850248dd287bdb3225c", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "067dffd4-d88f-4555-a20d-fe232cfee26e": {"doc_hash": "4ff68a784c56e2ce7a5e1c54b631255803deb688116c958bf3a36bbbc979c899", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "8bc37d72-b987-47db-bb74-b84031914057": {"doc_hash": "a25ba9b07a37507c56b7321e76822e42669deee49a15844efbf1a83f9d99f9f9", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "a145451b-04aa-411e-852c-1d240e1953f4": {"doc_hash": "b708c067fb911fc6bb9349431d95db8f1a3e6c202a1275b998cb32dcbc1cae4f", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "c2b4689b-7706-4cee-9cf7-579e598a2c5e": {"doc_hash": "cb2c66a0506ed10e82e0017d790b256bc9f87d56d892a02671eeb3eb1926ff10", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "8093fde2-b664-4e7e-8b0b-b82dc45479d4": {"doc_hash": "e81305d4378cec2d03ba2fa2a43eb96b6a3aa49ab1843aaa89383fca3834a5b8", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "0733c2dd-009a-4dce-9208-a181b613f1fb": {"doc_hash": "27ad7f65fb843c9525ba1a730e40cfd5f5d0873527ded798dc5791a7c898f18c", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "da4fc845-3f5a-4d76-98a6-df19c3268f67": {"doc_hash": "77ebd081542cba39885f05bcdc554880e91c9204d1b1e34349f2671077ebcd14", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "accbe91d-4ab3-42ca-be66-4ba269f7d9e7": {"doc_hash": "e6429f8f61e5e706f47cd9fb7ccd732d2f3da5f525f1b43b63e89b1899690374", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "d043c55b-659b-4144-b2e4-10b6ee234216": {"doc_hash": "b1a5604ed7e21316745cff8968b5c35b86cf037e5662ccbc20e257706ad1461a", "ref_doc_id": "24ca6300-8582-410b-ac65-383620795996"}, "b0339c0b-72f4-4168-a947-200eeeb8c279": {"doc_hash": "d4394cf792a108c95b6a3cb512bfdbafe1d74f77e87e29c94da0edd6bd3f4467", "ref_doc_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe"}, "5b5403c0-8977-4326-aa70-5ad85b94a629": {"doc_hash": "15893e98b0754903eb48dd231cdd5b47ea89f8b8f332526bb35d3fb5a95e9402", "ref_doc_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe"}, "7409afff-ae03-4163-abd4-ea41288a1ce6": {"doc_hash": "877f1937f50f6df266e1ed4fada968d871e34fa70a4a4147a6b93772d7c8b77f", "ref_doc_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe"}, "4303b010-b572-4c42-8a8d-8a9ef3f857f6": {"doc_hash": "d7654a81c4c33f101fbafd3a7b82018558cd88b9823a5d4d997b06a58a4f5855", "ref_doc_id": "0c8361cb-fd66-4e0d-8b57-2e3761e152fe"}}, "docstore/ref_doc_info": {"258f3f3e-c961-438e-8fa1-ae7ef3aa5684": {"node_ids": ["e94efa5e-508e-4712-946a-82f6743526cf", "04fd1cc1-6134-4fb5-b839-afec927aa143", "7c088867-0411-497a-8d52-19e4986beb64", "795015aa-4388-4b5a-8fc5-b6be3d33be8a", "4463fe6b-dc72-4eca-8cba-b924135d62ed", "2e505af9-42b7-4333-82e4-a8503c0f9b9a", "c055e7e5-45c1-4f21-8f2e-1bb35d0c1314", "bfe83f9f-ace3-4936-8a91-f77544081895", "4c4c153b-ffee-4ba3-99b2-2e9b75ead6b2", "c18946d8-1ba0-4e99-82c4-57826bc95a27", "23c9a8a2-8bc8-454c-9ac7-c85ad4f97646", "b758306d-90b8-4755-a409-66fdf63fc92d", "64143e5f-fd2c-42c2-a43e-5b51845795af"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.59 for the March quarter of fiscal 2022 compared to\n$2.10 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n27.3 percent to $3.22 in the fiscal second quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2022 Second Quar ter Results\n5/4/2022\nRevenues of $57.7 billion for the Second Quarter, a 17.4 Percent Increase Year-Over-Year\nSecond Quarter GAAP Diluted EPS of $2.59 and Adjusted Diluted EPS of $3.22\nAdjusted Diluted EPS Guidance Range Raised to $10.80 to $11.05 for Fiscal 2022\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2022\nsecond quarter ended March 31, 2022, revenue increased 17.4 percent year-over-year to $57.7 billion. ", "page_label": "1", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "4f7a9b09-b553-4394-9630-d98130a34259": {"node_ids": ["3e9e3225-451a-4d8a-8da0-9b2b9246f23f", "ba9fb942-00f7-4c6b-9d13-d87e7ceaaf35", "314084e8-1100-4d35-89f2-c8f5d637128e", "11fd6039-a9f7-41fb-99e7-45ef8e134919", "ab3200cc-1acf-41c4-a32b-55901fe281dc", "c9875db4-50a3-4ef3-8089-5f327312e6d8", "2bebfea0-2dac-44e2-9c07-ca574b45cab0", "f745ebb1-d467-4957-b965-e9a99e59501c", "dc8cc54b-2408-4151-a6d8-d8f56a80bb7c", "90dc0127-1733-4a39-9ba2-58f57f24777f", "2aca4a2d-78e1-42ad-8323-8e443e085fc4", "646bdd04-fa3a-49cb-a238-832cc1aa16a7", "89c11fbb-b031-4f27-91a3-3d4bb85b9088", "d2f7574d-08c8-4a21-9631-2c2e11b9e95e", "0b94b63e-0701-4a99-8e01-d9388f829f94", "a8eb2b95-ca04-4299-a0c0-333132b143ba", "d636dc89-2ac8-49f3-a90e-38053b7cde4b", "57686d9f-1a29-4dd6-9257-5a94506647bf", "1494e4a6-89b9-4289-b02c-31fe773e4788", "de64d609-8c02-4043-b374-997eac4a457b"], "metadata": {"window": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Second Quar ter GAAP R esults\nRevenue:  In the second quarter of fiscal 2022, revenue was $57.7 billion, up 17.4 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 585.3 percent increase in revenue within International Healthcare Solutions, which was\nprimarily driven by the June 2021 acquisition of Alliance Healthcare, and a 5.8 percent increase in U.S. ", "original_text": "Effectiv e Tax Rat e 23.7% 21.0%\nNet Income A ttributable t o Amerisour ceBer gen Corporation $548M $683M\nDilut ed Earnings P er Shar e $2.59 $3.22\nDilut ed Shar es Outstanding 212.0M 212.0M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f087d693-900b-4146-a315-74ec095a42d5": {"node_ids": ["e83ba077-aefb-4e8e-8bb7-029ad0096cc4", "1f47acf5-b980-47cf-9a6b-4fb4259dbc60", "46c8645e-0de5-41e1-9f6a-c052ef6a4de2", "354bd007-e730-4626-8176-c2e98604397b", "e8f6efa5-2f3b-4ef4-8877-881769f00dc3", "eb0a37a4-80b1-4825-bb61-ca4537ae757b", "dc54cf40-0fec-43b5-bc6d-2710c18f93eb", "231aa79d-6df6-45e2-b0c9-f5f1a00a92db", "a26b57e0-e998-4552-9db1-31e28d9031ac", "f6b241e4-3dc2-4479-bc2e-7f9a1f681ed6", "e32a2296-085c-40a8-93bd-187461cd2cbc", "8adb4f5c-64cf-4768-ab32-a848522e724f", "52353ed9-3a39-4162-b3b4-657b52e76590", "bc847b73-574d-4c1c-a052-afa88dd69360", "1cd69bc3-b886-421a-8798-2c1a3fb64c34", "c1eacad3-bd48-4d91-8330-e1587cb8c2ae", "7a1770e9-feb4-4b76-b1b5-9863e3905ac3", "cdf221cd-ec1e-4add-866b-4be0a7416a44", "4adebeee-b41b-434f-a2bb-96c92749a420", "ccfc9748-b531-4fb9-8a67-a169d12de2da", "180553d2-9bd4-4600-b1e0-73803e00e664", "ee7d7c45-d9c2-4a37-bddd-d8c2cccefde5", "71f1f1af-5aa6-4dab-a59c-0d482b03d6f4", "c55a5155-e1af-4e58-a00a-28bd21d91d8e", "e99c8d8d-bf37-43c5-b606-8d0f6093b3ab", "72d04838-777a-4df5-a88d-76c3421b2d2a", "ac9ece38-2107-4de6-b4fd-a51f703bd3de", "b522411a-0bdd-420c-bd93-1311970da561"], "metadata": {"window": "Healthcare, and a 5.8 percent increase in U.S.  Healthcare Solutions revenue.\n Adjusted Gross Profit:  Adjusted gross profit in the second quarter of fiscal 2022 was $2.2 billion, a 46.6 percent increase\ncompared to the same period in the previous fiscal year due to increases in gross profit in International Healthcare Solutions,\nwhich was primarily driven by the June 2021 acquisition of Alliance Healthcare, and U.S.  Healthcare Solutions. ", "original_text": "Healthcare, and a 5.8 percent increase in U.S. ", "page_label": "3", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6d9e2b04-cb98-416d-aed3-cdae338d095c": {"node_ids": ["98b3959f-f443-4ffd-8698-80fcac7785c2", "21d8a1f3-b77b-4cb7-b358-275a722a9024", "462d415d-ca2e-4b44-a2b0-f9c700d5f754", "8807c3a5-f3d7-46a1-be68-61b08c0b7dbf", "6820aa0c-810d-4ccb-8b8a-959a9fee043b", "ed4e622d-b4ee-4221-b30a-af4e5d864616", "71eeb3e4-57e4-4350-9f64-bfa36f5c859d", "6ded8d54-4da6-44fa-8f3b-f70fc533a967", "0e98362b-4f31-4b00-984a-b9d227e4411c", "2d117743-6f11-4f66-b3c8-a45695582ee3", "7d57945e-316a-44b9-8f36-9f3e15ccafc2", "51c710aa-3305-409d-b505-8173f4200474", "19e20805-d032-41da-b073-49da000834e3", "989c6c59-40a7-4a6b-882a-ba7bdd53d2e4", "4fc0e967-4e21-4ea3-b8fc-c4a86634d9d7", "3f47fe40-f102-44f9-bc64-1707ee2be94e", "16a3872e-02c9-4919-825e-def5ef9a7cfd", "85f8c535-b4f3-4b22-b6ab-a032a76499d2", "79b8ba9f-9f9a-4220-b34e-3995e1e1f06b"], "metadata": {"window": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare.  Segment operating\nincome in the second quarter of fiscal 2022 was $187.1 million, an increase of 260.8 percent, primarily due to the June 2021\nacquisition of Alliance Healthcare.\n Recent Comp any Highlights & Milest ones\nGood Neighbor Pharmacy, AmerisourceBergen\u2019s nationwide network of independent community pharmacies, has exceeded 5\nmillion COVID-19 vaccine doses allocated to independent pharmacies across the U.S.  This allocation effort is a part of the\nFederal Retail Pharmacy Program for COVID-19 Vaccination, a collaboration between the Federal Government, U.S. ", "original_text": "Revenue in International Healthcare Solutions was $6.8 billion in the second quarter of fiscal 2022, an increase from the previous\nfiscal year\u2019s second quarter of 585.3 percent, primarily due to the June 2021 acquisition of Alliance Healthcare. ", "page_label": "4", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "83f99185-ff18-4075-8aeb-8a775bfd1307": {"node_ids": ["4242b347-f9d9-4153-8483-237443db8a2f", "488adf8c-47cd-47bb-a703-4265d09feabf", "103aacfe-271b-48e9-bf23-07819c3c14f5", "44f94ba3-53ee-4d0c-b791-0e03b8dedd13", "4740808e-9b16-4b71-b391-ad4fb3c9fa4e", "b017f882-8322-45ed-acea-ee694b2528be", "4b3e931b-da63-4662-a218-9dbca34a9b81", "22fde089-bdcb-408e-a970-abedcbefe5f3", "9dd6fb4d-06f8-446a-82b3-d50ff8b30a2e", "7b97032b-c710-4582-9318-fdc441afd6a5", "6257716d-6e80-460b-bb94-edb98db4c886", "0cf08625-1431-4b93-8de7-c596669296a7", "593f6045-bf18-47fc-8f05-2b29f31d585a", "2faac357-bf13-4beb-867c-453b77dac32c", "597e4b85-0c8c-4383-a475-40c27f804b5a", "6ef014f3-43a1-4c58-8a43-27190091ef23", "484e598f-1ac1-400c-ba0c-f1197042861b", "cc9b46fd-5649-4177-9e13-42d5510fef11", "833a17d1-2323-434c-bfa7-e1a085e39577", "83bf0ee2-9009-4cbf-ac82-7f827a9bf1c9", "6ca59679-c366-442d-80d7-36cdda02b700", "d4157708-8f92-43cb-a55d-2f610856720f", "d065aa5c-1999-454b-865c-aba17464c457", "f241e625-2f9c-48bc-9fec-c06ea3bf6c74", "ff13e224-b6a9-4ff2-bb5e-7e8f1603e8f1", "0fa9bdc2-73bf-4e24-b88e-4b00f63a95df", "705ca2c7-a175-4404-9a60-de1da4b879b7", "22991bc1-76dc-4a25-8b3e-f3e8ad49e5a2"], "metadata": {"window": "stockholders of record at the close of business on May 16, 2022.\n Opioid Litigation\nAs previously disclosed, on April 2, 2022, a comprehensive settlement agreement to settle a substantial majority of opioid lawsuits\nfiled by state and local governmental entities became effective.  As of April 2, 2022, 46 of 49 eligible states, as well as the District of\nColumbia and all eligible territories, as well as over 98 percent of eligible subdivisions in the states, as calculated by population\nunder the agreement, agreed to participate in the settlement.  The Company will pay approximately $5.9 billion over 18 years and\ncomply with other requirements, including the establishment of a clearinghouse that will consolidate data from all three national\ndistributors. ", "original_text": "stockholders of record at the close of business on May 16, 2022.\n", "page_label": "5", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f803da6e-e164-4c57-a964-33e1db35ad98": {"node_ids": ["c079881e-f114-4a48-a7db-2aabf8e89d1c", "e025d946-88f4-4f27-9985-22495e59db27", "b7f5569a-7c96-4564-9ba3-66c67245142b", "22af84e4-724d-4229-9c41-71315f000233", "a276d49b-b3e0-4a8b-84d0-5a0c3c2cf3c5", "098af4ff-9881-4fb1-ba71-c08f53460feb", "f2a53a42-0297-474d-9b82-ad070b73d156", "46f6747d-ef25-445e-9c19-019314018ff6"], "metadata": {"window": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\"\n\"continue,\" \"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such\nwords, and similar expressions are intended to identify such forward-looking statements.  These statements are based on\nmanagement's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date\nhereof.  These statements are not guarantees of future performance and are based on assumptions and estimates that could prove\nincorrect or could cause actual results to vary materially from those indicated. ", "original_text": "\"Certain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of\nthe Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities\nExchange Act\"). ", "page_label": "6", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9c707c5d-b490-46d9-b0f7-a3241e9cd3a3": {"node_ids": ["2355ee4e-15c7-4a60-851e-525ca5cd5383", "e6116c66-c2ad-4f33-8fdf-96057aa15a2a", "82de5b40-996a-4d3d-b5ff-dcf11a914c54"], "metadata": {"window": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company undertakes no obligation to\npublicly update or revise any forward-looking statements, except as required by the federal securities laws.\"\n AMERISOURCEBERGEN CORPORATION\nFINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Three \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$57,719,446 \u00a0\u00a0\u00a0 \u00a0$49,154,171 \u00a0\u00a0 \u00a017.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a055,484,366 \u00a0\u00a0\u00a0 \u00a0\u00a047,620,790 \u00a0\u00a0 \u00a016.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a02,235,080 \u00a0\u00a03.87 %\u00a0\u00a01,533,381 \u00a03.12 %\u00a045.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a01,203,238 \u00a0\u00a02.08 %\u00a0\u00a0730,081 \u00a01.49 %\u00a064.8 %\nDepreciation and amortization \u00a0\u00a0175,290 \u00a0\u00a00.30 %\u00a0\u00a0100,797 \u00a00.21 %\u00a073.9 %\nEmployee severance, litigation, and other 2 \u00a0\u00a076,395 \u00a0\u00a0\u00a0 \u00a0\u00a078,156 \u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a01,454,923 \u00a0\u00a02.52 %\u00a0\u00a0909,034 \u00a01.85 %\u00a060.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a0780,157 \u00a0\u00a01.35 %\u00a0\u00a0624,347 \u00a01.27 %\u00a025.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(948 )\u00a0\u00a0 \u00a0\u00a023,310 \u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a052,916 \u00a0\u00a0\u00a0 \u00a0\u00a034,526 \u00a0\u00a0 \u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a0728,189 \u00a0\u00a01.26 %\u00a0\u00a0566,511 \u00a01.15 %\u00a028.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and elsewhere in that report\nand (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "7", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "458275a2-71b5-45ea-a781-2656edd18979": {"node_ids": ["a4c32ca0-3930-44ed-a82a-515e5c20f4ab", "b6df763b-df29-4aaa-878a-cd9a076b0bea", "db634f03-f47c-4654-a5c9-413bf1aa90f7", "a50e3555-ded4-4979-ac68-014ba5e7a894", "135be957-9f9d-4eb8-b6a1-38099b170c47"], "metadata": {"window": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.3 million of employee severance, $29.8 million legal accrual related to opioid litigation settlements, $22.3 million of\nlegal fees in connection with opioid lawsuits and investigations, and $18.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the three months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $24.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $36.2 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the three months ended March 31, 2021.\n\u00a0\n 3 Includes $2.7 million and $21.4 million of losses on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the three months ended March 31, 2022 and 2021, respectively.\n", "original_text": "Income tax expense \u00a0\u00a0172,944 \u00a0\u00a0\u00a0 \u00a0\u00a0132,506 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a0555,245 \u00a0\u00a00.96 %\u00a0\u00a0434,005 \u00a00.88 %\u00a027.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0\u00a0(7,231 )\u00a0\u00a0 \u00a0\u00a01,262 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$548,014 \u00a0\u00a00.95 %\u00a0$435,267 \u00a00.89 %\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$2.62 \u00a0\u00a0\u00a0 \u00a0$2.12 \u00a0\u00a0 \u00a023.6 %\nDiluted \u00a0$2.59 \u00a0\u00a0\u00a0 \u00a0$2.10 \u00a0\u00a0 \u00a023.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0209,244 \u00a0\u00a0\u00a0 \u00a0\u00a0204,916 \u00a0\u00a0 \u00a02.1 %\nDiluted \u00a0\u00a0211,991 \u00a0\u00a0\u00a0 \u00a0\u00a0207,315 \u00a0\u00a0 \u00a02.3 %\n________________________________________\n1 Includes $16.1 million and $20.9 million of LIFO credits in the three months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "8", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a8cb832c-05d7-47d7-bf07-4094322403aa": {"node_ids": ["585eb775-e6a4-4025-a526-3236708cfef7"], "metadata": {"window": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "original_text": "FINANCIAL SUMMARY\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six \nMonths Ended \nMarch 31, 2022 \u00a0% of \n Revenue \u00a0Six \nMonths Ended \nMarch 31, 2021 \u00a0% of \n Revenue \u00a0% \n Change\nRevenue \u00a0$117,348,256 \u00a0\u00a0\u00a0 \u00a0$101,670,727 \u00a0\u00a0\u00a0 \u00a015.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0\u00a0113,052,817 \u00a0\u00a0\u00a0 \u00a0\u00a098,685,116 \u00a0\u00a0\u00a0 \u00a014.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a0\u00a04,295,439 \u00a0\u00a03.66 %\u00a0\u00a02,985,611 \u00a0\u00a02.94 %\u00a043.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative \u00a0\u00a02,373,348 \u00a0\u00a02.02 %\u00a0\u00a01,465,149 \u00a0\u00a01.44 %\u00a062.0 %\nDepreciation and amortization \u00a0\u00a0351,219 \u00a0\u00a00.30 %\u00a0\u00a0200,350 \u00a0\u00a00.20 %\u00a075.3 %\nEmployee severance, litigation, and other 2 \u00a0\u00a0141,364 \u00a0\u00a0\u00a0 \u00a0\u00a0148,537 \u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of assets \u00a0\u00a04,946 \u00a0\u00a0\u00a0 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a0\u00a02,870,877 \u00a0\u00a02.45 %\u00a0\u00a01,814,036 \u00a0\u00a01.78 %\u00a058.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0\u00a01,424,562 \u00a0\u00a01.21 %\u00a0\u00a01,171,575 \u00a0\u00a01.15 %\u00a021.6 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net  3 \u00a0\u00a0(6,120 )\u00a0\u00a0 \u00a0\u00a09,042 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0\u00a0106,288 \u00a0\u00a0\u00a0 \u00a0\u00a068,140 \u00a0\u00a0\u00a0 \u00a056.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0\u00a01,324,394 \u00a0\u00a01.13 %\u00a0\u00a01,094,393 \u00a0\u00a01.08 %\u00a021.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense \u00a0\u00a0319,733 \u00a0\u00a0\u00a0 \u00a0\u00a0281,681 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0\u00a01,004,661 \u00a0\u00a00.86 %\u00a0\u00a0812,712 \u00a0\u00a00.80 %\u00a023.6 %\n9", "page_label": "9", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ee75d1a8-ad67-4f17-a43c-dc609c51af18": {"node_ids": ["a518b054-8323-4a1d-a1aa-6b79925be813", "001a89c8-f839-4ac5-b57f-278c47c0531b", "84fcb708-fdde-41dc-b189-271ba7da22bc", "d8737215-aa25-4ed1-94df-c7c9f1060ffb", "4260692c-3a0a-4a6c-9cb3-446787a3ff05"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n 2 Includes $6.6 million of employee severance, $36.6 million legal accrual related to opioid litigation settlements, $48.1 million of\nlegal fees in connection with opioid lawsuits and investigations, and $50.0 million of other costs in connection with acquisition-\nrelated deal and integration costs, business transformation efforts, and other restructuring initiatives in the six months ended\nMarch 31, 2022.  Includes a $17.1 million legal accrual related to opioid litigation settlements, $56.9 million of legal fees in\nconnection with opioid lawsuits and investigations, and $74.5 million of other costs in connection with acquisition-related deal and\nintegration costs, business transformation efforts, and other restructuring initiatives in the six months ended March 31, 2021.\n\u00a0\n 3 Includes a $2.6 million gain and a $7.3 million loss on the currency remeasurement of deferred tax assets relating to Swiss tax\nreform in the six months ended March 31, 2022 and 2021, respectively.\n", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0\u00a0(7,542 )\u00a0\u00a0 \u00a0\u00a0(2,600 )\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$997,119 \u00a0\u00a00.85 %\u00a0$810,112 \u00a0\u00a00.80 %\u00a023.1 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$4.77 \u00a0\u00a0\u00a0 \u00a0$3.96 \u00a0\u00a0\u00a0 \u00a020.5 %\nDiluted \u00a0$4.71 \u00a0\u00a0\u00a0 \u00a0$3.91 \u00a0\u00a0\u00a0 \u00a020.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0\u00a0208,900 \u00a0\u00a0\u00a0 \u00a0\u00a0204,804 \u00a0\u00a0\u00a0 \u00a02.0 %\nDiluted \u00a0\u00a0211,580 \u00a0\u00a0\u00a0 \u00a0\u00a0207,063 \u00a0\u00a0\u00a0 \u00a02.2 %\n________________________________________\n1 Includes $60.7 million and $46.6 million of LIFO credits in the six months ended March 31, 2022 and 2021, respectively.\n\u00a0\n", "page_label": "10", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5234217e-100a-4867-9e7e-13297173591a": {"node_ids": ["f9ecc5fa-1d73-4ae6-846b-853115165e2f", "96f565c9-2f32-446a-8094-820363845bc3"], "metadata": {"window": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n prior year \u00a046.6% \u00a061.4% \u00a029.7% \u00a029.4% \u00a024.0% \u00a0\u00a0 \u00a030.3% \u00a027.3% \u00a0\n11", "original_text": "\u00a0 \u00a0Three Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income \n Taxes \u00a0Income \n Tax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per \n Share \u00a0\nGAAP\n\u00a0$ 2,235,080 \u00a0$ 1,454,923 \u00a0$ 780,157 \u00a0$ 728,189 \u00a0$\n172,944 \u00a0$ (7,231) \u00a0$ 548,014 \u00a0$ 2.59 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(1,835) \u00a0\u2014 \u00a0(1,835) \u00a0(1,835) \u00a0(427) \u00a0\u2014 \u00a0(1,408) \u00a0(0.01) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(16,059) \u00a0\u2014 \u00a0(16,059) \u00a0(16,059) \u00a0(3,897) \u00a0\u2014 \u00a0(12,162) \u00a0(0.06) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(77,952) \u00a077,952 \u00a077,952 \u00a018,431 \u00a0(1,764) \u00a057,757 \u00a00.27 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\nother \u00a0\u2014 \u00a0(76,395) \u00a076,395 \u00a076,395 \u00a011,064 \u00a0\u2014 \u00a065,331 \u00a00.31 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0(7,900) \u00a06,840 \u00a014,740 \u00a00.07 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a02,737 \u00a0(8,329) \u00a0\u2014 \u00a011,066 \u00a00.05 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,217,186 \u00a0$ 1,300,576 \u00a0$ 916,610 \u00a0$ 867,379 \u00a0$\n181,886 \u00a0$ (2,155) \u00a0$ 683,338 \u00a0$ 3.22 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP %\nchange vs.\n", "page_label": "11", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b0aa7eba-703f-4312-a005-04dc17c0df5c": {"node_ids": ["54c24de9-d2c7-44e9-aa06-b80ab0648f6a", "d0cd34de-16ac-47f0-9ebe-1711b0235718", "92d0f0cf-adf7-4c18-93af-da9465a7771f"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31, 2021\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Loss \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare\nGAAP \u00a0$1,533,381 \u00a0\u00a0$909,034 \u00a0\u00a0$624,347 \u00a0\u00a0$566,511 \u00a0\u00a0$132,506 \u00a0\u00a0$1,262 \u00a0\u00a0$435,267 \u00a0\u00a0$2.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nLIFO credit \u00a0\u00a0(20,918 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(20,918 )\u00a0\u00a0(20,918 )\u00a0\u00a0(4,957 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(15,961 )\u00a0\u00a0(0.08 )\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAcquisition-related\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(24,973 )\u00a0\u00a024,973 \u00a0\u00a0\u00a024,973 \u00a0\u00a0\u00a03,302 \u00a0\u00a0\u00a0(437 )\u00a0\u00a021,234 \u00a0\u00a0\u00a00.10 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEmployee severance,\nlitigation, and other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(78,156 )\u00a0\u00a078,156 \u00a0\u00a0\u00a078,156 \u00a0\u00a0\u00a018,494 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a059,662 \u00a0\u00a0\u00a00.29 \u00a0\n12", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.87% \u00a03.84%\nOperating expenses \u00a02.52% \u00a02.25%\nOperating income \u00a01.35% \u00a01.59%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "12", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "40d0e19c-4972-473d-aaae-cbcd2233b421": {"node_ids": ["353d6b08-4fd6-4b0b-a177-5021d59454c7", "ed46ea73-5fb4-4b81-bea8-f1dd57fa7b2b", "4e5f99e1-5d6e-451f-806c-13dfb0172016"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2022 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,295,439 \u00a0\u00a0$2,870,877 \u00a0\u00a0$1,424,562 \u00a0\u00a0$1,324,394 \u00a0\u00a0$319,733 \u00a0\u00a0$(7,542 )\u00a0$997,119 \u00a0\u00a0$4.71 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\n13", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nTax reform  1 \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a021,368 \u00a0\u00a0\u00a0(2,701 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a024,069 \u00a0\u00a0\u00a00.12 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted Non-GAAP \u00a0$1,512,463 \u00a0\u00a0$805,905 \u00a0\u00a0$706,558 \u00a0\u00a0$670,090 \u00a0\u00a0$146,644 \u00a0\u00a0$825 \u00a0\u00a0$524,271 \u00a0\u00a0$2.53 \u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.12% \u00a03.08%\nOperating expenses \u00a01.85% \u00a01.64%\nOperating income \u00a01.27% \u00a01.44%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "13", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7a4f6c20-e183-4d33-8b81-cef783d12165": {"node_ids": ["51cbdc35-73e9-4f0a-86fd-8a257bd9306c", "04d814b8-29c7-4c4c-a26a-1e98b8aeb3b4"], "metadata": {"window": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a0\u00a044.0 %\u00a0\u00a058.9 %\u00a0\u00a025.9 %\u00a0\u00a024.7 %\u00a0\u00a020.0 %\u00a0\u00a0 \u00a0\u00a026.0 %\u00a0\u00a023.4 %\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a03.66% \u00a03.61%\n14", "original_text": "antitrust\nlitigation\nsettlements \u00a0\u00a0(1,835 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,835 )\u00a0\u00a0(1,835 )\u00a0\u00a0(427 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(1,408 )\u00a0\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0\u00a0(60,738 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(60,738 )\u00a0\u00a0(60,738 )\u00a0\u00a0(14,142 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(46,596 )\u00a0\u00a0(0.22 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(157,458 )\u00a0\u00a0157,458 \u00a0\u00a0\u00a0157,458 \u00a0\u00a0\u00a036,661 \u00a0\u00a0\u00a0(3,554 )\u00a0\u00a0117,243 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(141,364 )\u00a0\u00a0141,364 \u00a0\u00a0\u00a0141,364 \u00a0\u00a0\u00a024,397 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0116,967 \u00a0\u00a0\u00a00.55 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof assets \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(4,946 )\u00a0\u00a04,946 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a04,946 \u00a0\u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nexpense \u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(18,979 )\u00a0\u00a06,840 \u00a0\u00a0\u00a025,819 \u00a0\u00a0\u00a00.12 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 1\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(2,570 )\u00a0\u00a0(17,204 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a014,634 \u00a0\u00a0\u00a00.07 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,232,866 \u00a0\u00a0$2,567,109 \u00a0\u00a0$1,665,757 \u00a0\u00a0$1,563,019 \u00a0\u00a0$330,039 \u00a0\u00a0$(4,256 )\u00a0$1,228,724 \u00a0\u00a0$5.81 \u00a02\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "fe06b43e-7c81-4884-92bc-2ad416d9a21d": {"node_ids": ["11789843-5d5a-4be4-9dc9-6f9531bcb2a0", "ee67690e-9d15-4a4a-b3b6-5268a62044cf", "c16f485c-30fb-4d53-b3cd-06c5e34f4781", "28dedf1b-6c18-47f8-a8ce-c6a393ca746d"], "metadata": {"window": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 2 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nGAAP TO NON-GAAP RECONCILIATIONS\n(in thousands, except per share data)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e \n Income\nTaxes \u00a0Income\nTax \n Expense \u00a0Net Income \n Attributable t o \n Noncontr olling \n Interests \u00a0Net Income \n Attributable \n to ABC \u00a0Dilut ed \n Earnings \n Per Shar e\u00a0\nGAAP\n\u00a0$ 2,985,611 \u00a0$ 1,814,036 \u00a0$ 1,171,575 \u00a0$\n1,094,393 \u00a0$\n281,681 \u00a0$ (2,600) \u00a0$ 810,112 \u00a0$ 3.91 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(46,645) \u00a0\u2014 \u00a0(46,645) \u00a0(46,645) \u00a0(9,933) \u00a0\u2014 \u00a0(36,712) \u00a0(0.18) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(50,007) \u00a050,007 \u00a050,007 \u00a07,398 \u00a0(874) \u00a041,735 \u00a00.20 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation, and\n15", "original_text": "Operating expenses \u00a02.45% \u00a02.19%\nOperating income \u00a01.21% \u00a01.42%\n________________________________________\n1 Includes tax expense relating to Swiss tax reform and a gain on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n", "page_label": "15", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b2a8dbb4-47d2-4e6f-97dd-569c1f7ae190": {"node_ids": ["e6848c4e-35ef-4c16-9fa9-e93f784350a0", "c1b785e4-303d-4fce-bc52-caee2fb051f0", "d3e170d2-0a9c-4505-ba0e-9322395d61ff", "c9bff665-24e6-454d-8011-9b36d752eb6e", "cbe14817-0498-4526-b797-437f98508788"], "metadata": {"window": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n 2 Includes tax expense relating to Swiss tax reform and a loss on the currency remeasurement of the related deferred tax assets,\nwhich is recorded within Other (Income) Loss, Net.\n\u00a0\n 3 The sum of the components does not equal the total due to rounding.\n\u00a0\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "other \u00a0\u2014 \u00a0(148,537) \u00a0148,537 \u00a0148,537 \u00a030,468 \u00a0\u2014 \u00a0118,069 \u00a00.57 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a020,425 \u00a0\u2014 \u00a0(20,425) \u00a0(0.10) \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform  2 \u00a0\u2014 \u00a0\u2014 \u00a0\u2014 \u00a07,329 \u00a0(55,019) \u00a0\u2014 \u00a062,348 \u00a00.30 \u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$ 2,938,966 \u00a0$ 1,615,492 \u00a0$ 1,323,474 \u00a0$\n1,253,621 \u00a0$\n275,020 \u00a0$ (3,474) \u00a0$ 975,127 \u00a0$ 4.71 3\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed \n Non-GAAP\nGross profit \u00a02.94% \u00a02.89%\nOperating expenses \u00a01.78% \u00a01.59%\nOperating income \u00a01.15% \u00a01.30%\n________________________________________\n1 Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of\nthe PharMEDium business.\n\u00a0\n", "page_label": "16", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5c205791-403d-4d88-bfb4-785968f8e65d": {"node_ids": ["1d8cb3a4-1036-4cbc-a9c5-c0d846742570", "d9dc1d43-0913-4ec8-81e7-eebfb6e3122f", "5ba61ebc-f434-425e-aa97-924f5ac3caf9", "74c13e53-716d-4f7e-a2db-fd0de583dbb8"], "metadata": {"window": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$50,942,763 \u00a0\u00a0$48,165,587 \u00a0\u00a05.8 %\nInternational Healthcare Solutions \u00a0\u00a06,777,691 \u00a0\u00a0\u00a0989,032 \u00a0\u00a0585.3 %\nIntersegment eliminations \u00a0\u00a0(1,008 )\u00a0\u00a0(448 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$57,719,446 \u00a0\u00a0$49,154,171 \u00a0\u00a017.4 %\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$729,542 \u00a0\u00a0$654,715 \u00a0\u00a011.4 %\nInternational Healthcare Solutions \u00a0\u00a0187,068 \u00a0\u00a0\u00a051,843 \u00a0\u00a0260.8 %\nTotal segment operating income \u00a0\u00a0916,610 \u00a0\u00a0\u00a0706,558 \u00a0\u00a029.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a016,059 \u00a0\u00a0\u00a020,918 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(77,952 )\u00a0\u00a0(24,973 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(76,395 )\u00a0\u00a0(78,156 )\u00a0\u00a0\nOperating income \u00a0$780,157 \u00a0\u00a0$624,347 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.87 %\u00a0\u00a02.73 %\u00a0\u00a0\n17", "original_text": "(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Three Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a0\u00a02021 \u00a0% Change\nU.S. ", "page_label": "17", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d24bf951-b9df-4bf0-872c-f71ee8c7d329": {"node_ids": ["9207d99c-05d7-4198-b5dc-adcc15b74f77", "83b88e64-61d3-4657-96e4-e0828024c6a6"], "metadata": {"window": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nSUMMARY SEGMENT INFORMATION\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nRevenue \u00a02022 \u00a02021 \u00a0% Change\n18", "original_text": "Operating expenses \u00a0\u00a01.44 %\u00a0\u00a01.37 %\u00a0\u00a0\nOperating income \u00a0\u00a01.43 %\u00a0\u00a01.36 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nInternational Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.15 %\u00a0\u00a020.11 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.39 %\u00a0\u00a014.86 %\u00a0\u00a0\nOperating income \u00a0\u00a02.76 %\u00a0\u00a05.24 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.87 %\u00a0\u00a03.12 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.52 %\u00a0\u00a01.85 %\u00a0\u00a0\nOperating income \u00a0\u00a01.35 %\u00a0\u00a01.27 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.84 %\u00a0\u00a03.08 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.25 %\u00a0\u00a01.64 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.59 %\u00a0\u00a01.44 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "d91dd428-3273-426e-aa59-2c6b6451e994": {"node_ids": ["993f2780-0368-404c-9693-23fe51ee6b62", "8cf5ecf2-f8d2-47e4-8555-a33d303f2990", "62030fc7-5f99-4edb-840e-9052d898cadf", "3060a3a0-58b0-460c-b305-fad338f3c384"], "metadata": {"window": "U.S.  Healthcare Solutions \u00a0$103,922,410 \u00a0\u00a0$99,738,168 \u00a0\u00a04.2 %\nInternational Healthcare Solutions \u00a0\u00a013,427,473 \u00a0\u00a0\u00a01,933,343 \u00a0\u00a0594.5 %\nIntersegment eliminations \u00a0\u00a0(1,627 )\u00a0\u00a0(784 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$117,348,256 \u00a0\u00a0$101,670,727 \u00a0\u00a015.4 %\n\u00a0 \u00a0Six Months Ended Mar ch 31,\nOperating income \u00a02022 \u00a02021 \u00a0% Change\nU.S.  Healthcare Solutions \u00a0$1,298,629 \u00a0\u00a0$1,220,642 \u00a0\u00a06.4 %\nInternational Healthcare Solutions \u00a0\u00a0367,128 \u00a0\u00a0\u00a0102,832 \u00a0\u00a0257.0 %\nTotal segment operating income \u00a0\u00a01,665,757 \u00a0\u00a0\u00a01,323,474 \u00a0\u00a025.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0\u00a01,835 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nLIFO credit \u00a0\u00a060,738 \u00a0\u00a0\u00a046,645 \u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0\u00a0(157,458 )\u00a0\u00a0(50,007 )\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0\u00a0(141,364 )\u00a0\u00a0(148,537 )\u00a0\u00a0\nImpairment of assets \u00a0\u00a0(4,946 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\nOperating income \u00a0$1,424,562 \u00a0\u00a0$1,171,575 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of Revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nU.S.  Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a02.64 %\u00a0\u00a02.56 %\u00a0\u00a0\nOperating expenses \u00a0\u00a01.39 %\u00a0\u00a01.34 %\u00a0\u00a0\nOperating income \u00a0\u00a01.25 %\u00a0\u00a01.22 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n19", "original_text": "U.S. ", "page_label": "19", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "44db08ce-466b-43cb-9f83-18d9eae976f5": {"node_ids": ["094ce54d-107f-4ad5-9403-75add22b35c0", "aaadef10-4643-4833-b79a-7d8a10d3c0d6"], "metadata": {"window": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED BALANCE SHEETS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 March 31, \u00a0September 30,\n\u00a0 2022 \u00a02021\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\n20", "original_text": "International Healthcare Solutions \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a011.12 %\u00a0\u00a019.91 %\u00a0\u00a0\nOperating expenses \u00a0\u00a08.38 %\u00a0\u00a014.60 %\u00a0\u00a0\nOperating income \u00a0\u00a02.73 %\u00a0\u00a05.32 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a0\u00a03.66 %\u00a0\u00a02.94 %\u00a0\u00a0\nOperating expenses \u00a0\u00a02.45 %\u00a0\u00a01.78 %\u00a0\u00a0\nOperating income \u00a0\u00a01.21 %\u00a0\u00a01.15 %\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a0\u00a03.61 %\u00a0\u00a02.89 %\u00a0\u00a0\nAdjusted operating expenses \u00a0\u00a02.19 %\u00a0\u00a01.59 %\u00a0\u00a0\nAdjusted operating income \u00a0\u00a01.42 %\u00a0\u00a01.30 %\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a59449a8-516a-48fa-9d30-a5af4a37abf6": {"node_ids": ["44da69d5-b5e4-43ff-a9df-6d4a6e0c184e"], "metadata": {"window": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "original_text": "Cash and cash equivalents $2,960,759 \u00a0$2,547,142\nAccounts receivable, net \u00a018,111,080 \u00a0\u00a018,167,175\nInventories \u00a015,514,851 \u00a0\u00a015,368,352\nRight to recover assets \u00a01,451,687 \u00a0\u00a01,271,557\nPrepaid expenses and other \u00a01,371,363 \u00a0\u00a01,448,383\nTotal current assets \u00a039,409,740 \u00a0\u00a038,802,609\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net \u00a02,138,598 \u00a0\u00a02,162,961\nGoodwill and other intangible assets \u00a013,686,304 \u00a0\u00a014,287,458\nDeferred income taxes \u00a0267,200 \u00a0\u00a0290,791\nOther long-term assets \u00a01,806,311 \u00a0\u00a01,793,986\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $57,308,153 \u00a0$57,337,805\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $38,210,623 \u00a0$38,009,954\nOther current liabilities \u00a02,777,298 \u00a0\u00a03,048,474\nShort-term debt \u00a01,809,660 \u00a0\u00a0300,213\nTotal current liabilities \u00a042,797,581 \u00a0\u00a041,358,641\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt \u00a04,646,712 \u00a0\u00a06,383,711\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes \u00a0292,949 \u00a0\u00a0281,070\nDeferred income taxes \u00a01,692,347 \u00a0\u00a01,685,296\nOther long-term liabilities \u00a01,037,040 \u00a0\u00a01,082,723\n21", "page_label": "21", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "140b4649-c00d-49cb-891d-ea10aa648372": {"node_ids": ["534376e3-8853-4b1b-bc4c-db85a0b1319f"], "metadata": {"window": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "original_text": "Accrued litigation liability \u00a05,935,459 \u00a0\u00a05,961,953\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity \u00a0906,065 \u00a0\u00a0584,411\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity $57,308,153 \u00a0$57,337,805\nAMERISOURCEBERGEN CORPORATION\nCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS\n(in thousands)\n(unaudited)\n\u00a0\n\u00a0 Six Months Ended Mar ch 31,\n\u00a0 2022 \u00a02021\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,004,661 \u00a0\u00a0$812,712 \u00a0\nAdjustments to reconcile net income to net cash provided by operating activities \u00a0423,420 \u00a0\u00a0\u00a0415,159 \u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable \u00a0(527,521 )\u00a0\u00a0(193,770 )\nInventories \u00a0(215,479 )\u00a0\u00a0(314,294 )\nAccounts payable \u00a0598,411 \u00a0\u00a0\u00a0(292,555 )\nOther, net \u00a0(153,496 )\u00a0\u00a021,898 \u00a0\nNet cash provided by operating activities \u00a01,129,996 \u00a0\u00a0\u00a0449,150 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures \u00a0(209,343 )\u00a0\u00a0(151,612 )\nCost of acquired companies, net of cash acquired \u00a0(124,158 )\u00a0\u00a0\u2014 \u00a0\nCost of equity investments \u00a0\u2014 \u00a0\u00a0\u00a0(162,620 )\nOther, net \u00a0(3,663 )\u00a0\u00a0\u2014 \u00a0\n22", "page_label": "22", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f12da2ed-7d12-4574-a7f1-73d6cf693dfd": {"node_ids": ["a03694b3-b9d5-4ae1-b0bb-a455ee7fe5b9"], "metadata": {"window": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "original_text": "Net cash used in investing activities \u00a0(337,164 )\u00a0\u00a0(314,232 )\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet debt (repayments) borrowings \u00a0(208,790 )\u00a0\u00a02,069,645 \u00a0\nPurchases of common stock \u00a0(11,396 )\u00a0\u00a0(82,150 )\nExercises of stock options \u00a072,973 \u00a0\u00a0\u00a0130,326 \u00a0\nCash dividends on common stock \u00a0(197,923 )\u00a0\u00a0(182,365 )\nOther \u00a0(39,451 )\u00a0\u00a0(26,940 )\nNet cash (used in) provided by financing activities \u00a0(384,587 )\u00a0\u00a01,908,516 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nEffect of exchange rate changes on cash, cash equivalents, and restricted cash \u00a0(5,055 )\u00a0\u00a0\u2014 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nIncrease in cash, cash equivalents, and restricted cash, including cash classified within assets held for\nsale \u00a0403,190 \u00a0\u00a0\u00a02,043,434 \u00a0\nLess: Increase in cash classified within assets held for sale \u00a0(516 )\u00a0\u00a0\u2014 \u00a0\nIncrease in cash, cash equivalents, and restricted cash \u00a0402,674 \u00a0\u00a0\u00a02,043,434 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 1 \u00a03,070,128 \u00a0\u00a0\u00a04,597,746 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period 1 $3,472,802 \u00a0\u00a0$6,641,180 \u00a0\n________________________________________\n1 The following represents a reconciliation of cash and cash equivalents in the Condensed Consolidated Balance Sheets to cash,\ncash equivalents, and restricted cash used in the Condensed Consolidated Statements of Cash Flows:\n\u00a0 \u00a0March 31, \n2022 \u00a0September 30, \n2021\nCash and cash equivalents \u00a0$2,960,759 \u00a0$2,547,142\n23", "page_label": "23", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c52faaa4-e7ab-4672-b6c9-8974262d6f3f": {"node_ids": ["cde0875d-e0e0-403f-8d66-48b239fb5d83", "116d8525-d9ae-4b38-9dbb-b0ff041b17ad", "51072f9d-ea79-453c-a19c-0958f6a650e7", "ce9d676a-7d2c-48ec-a4dc-14a8f602df52", "efc52a5b-46f2-4dfe-9d87-94fa6acbd630", "e3b1ab5c-608b-4dfa-aab1-4cbf0b806247", "2b7eddd4-4bb7-4db9-871c-7aad83a6689a", "df18d41b-d265-45bb-9c43-f438ec9227d7", "663b95e0-9562-4796-a711-f3f7e8c36dce", "e59f16b9-08ef-4151-9e4a-8a7cc6742023", "15e9b2dd-b31c-4fb9-836c-d62820386994", "9a10bcd6-1f42-4eb0-b849-d1cb64e77c28", "b352446f-a8f4-48a7-a9a5-d0b578a9f4d1", "b130470a-5503-4256-80a8-fa09c68bfa6f", "fde7b26d-2196-4fde-8ced-d433f54ec88e", "962c1627-cc6b-4b76-ab3b-f6e53942d33c", "03660060-2a1a-461f-95be-68bc149be816", "56387cc2-1cac-4b93-b0da-98a50de88e3b", "d8bc301b-ef19-41ef-bb3b-006b77d99327", "c2fb26cf-26be-47b2-9101-3930412859c6", "95873e01-c9cd-4822-b8fb-dadc85e0446c", "1db362ef-c16f-4cc3-8385-9416412ffb48", "06384128-4446-4dbb-82b3-b28fbc9fe756", "85795e66-3c1c-4e46-aa12-41156f1b5739"], "metadata": {"window": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "Restricted cash (included in Prepaid Expenses and Other) \u00a0\u00a0452,014 \u00a0\u00a0462,986\nRestricted cash (included in Other Long-Term Assets) \u00a0\u00a060,029 \u00a0\u00a060,000\nCash, cash equiv alents, and r estrict ed cash \u00a0$3,472,802 \u00a0$3,070,128\nSUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "24ca6300-8582-410b-ac65-383620795996": {"node_ids": ["7762a227-b8a5-45d8-88f9-63a719dc8afc", "b7aee071-862a-47d6-b0b6-097cdae9003d", "9522e131-6b25-46d7-89ee-82fd3ff30f9e", "38dd4cd5-128a-49a6-b675-5b0edf9c4e84", "fa52b698-0f61-4c6d-bd34-2cd73a376484", "b85ef90a-6b5a-4931-b83d-804db84156bc", "275f5f0d-dbdd-4298-ad25-8c6e07c551f8", "72aee4de-f57a-4db3-9b5d-7ee87f67b17e", "6c2ae45f-62e2-4fe5-8d13-419cf069e150", "664a7b21-8db4-43c0-896a-0483caa962f1", "b752543a-3ee5-49fb-8ef7-c349192c3864", "dc96b775-b3a5-4960-a754-395e46a75d26", "a6989bb7-5439-4667-b222-dcbfa59440c8", "79fa5a85-dff9-422b-a9f8-e5effd00074e", "067dffd4-d88f-4555-a20d-fe232cfee26e", "8bc37d72-b987-47db-bb74-b84031914057", "a145451b-04aa-411e-852c-1d240e1953f4", "c2b4689b-7706-4cee-9cf7-579e598a2c5e", "8093fde2-b664-4e7e-8b0b-b82dc45479d4", "0733c2dd-009a-4dce-9208-a181b613f1fb", "da4fc845-3f5a-4d76-98a6-df19c3268f67", "accbe91d-4ab3-42ca-be66-4ba269f7d9e7", "d043c55b-659b-4144-b2e4-10b6ee234216"], "metadata": {"window": "rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "rate.\n", "page_label": "25", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0c8361cb-fd66-4e0d-8b57-2e3761e152fe": {"node_ids": ["b0339c0b-72f4-4168-a947-200eeeb8c279", "5b5403c0-8977-4326-aa70-5ad85b94a629", "7409afff-ae03-4163-abd4-ea41288a1ce6", "4303b010-b572-4c42-8a8d-8a9ef3f857f6"], "metadata": {"window": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely dependent upon\nthe future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and acquisition-\nrelated intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably estimated.\n Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20220503006098/en/\nBennett S. Murphy \nSenior Vice Pr esident, Inv estor Relations \n610-727-3693 \nbmurphy@amerisour ceber gen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance of which cannot\nbe determined, is not available and cannot be reasonably estimated. ", "page_label": "26", "file_name": "CEN-Q2-FY22-ECT.pdf", "file_path": "pdfs\\CEN-Q2-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 222109, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}